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‘Nexus – the search for’     2018 
This work was inspired by a research study into physical performance related 
fatigue in physically active MS patients, before, during and after exercise. Also 
the evolution of motor fatigability over time. Depicted in the searing landscape 
is a figure representing the tireless search for a connection – a clue – and 
answer to the many questions agonized by researchers, who are hardly ever 
seen. Behind the image are a trail of computerised images, similar to the 
images, utilised to assist accurate patient measurement of movement.  
 
B.J. Leslie, MS participant  
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Abstract 
 
People with Multiple Sclerosis (pwMS) often experience walking impairments 
such as foot drop which can lead to trip and falls. Foot drop can be either transient 
and is often induced by exercise (fatigability) in pwMS whose walking ability is 
not affected and can become more fixed with disease progression. The overall 
aim of this PhD was to explore foot drop, its presence in pwMS with different 
disability levels and the psychometric properties of outcomes used to evaluate 
walking impairments. The first study in this thesis was a systematic review into  
the level of evidence for the  psychometric properties of walking measures that 
have been  used to evaluate the effect of assistive technology such as FES for 
foot drop in MS. Moderate to strong psychometric evidence was  found for the 
Multiple Sclerosis Walking Scale, Timed 25 Foot Walk, 6 minute and 10 meter 
walk tests. There were no psychometric studies for three-dimensional (3D) gait 
kinematics in pwMS even though it was one of the most frequently used outcome 
measures. The second study assessed the test-retest reliability of 3D ankle 
kinematics and spatiotemporal parameters in pwMS, with low Expanded 
Disability Status Scale (EDSS < 3.5) and in those with moderate to high EDSS 
(EDSS: 4-6). Reliability was excellent for ankle kinematics and spatiotemporal 
parameters in both groups, with lower minimal detectable change (MDC95%) 
values in the low EDSS group compared to the higher EDSS group. The third 
study investigated transient exercise induced foot drop in highly physically active 
pwMS (EDSS < 3.5) and health controls using 3D kinematics. It was found that 
6 out of 15 pwMS and none of the healthy controls presented this phenomenon. 
The fourth study examined the direct orthotic effect of FES during dual-tasking 
(i.e. walking combined with a cognitive task) and after inducing fatigability. Low 
to moderate effect sizes indicated that the direct orthotic effect was higher under 
dual-task and fatiguing conditions but this needs to be confirmed in appropriately 
powered studies. 
In conclusion, the studies in this thesis have contributed  to the psychometric 
evidence of gait kinematics in pwMS, have objectively documented the presence 
of transient foot drop in highly physically active pwMS and orthotic effect of 
FES under a variety of conditions simulating the   perceived benefits in ‘real life’ 
reported by FES users.  
 
Key words: multiple sclerosis, foot drop, fatigability, FES, psychometric 
properties, 3D gait kinematics   
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 1 
 
Chapter 1. Introduction  
 
Multiple sclerosis (MS) is chronic inflammatory demyelinating disease that 
affects the central nervous system (CNS) and typically strikes adults (McDonald 
& Sears, 1970). Usually it presents between the ages of 20-40 and it affects 2.3 
million people worldwide with twice as many women affected compared to men 
(Browne et al, 2014). According to the Scottish MS Register, 425 people 
diagnosed with MS in 2017 and it is estimated that the incidence for Scotland is 
8.6 per 100,000/year (Scottish MS Register, viewed online 2018). Multiple 
sclerosis affects people in different ways, with people experiencing a variety of 
symptoms. The most commonly reported symptoms are fatigue, weakness and 
movement disturbances (Crayton & Rossman, 2006). In a study by Hessen et al. 
(2008) gait function was most frequently rated as the most important domain by 
pwMS. 
 The Expanded Disability Status Scale (EDSS) is a clinician-administered scale 
that assesses the neurological disability in MS population and describes the 
disease progression based on an ordinal system ranging from 0 (normal 
neurological status) to 10 (death due to MS) (Kurtzke, 1983). Although increased 
severity of walking impairments is associated with a longer disease duration and 
higher EDSS, small gait deficits have also been observed in people who are 
relatively mildly affected by MS (Benedetti et al, 1999; Nogueira et al, 2013).  
One common walking impairment is foot drop (drop-foot or dropped foot), which 
is the decreased ankle dorsiflexion during the swing phase of gait and can result 
in trips and falls. The prevalence of foot drop has not been reported in peer-
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reviewd literature, but based on the records of the MS Therapy Centre Lothian it 
is estimated that 48% of the pwMS that visit the centre experience foot drop. 
Further, there are anecdotal reports of foot drop even at early stages of the 
disease. This type of foot drop often comes on during intense or long duration 
physical activities such as walking or running, but recovers after a period of rest. 
To the author’s knowledge, this type of foot drop has not been objectively 
documented for example by gait analysis.  
Fixed foot drop is commonly experienced by people with EDSS of 4 onwards 
and is often treated by Ankle Foot Orthoses (AFOs) or Functional Electrical 
Stimulation (FES). The use of FES has gained popularity over the latest decade, 
with some pwMS reporting benefits including improvement of gait, reduced 
fatigue and reduced tripping and falling (Taylor et al, 1999; Bulley et al, 2015; 
(Miller) Renfrew et al, 2018). Another important benefit of FES reported by 
pwMS is that it reduces the mental effort of walking and as a result less 
concentration is needed to walk (Bulley et al, 2015; (Miller) Renfrew et al, 2018). 
This is of great importance, since most of the daily activities include performing 
a motor and a cognitive task at the same time. The execution of a motor task 
simultaneous with a cognitive task is termed dual-tasking and studies have 
indicated that when performing a cognitive task together with a walking task, 
pwMS exhibited deterioration in gait performance. However, this perceived 
benefit of FES use while performing a cognitive task has not been documented 
objectively.  
There is wide variety of outcome measures to assess walking performance, for 
example with and without FES, in clinical and research settings for the MS 
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population, such as self-reported questionnaires, clinician-assessed rating scales 
and short or long distance walking performance tests and three-dimensional (3D) 
gait analysis. The latter is often considered the ‘gold’ standard as it can detect 
even subtle changes. In order to allow for meaningful interpretation of the results, 
the outcome measures should be reliable, valid and responsive to change, as well 
as practical and appropriate for each setting. Consequently, there is an increase 
on the number of studies investigating the level of evidence for the psychometric 
properties of outcome measures and specific guidelines have been developed [i.e. 
COnsensus-based Standards for the selection of health Measurement 
INstruments (COSMIN)] in order to evaluate and summarize the level of 
evidence of outcome measures.  
This thesis will focus on foot drop and treatment of foot drop using FES in 
pwMS. The following Chapter 2 will therefore first describe the definition, 
prevalence and symptoms of MS. This is then followed by a detailed report on 
the walking impairments and especially foot drop (both transient and fixed) in 
pwMS with different walking abilities and treatment options for foot drop such 
as FES. In addition, this literature review includes a description of the 
psychometric properties of outcome measures of walking performance in pwMS, 
along with the current knowledge on dual-task performance in the MS 
population. Both topics are of importance for the assessment of the impact of 
FES to treat foot drop in pwMS. Finally, at the end of Chapter 2 the overall aim, 
objectives and research questions of this thesis will be presented. 
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Chapter 2. Literature review 
 
2.1 Purpose of the chapter  
 
This chapter will present an overview of multiple sclerosis (MS) in terms of its 
clinical definition, pathophysiology, incidence and prevalence and symptoms 
focusing mostly in performance related fatigue versus perceived fatigue. Further, 
in this chapter gait impairments which are common in the MS population, such 
as foot drop, will be explored as well as assistive technology to treat foot drop 
[Functional electrical stimulation (FES)]. Another part of the literature review 
will describe those outcome measures that have been used to assess walking 
performance in the MS population and the importance and need for 
psychometrically robust outcomes in this population will be highlighted. The 
next part will provide a background on dual tasking (i.e. performing motor and 
cognitive tasks simultaneously) in people with MS (pwMS) and how it affects 
walking performance. At the end of this literature review, gaps in evidence 
identified will be highlighted and the rationale of the four studies that form this 
thesis will be explained.  
 
2.2 Multiple Sclerosis – An overview 
 
2.2.1 Multiple sclerosis and pathology 
 
Multiple sclerosis (MS) was defined more than a century ago and is an immune-
mediated demyelinating disease of the central nervous system (CNS). It is 
manifested with the presence of focal areas of inflammatory-mediated 
demyelination of the brain and spinal cord (Trapp et al, 2008). Early in the 19th 
century Robert Carswell (1838) and Jean Cruveilhier (1841) macroscopically 
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recorded scarring or lesions on the brain and spinal cord which was the first 
reporting of the pathology of MS. Jean Martin Charcot (1868) described in detail 
the lesions and reported on the inflammation and structural changes such as 
demyelination and axonal destruction, naming the condition ‘sclérose en plaques 
disseminées’. Although, the primary cause of MS is still unknown, it has been 
established that both genetic and environmental risk factors contribute to disease 
susceptibility (Witte et al, 2014). The genetic component is suggested by familial 
aggregation in MS and few genes have been identified consistently to influence 
disease susceptibility which are located on chromosome 6 and are the HLA-
DR15 and HLA-DQ6 (Hauser & Oksenberg, 2006). Environmental factors that 
have been linked with the occurrence of MS are viral and bacterial infections, 
exposure to vitamin D, smoking and dietary factors (Hauser & Oksenberg, 2006). 
Nonetheless, there is lack of proof of the pathogenic roles of these factors (Witte 
et al, 2014).  
The most widely used instrument to assess neurological disability in MS 
population is the Expanded Disability Status Scale (EDSS) and it is considered 
as a ‘gold’ standard (Bethoux & Bennett, 2011). It was developed by Kurtzke 
(1983) to describe disease progression and it consists of an ordinal system 
ranging from 0 (normal neurological status) to 10 (death due to MS) (Table 2.1). 
The EDSS is a clinician-administered scale that evaluates the functional systems 
of the CNS. The measurement of impairments in the lower range of EDSS is 
based mostly on neurological examination, whilst the upper range (EDSS 4-7.5) 
depends mostly on the walking abilities of each individual with MS.  
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Table 2.1 Expanded Disability Status Scale (adapted by Kurtzke, 1983). 
Score Description 
1.0 No disability, minimal sings in one FS 
1.5 No disability, minimal signs in more than one FS 
2.0 Minimal disability in one FS 
2.5 Mild disability in one FS or minimal disability in two FS 
3.0 Moderate disability in one FS or mild disability in three or four 
FS. No impairment to walking 
3.5 Moderate disability in one FS and more than minimal in several 
others. No impairment to walking 
4.0 Significant disability but self-sufficient and up and about some 
12 hours a day. Able to walk without aid or rest for 500m 
4.5 Significant disability but up and about much of the day, able to 
work a full day, may otherwise have some limitation of full 
activity or require minimal assistance. Able to walk without aid 
or rest for 300m 
5.0 Disability severe enough to impair full daily activities and ability 
to work a full day without special provisions. Able to walk 
without aid or rest for 200m 
5.5 Disability severe enough to preclude full daily activities. Able to 
walk without aid or rest for 100m  
6.0 Requires a walking aid (e.g. cane, crutch, etc.) to walk about 
100m with or without resting 
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6.5 Requires two walking aids (e.g. pair of canes, crutches, etc.) to 
walk about 20m without resting 
7.0 Unable to walk beyond approximately 5m even with aid. 
Essentially restricted to wheelchair; though wheels self in 
standard wheelchair and transfers alone. Up and about in 
wheelchair some 12 hours a day 
7.5 Unable to make more than a few steps. Restricted to wheelchair 
and may need aid in transferring. Can wheels self but cannot 
carry on in standard wheelchair for a full day and may require a 
motorised wheelchair  
8.0 Essentially restricted to bed or chair or pushed in wheelchair. 
May be out of bed itself much of the day. Retains many self-care 
functions. Generally has effective use of arms 
8.5 Essentially restricted to bed much of the day. Has some effective 
use of arms, retains some self-care functions 
9.0 Confined to bed. Can still communicate and eat 
9.5 Confined to bed and totally dependent. Unable to communicate 
effectively or eat/swallow 
10.0 Death due to MS 
Abbreviations: FS: Functional system 
 
 
2.2.2 Incidence and prevalence 
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Multiple sclerosis is the most common cause of chronic neurological disability 
in early to middle adult life and it has been estimated that the number of pwMS 
worldwide is 2.3 million (Hauser & Oksenberg, 2006; Browne et al, 2014). 
Prevalence, has increased from 30 in 2008 to 33 in 2013 per 100,000 (Browne et 
al, 2014). The pooled prevalence, which is a measure that takes into account the 
relative size of a country’s population, was 1.6 million from the 92 countries that 
provided data in 2013 (Browne et al, 2014). This increase in prevalence from 
2008 to 2013 could possibly be explained by the increased survival rate both in 
MS and the general population, but it could also be attributed to improvements 
in diagnosis and reporting of MS (Browne et al, 2014). The incidence of MS was 
reported in 52 countries, with higher incidence rates been in San Marino (13.75 
per 100,000/year), Canada (13.4 per 100,000/year) and Northern European 
countries (10-12 per 100,000/year) and lower incidence rates in South American 
countries (0.25-0.6 per 100,000/year) and Eastern Asian countries (0.5-0.63 per 
100,000/year) (Browne et al, 2014). It has been estimated that overall there are 
twice as many women as men living with MS and even though people can be 
diagnosed at any age, the average age of MS onset is 30 years old (Browne et al, 
2014).  In UK the prevalence of MS in 2010 was 203.4 per 100,000 population 
and the incidence was 9.64 per 100,000/year (Mackenzie et al, 2014). The 
Scottish MS Register that was published in 2018 reported that 425 people 
diagnosed with MS in 2017 and the incidence for Scotland was 8.6 per 
100,000/year, with the higher rate observed in NHS Orkney (17.3 per 
100,000/year) and the lowest in NHS Borders (6.2 per 100,000/year) (Scottish 
MS Register, viewed online 2018). The annual age specific incidence in Scotland 
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per 100,000 was twice as high for female at the age range 35-39 with a rate of 
26.9 as for male at the age range of 40-44 with a rate of 12.1 for the period 2010-
2017 (Scottish MS Register, viewed online 2018).  
 
2.2.3 Types of MS 
 
The clinical course of MS may be variable over time and the typical manifestation 
includes either gradual deterioration of neurologic function, acute episodes of 
worsening or combination of both. Depending on the current medical status and 
history, the MS phenotypes can be categorized to either relapsing or progressive. 
Nevertheless, since MS is a progressive disease the subtype from the initial 
assessment might change over time, for example from a relapsing-remitting (RR) 
subtype to evolve to a secondary progressive (SP) subtype (Lublin et al, 2014).  
Clinically isolated syndrome (CIS) is defined as the first clinical manifestation 
of a disease that demonstrates inflammatory demyelination that could be MS, but 
still needs to fulfil the criteria in time (Miller et al, 2005). The clinical 
presentation of CIS and early MS has been reported to affect the prognosis over 
time. Especially, the number of lesions on the magnetic resonance imaging 
(MRI) can have an effect on the course of the disease and those with an abnormal 
scan are on a greater risk of having a second diagnosis-defining episode 
(Morrissey et al, 1993; Jacobs et al, 1997).  
The consensus of the definition of RR MS is: “clearly defined disease relapses 
with full recovery or with sequelae and residual deficit upon recovery; periods 
between disease relapses characterized by a lack of disease progression” (Lublin 
et al, 1996) (Figure 2.1). Nearly 85% of MS patients are diagnosed with RRMS 
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and it is almost twice more likely for females to be diagnosed than males. The 
clinical course of RRMS can last from years to decades and the relapse rate is 
highly variable from patient to patient, with average of one or two episodes per 
year (Trapp & Nave, 2008).  
 
 
 
 
The definition of primary progressive (PP) MS is as follows: “disease 
progression from onset with occasional plateaus and temporary minor 
improvements allowed” (Lublin et al, 1996) (Figure 2.2). Approximately, 15% 
of pwMS are diagnosed with PPMS and the incidence is similar for females and 
males, unlike RRMS. The course of the disease begins later in life compared to 
RRMS and usually relapses are rare or non-existent (Trapp & Nave, 2008). 
Secondary progressive (SP) MS is defined as “initial RR disease course followed 
by progression with or without occasional relapses, minor remissions and 
plateaus” (Lublin et al, 1996) (Figure 2.2). The majority of RRMS patients 
typically after eight to twenty years will enter the next phase of the disease. In 
SPMS stage, there is a continuous and irreversible neurological deficit which is 
Figure 2.1 Multiple sclerosis phenotype description for relapsing disease. 
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not related with the relapses and usually affects quality of life, physical and 
cognitive function (Trapp & Nave, 2008).  
 
 
 
 
2.2.4 Symptoms  
 
Multiple sclerosis is a chronic demyelinating disease of the CNS with its course 
being highly variable with many people developing irreversible disability. The 
initial presentation of MS depends on the location of lesions and the type of onset 
(i.e. relapsing or progressive) (Brownlee et al, 2017). Along the course of the 
disease the symptoms that are frequently reported are fatigue, pain, gait 
impairments, cognitive impairments, spasticity, bladder dysfunction and heat 
sensitivity and these symptoms are discussed in the section below. Gait 
impairments will be discussed in more detail in section 2.3.1. 
 
Figure 2.2 Multiple sclerosis phenotype description for progressive disease. 
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2.2.4.1 Fatigue 
 
Fatigue is a typical symptom of neurological diseases such as multiple sclerosis, 
post-poliomyelitis, post-stroke and chronic fatigue syndrome (Chaudhuri & 
Behan, 2004). In the MS population the prevalence has been reported to be 
68.7%-78%, with a higher percentage of people with progressive MS (81.1%) 
reporting fatigue compared to non-progressive types of MS (64.1%). Fifty-six 
percent of pwMS report that fatigue is the most disabling symptom affecting their 
ability to perform activities of daily living (Bakshi, 2003; Rooney et al, 2019). A 
recent systematic review evaluating the pathophysiological pathways of MS 
fatigue suggested that fatigue mainly originates from a dysfunction of the CNS 
neural circuits such as greater excitability, less inhibition, reduced cortico-
subcortical interaction, secondary to demyelination, increased inflammation and 
axonal lesions (Langeskov-Christensen et al, 2017). These pathophysiological 
pathways have been linked to secondary sources of MS fatigue (i.e. cognitive 
impairments, sleep disturbances and deconditioning) (Langeskov-Christensen et 
al, 2017).  
Despite the impact of fatigue as a disabling symptom in MS population, there are 
no standard definitions of fatigue. Kluger et al (2013) proposed a unified 
taxonomy by differentiating perceptions of fatigue that are ‘subjective sensations 
of weariness and increasing sense of effort’ from fatigability defined as ‘exercise-
induced reduction in the ability of muscles to produce force or power whether a 
task can be sustained’. Measurements of perceived fatigue usually are determined 
through self-reported questionnaires (i.e. Fatigue Severity Scale, Modified 
Fatigue Impact Scale, Fatigue Scale for Motor and Cognitive Functions, etc.) 
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which can be influenced by other symptoms of MS and are completely subjective 
(Rudroff et al, 2016). Objective quantification of fatigability is usually measured 
during motor tasks and is characterized by a decline in peak force or power, 
deceleration of walking speed during endurance walking tests such as the 6-
minute walk test (6MWT) or changes in the kinematic or spatiotemporal 
parameters during gait (Phan-Ba, et al, 2012; McLoughlin et al, 2016; Rudroff et 
al, 2016; van der Linden et al, 2018). The relation between fatigue and fatigability 
is unclear. Some studies failed to show a clear association of self-reported fatigue 
with fatigability which was measured either through recording muscle strength 
of the hand or by maximal voluntary contractions of the thumb (Iriarti & de 
Castro, 1998; Romani et al, 2004). However, other studies have found strong 
associations of perceived fatigue and the decline in force during a sustained 
maximal contraction either of the hand or lower limb muscles (Andreasen et al, 
2009; Steens et al, 2012).  
Fatigability is important to consider in the MS population since it affects the 
ability to perform sustained activities in daily life (Rudroff et al, 2016). Thus far, 
in a number of studies quantifying fatigability it is suggested that the reduced 
performance over time is partly of central origin and that it could be a 
compensatory mechanism for the effects of demyelination on conduction in 
motor pathways (Ng et al, 2004; Thickbroom et al, 2008; Andreasen et al, 2009). 
Some studies have examined fatigability as the reduced performance e.g. walking 
speed during or after longer distance walking tests. People with MS with higher 
disability levels demonstrated greater deterioration either in walking speed or 
 14 
 
kinematic and kinetic parameters during or after the fatiguing tasks compared to 
mildly impaired pwMS (Phan-Ba et al, 2012; Leone et al, 2016).  
In a recent systematic review, Severijns et al. (2017) presented the assessment 
protocols and outcome measures of fatigability and concluded that currently, no 
existing protocol can be recommended for clinical use. This is because no studies 
have compared different protocols to record fatigability and there is limited 
evidence for the psychometric properties of fatigability outcome measures used 
so far. Overall, there is a need for standardization among existing protocols 
assessing fatigability and more importantly to define from the beginning which 
aspect of fatigability is assessed.  
 
2.2.4.2 Pain 
 
People with MS experience pain and it can be generally categorised as 
neuropathic, somatic or psychogenic as well as acute or chronic (Crayton & 
Rossman, 2006). The prevalence of pain in a sample of 1672 patients with MS 
was 18.1% for dysesthetic pain, 16.4% back pain, painful tonic spasms 11%, 
Lhermitte’s sign 9% and trigeminal neuralgia 2% (Solaro et al, 2004). It has also 
been reported that different types of pain experienced by pwMS (i.e. back pain, 
tonic spasms, etc.) are significantly correlated with age, EDSS level, disease type 
and disease duration (Solaro et al, 2004). It has been demonstrated that pwMS 
with pain have greater disability (i.e. higher EDSS), more severe symptoms of 
depression and decreased self-reported overall health compared to pwMS with 
no pain (Ehde et al, 2003). Since pain in MS can be related to various causes (e.g. 
diseases course, spasticity, etc.), managing the symptoms may alleviate pain 
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along with analgesic and anticonvulsant medications if additional relief is needed 
(Crayton & Rossman, 2006). However, a recent systematic review concluded that 
there is limited evidence for non-pharmacological interventions (i.e. 
transcutaneous electrical nerve stimulation, hydrotherapy, transcranial direct 
stimulation, etc.) and this was due to low methodological quality within the 
studies (Amatya et al, 2018). 
 
2.2.4.3 Bladder dysfunction 
 
Bladder dysfunction is a common problem in MS and depending on the severity 
of the neurological disability the report of lower urinary tract symptoms can reach 
up to 75% and usually is rare at onset of the disease (Marrie et al, 2007; Panicker 
& Fowler, 2015). The quality of life of those pwMS with bladder symptoms is 
negatively affected compared to pwMS without any bladder problems and it can 
also be a psychosocial burden to the patients, the carers but also increase the 
healthcare costs (Panicker & Fowler, 2015). Previous studies have demonstrated 
that there is a correlation between bladder and sexual dysfunction in the MS 
population, since sexual response originates from the nerves on the S2, S3 and 
S4 spinal levels where bladder innervation also occurs (Betts et al, 1994; 
Nortvedt et al, 2001). A recent review summarised all the symptoms of the lower 
urinary tract in MS that comprise by storage symptoms (e.g. overactive bladder, 
urinary incontinence, nocturia, etc.) and voiding symptoms (e.g. urinary 
retention, poor stream, etc.) which can affect the quality of life of pwMS 
(Sakakibara, 2019). Non-pharmacologic interventions for the management of 
bladder symptoms include pelvic floor exercises, timed voiding, good fluid 
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intake, but for more severe problems as the course of the disease progresses 
indwelling catheterization or surgical procedures are offered as treatment options 
in order to improve the quality of life of pwMS (Gibson & Frank, 2002; Crayton 
& Rossman, 2006). 
 
2.2.4.4 Heat sensitivity  
 
Over the past century, an ophthalmologist named Wilhelm Uhthoff reported that 
with increased core body temperature there was a worsening of vision and other 
MS-related symptoms. This increase of MS-related symptoms with increasing 
body temperature is called Uhthoff phenomenon (Fraser et al, 2012). It has been 
hypothesized that this phenomenon is a result of damage to the myelin sheath 
which results in axonal conduction block when core body temperature is 
increased (Raminsky, 1973). Heat sensitivity is a common symptom in MS 
population and Flensner et al. (2011) observed that at least 58% of pwMS report 
intolerance to heat. Heat sensitivity has been shown to be a significant correlate 
of many symptoms in the MS population. More specifically, pwMS that are heat 
sensitive reported higher occurrence of symptoms such as fatigue, weakness in 
legs, concentration difficulties and pain compared to pwMS that are not affected 
by sensitivity to increased core body temperature (Flensner et al, 2011). 
However, evidence for the Uhthoff’s phenomenon is non-conclusive. For 
example, although some studies observed effects of heat sensitivity on cognitive 
performance (Hämäläinen et al, 2012), other studies reported no significant 
decrease of cognitive performance in pwMS who had been exposed either to 
exercise or sauna to increase their core body temperature (Sandroff et al, 2016). 
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A number of studies have postulated that a relationship exists between heat 
sensitivity and fatigue. A study comparing resting body temperature in people 
with RRMS and healthy individuals found that pwMS had elevated body 
temperature compared to the healthy population and that this raised body 
temperature was related to fatigue (Sumowski et al, 2014). Similarly, it has been 
suggested that pwMS who are heat sensitive report higher levels of fatigue and 
also decreased participation in physical activity compared to pwMS that did not 
report heat sensitivity (Fjeldstad et al, 2010). Skjerbaek et al. (2013) showed that 
an increase in core body temperature due to exercise was related to increase in 
perceived symptoms by pwMS. 
Even though Uhthoff’s phenomenon may be able to explain the onset of exercise-
induced fatigability, the changes in core temperature might not fully explain why 
fatigability changes over time both during an exercise session and with disease 
progression. It is of great interest to further investigate the presence of Uhthoff’s 
phenomenon in relation to the gait characteristics in pwMS, in order to 
understand the underlying mechanisms of exercise-induced fatigability. 
 
2.2.4.5 Depression 
  
Depression is a common symptom in MS with a lifetime rate reaching to 50% 
and it is related both to the disease itself and the side effects of the disease 
medications (Sadovnick et al, 1996; Crayton & Rossman, 2006). Previous studies 
have investigated the clinical impact of depression in pwMS and it was reported 
that it contributes to decreased cognitive function and quality of life, with 
increased time away from work and long-term affecting general health with 
 18 
 
decreased adherence to treatments (Mohr et al, 1997; Arnett et al, 1999; Wang et 
al, 2000; Beal et al, 2007). Data from a study on the rate of suicides in the MS 
population reported that in 15% of all cases the cause of death was suicide and 
depression was a major risk factor (Sadovnick et al, 1996). Goldman (2005) 
states that the treatment of depression and depressive symptoms in pwMS should 
incorporate both psychotherapy and pharmacological treatment (i.e. 
antidepressants) with a view of the potential adverse effects of certain 
combinations of medications.  
 
2.2.4.6 Cognitive dysfunction 
 
Cognitive impairment is a common symptom in MS and it may occur at any stage 
of the disease course. The prevalence in the relapsing-remitting stage and in those 
with low neurological disability has estimated to be roughly 35%, while in 
secondary and progressive stages the prevalence of cognitive impairment can 
reach 60% (Benedict et al, 2006; Patti, 2009). The most commonly affected 
domains of cognitive function are information processing speed, episodic and 
working memory that usually reflect damage in specific brain regions (Rovaris 
& Filippi, 2000; Benedict & Zivadinov, 2011). A recent systematic review 
summarised the risk factors that could predict cognitive impairment in MS with 
most noteworthy being the early age of disease onset, progressive disease course, 
male sex and low average intelligence, as well as certain health behaviours and 
personality traits, such as smoking (Benedict & Zivadinov, 2011). It has been 
suggested that cognitive impaired pwMS participate less in social activities and 
activities of daily living, have a lower working capacity and are more likely to 
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require personal assistance (Rao et al, 1991; Kalmar et al, 2008). Thus far, even 
though research into cognitive impairments in MS is increasing, there is 
inconsistent evidence for any medical or behavioural therapy to improve 
cognition in MS population (Benedict & Zivadinov, 2011).   
 
2.2.4.7 Spasticity  
 
Spasticity is defined as a ‘velocity-dependent increase in tonic stretch reflexes’ 
and often contributes to the disability in MS (Paisley et al, 2002). Previous 
studies have reported that spasticity affects between 40% and 85% of all pwMS 
(Paisley et al, 2002; Rizzo et al, 2004). A cross-sectional study highlighted that 
higher levels of spasticity were significantly associated with disease duration, 
gait disability and with actively progressing MS (Rizzo et al, 2004). Another 
important aspect of spasticity is the management and treatment in the MS 
population. Often, exercise programs including stretching, aerobic and relaxation 
exercises are used in order to manage spasticity in daily activities (Schapiro & 
Langer, 1994). However, the most common treatment of spasticity is through a 
number of medications such as baclofen, gabapentin and botulinum toxin A 
(Rizzo et al, 2004). Balantrapu et al. (2014) examined the association between 
leg spasticity and walking performance tests and found that pwMS who presented 
with leg spasticity (EDSS mean: 6.0) had worse performance in measures such 
as the 6MWT, timed up and go test (TUG) and the timed 25 foot walk (T25FW), 
along with decreased walking speed and cadence compared to pwMS without leg 
spasticity (EDSS mean: 3.5).  
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2.3 Gait in MS 
 
2.3.1 Gait impairments 
 
As mentioned above, gait impairment is a common symptom in pwMS and this 
may negatively affect participation and quality of life (QoL) in general. Previous 
research has established that 85% of pwMS report gait disturbances during the 
course of the disease (Kelleher et al, 2010; Bethoux & Bennett, 2011) and in 
some cases in an early stage (e.g. within 15 years of disease onset) (Weinshenker 
et al, 1989; LaRocca et al, 2011). It has been reported that 50% of pwMS will 
require assistance for walking within 15 years since diagnosis and that 10% will 
be wheelchair dependent (Kelleher et al, 2010; Kempen et al, 2016). Whilst there 
are various factors that may contribute to gait impairment, the major contributors 
are considered to be sensory changes (proprioception) and resulting poor balance, 
spasticity, ataxia and lower limb muscular weakness (Cameron & Wagner, 
2011).  
A considerable amount of literature has been published on the gait patterns of 
pwMS with different levels of disability. The majority of the studies have 
examined the gait pattern of pwMS based on the spatiotemporal parameters such 
as walking speed and step length, with fewer studies also examining joint 
kinematics in this population. A recent systematic review and meta-analysis 
aimed to identify and quantify gait deficits in pwMS compared to healthy 
population. From the 32 studies included in the meta-analysis it was concluded 
that MS has a significant effect on gait both at a self-selected walking speed and 
increased pace, even in studies including pwMS with relatively low EDSS. 
Further, these detrimental effects on walking speed and stride length were found 
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to be more pronounced in those with higher EDSS levels (Comber et al, 2017). 
However, this systematic review reported only the spatiotemporal parameters and 
not the joint kinematics. Further, the range of EDSS of the pwMS included in the 
studies in the review was relatively broad so conclusions on whether or not 
people with very low EDSS scores (i.e. less than 2.5) also have gait deficits could 
not be drawn from this review. 
The general consensus is that the typical gait pattern of pwMS is to walk more 
slowly, with associated shorter stride and step length and prolonged double 
support phase (e.g. Benedetti et al, 1999; Givon et al, 2009; van der Linden et al, 
2014b). As also concluded in the systematic review by Comber et al. (2017) this 
is true not only for those whose walking ability is affected (EDSS > 4), but also 
in those with minimal disability. Usually, in minimally impaired pwMS (EDSS 
< 3.0) walking ability is not affected in daily life, but through assessment via 
laboratory based measures subtle changes can be observed. It has been 
demonstrated that even minimally impaired pwMS (EDSS < 3.0) walk slower, 
with decreased cadence, decreased step length and stride length, increased stride 
time and increased double support phase (Yahia et al, 2011; Sosnoff et al, 2012; 
Kalron et al, 2011; Kalron et al, 2013; Kalron et al, 2014). These gait deficits has 
been also reported to be evident even in adolescents with MS compared to age-
matched healthy population (Kalron et al, 2017). One of the first studies 
examining the gait characteristics of minimally impaired pwMS (EDSS range: 0-
2) found changes in all of the aforementioned spatiotemporal parameters 
compared to a healthy control group. Kinematic changes revealed increase in hip 
and knee flexion and decrease of ankle dorsiflexion at initial contact at heel strike 
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and there was an increase in hip flexion and in ankle dorsiflexion during the 
swing phase of gait (Benedetti et al, 1999). Other studies also demonstrated a 
decrease of ankle angle at initial contact in pwMS (EDSS < 2.5) compared to 
healthy individuals (Benedetti et al, 1999; Martin et al, 2006; Kelleher et al, 
2010). However, there is no consensus with regard to the hip and knee kinematics 
in pwMS, with some studies reporting increased hip and knee flexion at heel 
strike (Benedetti et al, 1999; Kelleher et al, 2010), whilst other authors reporting 
no significant differences for hip and knee angles in pwMS compared to healthy 
individuals (Martin et al, 2006; Huisinga et al, 2013; Nogueira et al, 2013). Galea 
et al. (2017) investigated gait deterioration over a 12-month period in pwMS with 
EDSS < 3.0 with relapsing remitting MS. Results indicated that this group of 
pwMS had a statistically significant decrease in walking speed, increase in 
double support phase and decrease in cadence, but no significant decrease in step 
length after a one-year period. Interestingly, these changes were not reflected in 
the clinical status measured with the EDSS. Only one study has examined 
differences in the spatiotemporal parameters during jogging and inclined jogging 
between minimally impaired pwMS (EDSS range 0-3.5) and healthy controls 
(Kalron et al, 2014). It was found that in both conditions pwMS exhibited slower 
speed, increased step time duration, decreased step length and increased double 
support phase and step width when compared to a healthy age-matched control 
group (Kalron et al, 2014).   
It is well established from a variety of studies that the gait pattern in pwMS with 
higher disability (EDSS > 3.5) is altered and is similar with the less impaired 
population but with more pronounced changes. It has been shown that pwMS 
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with high EDSS level walk with decreased gait speed, decreased step length and 
cadence, increased step time and step width and increased double support phase 
when compared to healthy individuals (Givon et al, 2009; Kelleher et al, 2010; 
Gianfrancesco et al, 2011; Burschka et al, 2012; Socie et al, 2013). However, few 
studies have failed to demonstrate statistically significant decrease in cadence 
(Morris et al, 2002; Kelleher et al, 2010; Remelius et al, 2012; Nogueira et al, 
2013) and increase in double support phase (Morris et al, 2002; Givon et al, 2009; 
Nogueira et al, 2013) when comparing the MS population with a healthy control 
group. 
Another aspect of gait is gait variability (within-session) mostly reported for 
spatiotemporal parameters. Previous investigations have shown a significant 
increase in step time variability and step length variability in pwMS compared to 
healthy individuals, even at an early stage of the disease with minimal disability 
(EDSS < 3.5) (Flegel et al, 2012; Sosnoff et al, 2012; Socie et al, 2013). 
Conversely, Kaipust et al. (2012) did not observe any statistically significant 
changes in step length and step width variability in pwMS compared to a healthy 
control group, which could possibly be explained by the small sample size (n=10) 
and the varied disability spectrum of MS population included in the study (EDSS 
mean 3.95; EDSS range 1-6). Kalron (2016) reported on gait variability of 
spatiotemporal parameters in a large group of pwMS (n=381) with a wide range 
of disability level (EDSS range 0-6.5). In the lower end of the EDSS (0-3.5) there 
were no significant differences for the gait variability parameters, whereas step 
time variability was significantly increased for the group with EDSS > 4.0 and 
step length variability was significantly increased to the group with EDSS > 5.0. 
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One study examined the variability of kinematics in pwMS with a mean EDSS 
of 3.1 and it was found that there is no significant ankle joint variability measured 
on two different occasions, but there was increased hip, knee and ankle variability 
when comparing the MS population with healthy individuals (Crenshaw et al, 
2006). 
This section has attempted to provide a brief summary of the literature relating 
to gait deficits in pwMS with different levels of disability. Even though there is 
a great amount of research investigating gait abnormalities in pwMS during the 
different stages of the disease progress, there is a need for longitudinal studies to 
examine the deterioration in gait provisionally providing an understanding of 
disease progression.  
  
2.3.2 Gait impairments and fatigability  
 
Fatigability is important to consider in pwMS because it affects the ability to 
perform sustained activities in daily life and to participate in exercise. A recent 
systematic review by Severijns et al. (2017) reported on the protocols and 
outcomes measures used to assess and quantify fatigability in pwMS. It was 
highlighted that based on the International Classification of Functioning (ICF) 
body function level, most studies used repeated maximal isometric contraction 
protocols, while for the ICF activity level (e.g. walking performance) protocols 
inducing changes in performance, such as over a prolonged walking task, were 
predominantly used (Severijns et al, 2017). Further, it was concluded that there 
is no gold standard outcome nor protocol to measure fatigability in MS and 
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fatigability may be influenced by the disability level and the disease phenotype 
(Severijns et al, 2017). 
When focusing on the ICF activity level, most of the existing research has 
evaluated fatigability by the decrease in walking distance covered over a 
prolonged walking task. A study by Phan-Ba et al. (2012) recorded the mean 
walking speed and the deceleration index in a large group of pwMS (EDSS range 
0-6) compared to healthy individuals over a timed 100 meter walk (T100mW) 
and a timed 500 meter walk (T500mW). It was demonstrated that all subgroups 
of pwMS had a significantly lower mean walking speed compared to the healthy 
control group. The deceleration index was lower for the whole group of pwMS 
(i.e. EDSS < 2.0, 2.5-3.5, > 4.0) compared to the control group but it was not 
significant (Phan-Ba et al, 2012). The same pattern was observed in studies with 
pwMS with EDSS ranging from 0-6.5 (i.e. groups were divided based on the 
disability level) over the duration of a 6MWT with a decline in the walking speed 
in minute six compared to minute one (Burschka et al, 2012; Leone et al, 2016). 
Conversely, McLoughlin et al. (2016) reported no significant difference in 
walking speed before and directly after a 6MWT in pwMS with EDSS ranging 
from 3-6 and further no significant differences between pwMS compared to 
healthy individuals throughout the length of the test. Recent studies have been 
carried out to assess fatigability by the distance covered mostly over a 6MWT. A 
large cross-sectional multinational study (n=208) in pwMS with moderate 
disability (EDSS mean: 4.2; range: 0-6.5) investigated the distance walk index 
(DWI) over the duration of a 6MWT (Leone et al, 2016). It was reported that 
there was a significant decrease of the DWI from minute two to minute six and 
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further analysis  revealed a significant interaction between groups with different 
EDSS level and time of the 6MWT on the DWI showing that pwMS had a 
different pattern of DWI over the duration of the 6MWT, i.e. those with higher 
EDSS scores had increased DWI compared to those lower EDSS scores (Leone 
et al, 2016).  Likewise, similar studies evaluating fatigability with the decline in 
walking distance in pwMS with moderate disability (EDSS > 3.5), demonstrated 
a significant decrease of DWI throughout the course of the 6MWT (Dalgas et al, 
2014; Proessl et al, 2018).  
 Studies evaluating gait kinematics over the duration of the 6MWT or protocols 
of walking to exhaustion have reported mixed results. In a study with 15 pwMS 
(EDSS range: 4-6) who were using assistive devices (i.e. FES or AFOs), it was 
found that there was a significant decline in peak dorsiflexion in swing at the end 
of the 6MWT compared to the start, but there was no significant difference for 
the ankle angle at initial contact (van der Linden et al, 2018). Similarly, 
McLouglin et al. (2016) in a similar population group (EDSS range: 3-6) reported 
a significant decrease of ankle angle at initial contact at the end of a 6MWT with 
no significant differences in other phases of the gait for the ankle joint, with these 
changes potentially leading to trips and falls. Deterioration of gait kinematics has 
also been reported after a task involving walking until a rate of perceived exertion 
(RPE) of 17 (‘very hard’) or until 60 minutes had elapsed. The authors used a 
cut-off value on the Fatigue index Kliniken Schmieder (FKS) (i.e. score is based 
on three-dimensional acceleration measurements of two leg markers) and 
reported that just over 70% of the group of pwMS (EDSS range: 1-5.5) exhibited 
fatigability based on their kinematic changes (Sehle et al, 2014).    
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Although these studies contribute in several ways to our understanding of 
fatigability and how it affects the walking ability in pwMS, there is a need for 
standardized fatiguing protocols in order to emulate activities of daily living and 
outcomes measures that are reliable to capture this phenomenon. Thus far, to the 
authors’ knowledge, no studies have investigated fatigability-induced gait 
changes in kinematic parameters in pwMS with EDSS < 3.5, which could 
potentially be used as a prognostic biomarker if fatigability-induced gait 
deterioration worsens over time.  
 
2.3.3 Foot drop 
 
Foot drop is a common gait impairment in pwMS and is the lack of dorsiflexion 
during the swing phase of gait (Figure 2.3). Foot drop can be caused by an 
increased tone in the plantaflexor muscles, weakness of the dorsiflexor muscles 
and impaired neural control causing co-contraction of agonist and antagonist 
muscles (Barret et al, 2009). Weakness of the dorsiflexor muscles can be a direct 
result of MS; damage to the nerves can slow down or disrupt messages, mainly 
in the spinal cord, making it more difficult to use this muscle group effectively 
(Kent-Braun et al, 1994). Foot drop can also be temporary phenomenon because 
of fatigue of the dorsiflexor muscles after walking a certain distance or exercise 
(Mount & Dacko, 2006).  
Even though foot drop is common in many CNS disorders, the mechanisms 
contributing to foot drop in MS compared to non-progressive disorders (i.e. 
stroke) might differ. For example, stroke occurs after a sudden interruption of the 
blood flow in a specific area in the brain and the ischemic area will determine the 
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type of the deficits (Friedman, 1990). Whilst, for MS, since it is a 
neurodegenerative disease, foot drop could be a result of an interruption of neural 
transmission due to inflammation and demyelination of the myelin sheath and 
axons in the brain and spinal cord (Compston & Coles, 2008).   
 
Figure 2.3 The gait cycle of the ankle of a healthy individual (green) and a person with 
MS (blue: baseline, red: after a 6MWT), with dotted line indicating the toe-off time point 
of the healthy person. 
 
It has been demonstrated that foot drop can lead to foot dragging, tripping and 
falling (Gunn et al, 2014).  People with MS experiencing foot drop may also have 
increased fear of falling that could lead to a decline of habitual activity and 
increased sedentary time, which could have long-term negative implications in 
their general health (Peterson et al, 2007). In order to compensate for foot drop, 
whether permanent or temporary, pwMS may adopt strategies such as 
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circumduction and hip-hiking which may result in an increased effort of walking 
compared to healthy individuals (Paul et al, 2008).  
The prevalence in foot drop in MS population has not been established. However, 
as part of this PhD, an audit was conducted during the period from September 
2016-December 2018, in order to investigate the frequency of transient foot drop, 
activities that initiate transient foot drop and other characteristics such as when it 
comes on and how long it takes for the transient foot drop to disappear. More 
details with regard the methods and a table of the full results can be found in 
Appendix 1. In summary, of the 47 respondents who returned the audit, 70% 
reported experiencing temporarily foot drop. The majority of people reported that 
foot drop initiates after walking for an average of 1.6 miles or around 20 minutes, 
while foot drop could initiate earlier if the people were walking/exercising faster 
or if they were fatigued. People also reported that foot drop starts after running, 
cycling or climbing stairs and that they have to stop their activities (n=16) or slow 
down (n=18). The average time for recovery was reported to be 32 min with a 
range from one to ninety minutes.  
As the disease progresses, foot drop often becomes more established and 
recovery does not occur anymore. If this occurs, several treatment options exist 
which aim to maintain function in daily activities and quality of life and reduce 
the risk of tripping and falling. The most common treatments for foot drop and 
their impact on the walking ability of pwMS will be discussed in more detail in 
the next section.  
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2.3.4 Treatments for foot drop  
 
Conventionally, foot drop has been treated with physiotherapy, such as gait 
training or strengthening exercises for the dorsiflexor muscles. It has been 
demonstrated that people presenting foot drop secondary to MS after endurance 
exercise of the dorsiflexor muscles had an improvement of dorsiflexors control 
during walking (Mount & Dacko, 2006). The most common way though, is 
through AFOs and in recent years FES has been gaining popularity.  
An AFO is the first line treatment for foot drop and in the UK is funded by the 
NHS. It can have different forms and comprised by different materials, but 
always consists of a foot plate and a shin section and can be custom-made for 
each individual in order to produce the optimal effects (Wening et al, 2013). 
Existing evidence report that the use of AFOs can reduce the energy cost of 
walking and can improve static and dynamic balance (Bregman et al, 2012; 
McLoughlin et al, 2015). However, the use of AFOs has not been shown to 
significantly increase the walking distance or decreasing the perceived fatigue in 
pwMS with moderate disability (McLouglin et al, 2015). A qualitative study by 
Bulley et al. (2015) explored the impact of AFOs on pwMS who presented foot 
drop. People with MS reported that the use of AFO reduced tripping and falling, 
provided great stability and balance, but it was enhancing a non-normal gait 
pattern, was more cumbersome, and discomfort in use (Bulley et al, 2015).  
Functional Electrical Stimulation is increasingly used to treat foot drop in 
neurological disorders such as stroke and MS. Stimulation is applied through 
surface or implanted electrodes over the common peroneal nerve and the motor 
point of the tibialis anterior muscle to produce enough dorsiflexion of the ankle 
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during the swing phase of gait (Burridge et al, 1997). It has been suggested that 
regular use of FES can strengthen the activation of motor cortical areas and their 
residual descending connections that might explain possible therapeutic effects 
of FES on walking speed (Everaert et al, 2010). In two recent qualitative studies, 
the majority of pwMS reported that the use of FES reduces perceived fatigue and 
the mental effort of walking, improves the gait pattern, increases confidence and 
physical activity, but there is a difficulty in the placement of the electrodes with 
negative financial implications (Bulley et al, 2015; (Miller) Renfrew et al, 2018).  
A large and growing body of literature has investigated the effects of FES on 
walking performance in pwMS. The effects of FES are more commonly 
described in terms of orthotic and training effects. An orthotic effect is described 
as the change in walking performance with and without FES. The initial orthotic 
effect is the change in performance with and without FES the first day of its use, 
while the continuing orthotic effect is the change in walking with and without 
FES at a follow up point after a period of regular use of the device. The total 
orthotic effect represents a combined training and direct effect of the use of FES 
and is the change in walking with FES at a follow-up point compared to walking 
without FES at the beginning of the treatment (Taylor et al, 2013).  The training 
effect is the change of walking performance without FES at a follow-up point 
after regular use of FES relative to the walking performance without FES at the 
beginning and it describes the impact of regular use of FES on walking over time 
(Taylor et al, 2013).  
The greater part of the literature investigating the orthotic and training effects of 
FES for foot drop in MS has focused on changes in spatiotemporal parameters of 
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gait and primarily walking speed over short or long distance walking tests, with 
fewer studies examining changes in gait kinematics. Many studies have 
investigated the initial orthotic effect of FES and reported that there is a positive 
effect on walking speed (i.e. increased walking speed with FES on compared to 
without FES) mostly over short distance walking tests such as the 10-meter walk 
test (10mWT) (Taylor et al, 1999; Paul et al, 2008; Barrett & Taylor, 2010; Scott 
et al, 2013; Downing et al, 2014). Miller et al. (2016) investigated the effect of 
FES in pwMS walking at self-selected walking speeds (SSWS). It was reported 
that pwMS with SSWS < 0.8m/s had significant improvements in the walking 
speed and oxygen cost of gait with the use of FES, whilst the group of pwMS 
with SSWS > 0.8m/s did not show significant differences in walking speed with 
the use of FES (Miller et al, 2016). There are several possible explanations for 
this result, such as the higher disability status (EDSS mean: 6.0) and the potential 
adjustment to the energy demands of FES of the group with SSWS < 0.8m/s who 
used FES for a longer period of time compared to the pwMS with SSWS > 
0.8m/s.  A recent meta-analysis on the effects of FES on walking speed also 
concluded that there is a statistically significant initial orthotic effect of FES in 
foot drop in pwMS over short distance walking tests, but only small non-
significant initial orthotic effects over longer distance walking tests (Miller et al, 
2017). A possible explanation of this might be the presence of fatigability over 
longer distance walking tests and the benefits of FES might not be sufficient to 
overcome the gait deterioration. Studies examining changes in gait kinematics 
have reported that there is a significant increase in peak dorsiflexion in swing and 
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at ankle angle at initial contact with the use of FES compared to walking without 
FES (Scott et al, 2013; van der Linden et al, 2014a; van der Linden et al, 2014b).  
The training effect of FES on walking performance in pwMS has also been 
documented, although in fewer studies and not with consistent findings. A study 
examining the training effect of FES, indicated improvements in ankle angle at 
initial contact when walking without FES at the end of 12-week period compared 
to unassisted walking at baseline (van der Linden et al, 2014a). Stein et al. (2010) 
investigated the long-term training effect of FES over an 11-month period in both 
progressive (MS) and non-progressive (stroke) conditions. It was demonstrated 
that there is an improvement in walking speed over a 10mWT and a 4-minute 
walk test at 3-month follow-up for both stroke and MS patients, but at the 11-
month follow up a training effect was seen only the stroke population (Stein et 
al, 2010). Contrary to these findings, studies evaluating the training effect of FES 
for periods ranging from 18-20 weeks have failed to find significant changes in 
walking speed over short distance walking tests (Barrett et al, 2009; Barrett & 
Taylor, 2010; Street et al, 2015). Even though Street et al. (2015) did not observe 
a significant training effect of walking speed after 20 weeks of FES used, 31% 
of the participants achieved a clinically meaningful training effect (> 0.05m/s). 
Training effects have been consistently found in non-progressive conditions, 
such as stroke (Kafri & Laufer, 2014). However, this has not been the case for 
MS, which can partly be explained by the inflammatory and degenerative course 
of the disease.  
A number of authors have also shown that the use of FES can have a beneficial 
effect on the quality of life and the perceived walking ability of pwMS, with 
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improvements in activities of daily living and reducing the number of falls 
(Barrett & Taylor, 2010; Esnouf et al, 2010; Mayer et al, 2015). These perceived 
benefits of FES for foot drop have the potential to increase social participation, 
community mobility and daily activity for these individuals. One of the perceived 
benefits that pwMS report is the reduced concentration and mental effort during 
walking (Bulley, et al, 2015; (Miller) Renfrew et al, 2018). Thus far, these 
perceived benefits of FES have not been quantified and the aim of Chapter 6 is 
to explore the benefits of FES under dual-task and fatiguing conditions that 
pwMS experience daily.  
 
2.4 Psychometric properties and outcome measures  
 
2.4.1 Psychometrics of outcome measures 
 
Psychometric properties of outcome measures are essential information in both 
research and clinical practice. Outcome measures are utilized to provide 
information on a patient’s status, which can predict the success or failure of a 
treatment or an intervention based on the scores obtained (Mokkink et al, 2010a). 
Therefore, outcome measures need to have robust psychometric properties, such 
as reliability, validity and responsiveness, to allow for correct interpretation of 
the results. However, there is a lack of consensus about the definition and 
terminology used to describe measurement properties, along with how these 
measurement properties should be assessed (Terwee et al, 2012). The 
COnsensus-based Standards for the selection of health Measurement 
INstruments (COSMIN) initiative was developed in order to reach consensus on 
how these measurement properties should be defined (Table 2.2) and to develop 
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standards of how these measurement properties should be evaluated in terms of 
study design and statistical analysis (Mokkink et al, 2012). If the methodological 
quality of a study on measurements properties of an outcome measure is 
appropriate, the results can be more robust for use of the specific outcome 
studied, whilst if the methodological quality of a study is inadequate the results 
cannot be trusted and the quality of the outcome measure remains unclear 
(Higgins & Green, 2008). The COSMIN taxonomy proposes three main domains, 
which are reliability, validity and responsiveness and each domain contains one 
or more measurement properties (Mokkink et al, 2012). 
2.4.1.1 Reliability  
 
The overall definition of the reliability domain is the extent to which the scores 
of patients that have not changed are the same for repeated measurements and 
the degree to which the measurement is free from measurement error (Mokkink 
et al, 2010b). The reliability domain is sub-divided in three measurement 
properties, which are internal consistency, reliability and measurement error. 
Reliability and measurement error will now be considered in more detail given 
the focus of Chapter 4.  
The reproducibility of the results when a test is assessed in a repeated measures 
design over time is known as test-retest reliability; inter-rater reliability is when 
a test is implemented by different persons on the same occasion and intra-rater 
reliability is assessed when comparing the results from the same rater on different 
occasions (Mokkink et al, 2010b). 
The consistency of the results is considered the degree to which the results do not 
change over repeated measurements, whereas agreement refers to how close the 
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results of repeated measurements are, by estimating the measurement error over 
repeated measurements (de Vet et al, 2006b). 
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Table 2.2 Definitions of domains and measurement properties adapted by Mokkink et al. (2010b). 
Domain  Measurement 
property 
Definition  
Reliability   The degree to which the measurement is free from measurement error:  
The extent to which scores for patients who have not changed are the same for repeated 
measurement under several conditions, e.g. using different sets of items from the same 
health related patient-reported outcomes (HR-PROs) (internal consistency), over time 
(test-retest) by different persons on the same occasion (inter-rater) or by the same 
persons on different occasions (intra-rater)  
 Internal consistency  The degree of interrelatedness among the items 
 Reliability  The proportion of the total variance in the measurements which is because of ‘true’ 
differences among patient 
   
 Measurement error  The systematic and random error of a patient’s score that is not attributed to the true 
change in the construct to be measured 
Validity   The degree to which an instrument measures the construct(s) it purports to measure 
 Content   The degree to which the content of an instrument is an adequate reflection of the 
construct to be measured  
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Domain  Measurement 
property 
Definition  
 Construct  The degree to which the scores of an instrument are consistent with hypotheses (i.e. with 
regard to internal relationships, relationships to scores of other instruments or 
differences between relevant groups) based on the assumption that the instrument 
validly measures the construct to be measured  
 Criterion  The degree to which the scores of an instrument are an adequate reflection of a ‘gold 
standard’ 
Responsiveness   The ability of an instrument to detect change over time in the construct to be measured  
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Intra-Class correlation coefficients (ICC) are the most common method used to report 
reliability of an outcome measure in terms of its consistency. The ICC value obtained, 
between -1 and +1, demonstrate the strength of the relationship but also the direction. Zero 
values indicate no relationship, with ICC values of ≥ 0.75 regarded as excellent level of 
practical and clinical significance for reliability, while ‘good’ was between 0.60-0.74 and 
‘fair’ between 0.40-0.59 (Shrout & Fleiss, 1979; Cicchetti, 1994). Several ICC models 
exist and it is important to choose the correct one depending on the number of raters or 
tests included in the analysis (Shrout & Fleiss, 1979; Koo & Li, 2016). Two other methods 
of analysis are sometimes used to report consistency that are the Pearson correlation and 
Kappa coefficient (Streiner et al, 2014). Pearson’s correlations are used to assess the 
relationship between two sets of results. It has been suggested that Pearson coefficient is 
inadequate to use as it measures the linear relationship and not systematic differences 
(Streiner & Norman, 2008). Kappa coefficient is most appropriate when only two levels 
of outcome are expected; for example, when something is either present or absent in a test 
result (Streiner et al, 2014). Reliability parameters are highly dependent on the variation 
of the sample population and can be generalizable only to populations with similar 
variation (de Vet et al, 2006b). 
Measurement error (i.e. absolute agreement) is any systematic and random errors that are 
not attributed to true change in the construct to be measured (Mokkink et al, 2010b). 
Agreement parameters are a characteristic of the instrument itself and are expressed on 
the actual scale of the instrument (de Vet et al, 2006b). The indices that are widely used 
to assess measurement error are the standard error of measurement (SEM), minimal 
detectable change (MDC) or smallest detectable change (SDC) and the limits of agreement 
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(LoA) obtained through the Bland and Altman plots.  The SEM represents the variance 
between subjects or measurements and equals to the square root of the error of variance. 
The clinical interpretation of the SEM can be expressed as the MDC, as it provides 
information of the cut-off point above which a change can be regarded as ‘true’ change 
(de Vet et al, 2006b). The Bland & Altman plot was developed to describe the agreement 
between two different instruments or the repeatability of one instrument on repeated 
occasions. The graph is produced by plotting the mean difference of each of the 
participants data against the difference in their scores on the same two occasions and any 
systematic differences or obvious outliers can be seen graphically (Bland & Altman, 
1999).  
 
2.4.1.2 Validity  
 
According to the COSMIN taxonomy, the overall definition of validity is the degree to 
which an instrument measures the construct(s) it purports to measure. The three sub-
divisions in this domain address slightly different aspects of validity (Mokkink et al, 
2010b). Content validity, which is relevant mostly for questionnaires, is the degree to 
which the content of an instrument is an adequate reflection of the construct to be 
measured (Guyatt et al, 1993). The degree to which the scores of an instrument are 
consistent with the hypotheses (i.e. with regard to internal relationships, relationships to 
scores with other instruments or differences between relevant groups) is defined as 
construct validity. Criterion validity is the degree to which the scores of an instrument are 
an adequate reflection of a gold standard (Mokkink et al, 2010b). The most common 
method of analysis for validity is either the Pearson correlation or the Spearman’s rank 
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correlation coefficient. The strength of correlations is regarded as small if the values are 
between 0.1-0.3, moderate if they are between 0.3-0.5 and strong between 0.5-1.0 
(Portney & Watkins, 2000).  
 
2.4.1.3 Responsiveness  
 
The term responsiveness is defined as the ability of an instrument to detect clinically 
important changes over time, even if these changes are small (Guyatt et al, 1989). It has 
been considered by some to be a component of longitudinal validity (Terwee et al, 2003). 
However, Kirschner & Guyatt (1985) specified that an outcome measure has three 
properties; firstly reliability which characterizes intra-subject variability, secondly 
validity which outlines that any changes detected should be consistent with an external 
standard and finally responsiveness which should detect clinically important changes. 
There are several indices that measure the magnitude of change, such as effect size (ES), 
standardised response mean (SRM), paired t-tests, the Guyatt Responsiveness Index 
(GRI) and the Receiver operating characteristics (ROC) curve (Terwee et al, 2007). 
Another measure for responsiveness is the minimal clinically important difference 
(MCID) that provides information of how much change is enough change in an outcome 
measure to detect change in a clinical condition and focuses at an individual level (Terwee 
et al, 2007). Sensitivity to change to a treatment is seen as a characteristic of both the 
treatment and the variance of the population tested, and therefore responsiveness of an 
outcome measure is distinct for each clinical population (Beckerman et al, 2001).  
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2.4.2 Outcome measures of walking performance in MS and psychometric properties 
 
As mentioned in a previous part of this literature review, deterioration of gait is a common 
symptom in pwMS as it affects mobility and quality of life. Therefore, measurement of 
gait is a critical part of a patient’s assessment, as it can provide information into the clinical 
disease status and assess the efficacy of symptomatic and rehabilitation therapies. The 
outcome measures used to assess walking performance need to demonstrate robust 
psychometric properties, in order to allow meaningful interpretation of the results. Further, 
the feasibility of administering walking assessments (i.e. equipment and personnel 
needed), space and time requirements of both personnel and patients need to be regarded 
(Bethoux & Bennett, 2011). Particularly, in pwMS the interpretation of changes in scores 
of walking performance outcomes may be challenging due to the nature of the disease 
with fluctuations in performance from day to day, or time of the day being assessed and 
the presence of other impairments along with fatigue (Albrecht et al, 2001; Morris et al, 
2002; Crenshaw et al, 2006). As a result of this intrinsic variability the reliability of a 
walking performance outcome might be affected, and therefore studies examining 
reliability of an outcome measure should consider taking into account the disability or 
walking impairments level of the MS population.  
Various outcome measures have been utilized to evaluate walking performance in the MS 
population, by either self-reported questionnaires and rating scales or quantitative 
measures of gait characteristics such as motion analysis. Before the start of this PhD, two 
narrative reviews had summarised the outcome measures that have been used to assess 
walking performance in the MS population and provide more insight into their 
psychometric properties (Bethoux & Bennett, 2011; Kieseier & Pozzilli, 2012).  
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2.4.2.1 Clinical rating scales and self-reported outcomes of walking performance  
 
The EDSS in MS is the most common instrument to characterize disability and disease 
progression (Kurtzke, 1983). Walking ability is assessed in the middle range of the scale 
(4-7.5) and is based on the maximum distance walked by a patient. The characterization 
of disability with EDSS must be interpreted cautiously in this range, since there is a wide 
variability in the walking distance due to day to day fluctuations in a patient’s performance 
(Albrecht et al, 2001) or in environmental factors that can affect the distance walked. 
Interestingly, there is limited evidence for the psychometric properties of EDSS, 
demonstrating validity but generally poor reliability and responsiveness to change 
(Sharrack et al, 1999; Hobart et al, 2000). Even though EDSS is a useful instrument to 
assess disease severity in MS, it should probably not be used as an outcome to measure 
walking ability in routine clinical assessment (Bethoux & Bennett, 2011).  
The Hauser Ambulation Index (HAI) converts ambulation-related disability based on the 
T25FW into an ordinal scale. It is a 10-point scale (0-9), with 0 representing no 
impairment and 9 representing confinement to wheelchair and inability to transfer 
independently (Hauser et al, 1983). It has been demonstrated that the HAI exhibits 
excellent reliability, but it has shown weak responsiveness to clinical change (Sharrack et 
al, 1999). The HAI is useful tool to classify pwMS based on their walking performance 
and it is easier to administer than EDSS, although the weak responsiveness makes it less 
suitable for measuring performance after interventions (Bethoux & Bennett, 2011). 
The 12-Item MS Walking Scale (MSWS-12) was originally developed as patient-reported 
based outcome to capture the impact of MS on walking ability. It contains 12 items with 
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Likert-type responses with a recall period of two weeks. The higher the score, the greater 
the impact on walking ability (Hobart et al, 2003). The psychometric properties have been 
extensively examined in diverse MS population and in both community and hospital 
settings. The MSWS-12 has been shown to have strong internal consistency, excellent 
reliability, validity, and good generalizability and responsiveness to change (Hobart et al, 
2003; McGuigan et al, 2004; Motl & Snook, 2008; Baert et al, 2014; Learmonth et al, 
2013a; Andreopoulou et al, 2018). Comparing the MSWS-12 with other measures of 
physical and cognitive domains, showed stronger correlations with measures of physical 
domain that relate to mobility and lower extremity function (Motl et al, 2008). A strong 
correlation was found between the MSWS-12 and the EDSS between 1 to 4.5, whilst a 
weak correlation with EDSS scores ranging from 5 to 8. A strong correlation has been 
shown also with accelerometer counts and the MSWS-12, suggesting that there is a 
relationship between perceived and objective walking ability (Motl et al, 2008).  
The Rivermead Visual Gait Assessment (RVGA) is a measure of gait performance that 
was developed for clinical use in patients with neurologic diseases. It comprises of 20 
items that are scored in a 4-point scale (0: normal; 3:severe) depended on the joint 
movements during the swing and stance phase of gait (Lord et al, 1998). The RVGA has 
demonstrated good inter-rater and intra-rater reliability and sensitivity to treatment effects 
(Lord et al, 1998).  
 
2.4.2.2 Objective timed walking tests 
 
Objective walking tests can provide a quantitative measure of walking performance, either 
by recording the walking speed or the walking distance covered. There are short- and long-
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distance walking tests and even though they are not disease-specific they have been 
extensively utilized in the MS population.  
The T25FW was initially seen as part of the HAI (Hauser et al, 1983) and was later 
integrated as part of the Multiple Sclerosis Functional Composite (MSFC) along with the 
nine-hole peg test (9-HPT) and the paced auditory serial addition test (PASAT) (Fischer 
et al, 1999). The person is asked to walk as fast and safely as he/she can across a line of 
25ft. course without turns and the time to complete the task is recorded. Even though it 
was not designed as a disease-specific outcome for the MS population, it has been used 
widely in clinical and research settings and has been extensively examined for its 
psychometric properties. It has been found to have excellent test-retest, inter-rater and 
intra-rater reliability, with no apparent practice effects (Rosti-Otajarvi et al, 2008; 
Learmonth et al, 2012; Learmonth et al, 2013a; Hobart et al, 2013). The T25FW has been 
reported to have strong correlations with the MSWS-12, the 6MWT and the 100m walk 
test (Goldman et al, 2008; Cavanaugh et al, 2011; Phan-Ba et al, 2011; Hobart et al, 2013). 
The responsiveness of the T25FW has been examined after interventions, such as 
intravenous methylprednisolone (IVMP), dalfampridine or fampridine treatments and 
physical rehabilitation, and has been able to capture clinically important changes of the 
walking ability (van Winsen et al, 2010; Filipovic et al, 2011; Coleman et al, 2012; Baert 
et al, 2014; Jensen et al, 2016). There is a broad acceptance that a 20% change in the time 
taken to complete the T25FW is a meaningful change in walking performance in the MS 
population (Kragt et al, 2006; Coleman et al, 2012; Hobart et al, 2013; Cohen et al, 2014).  
Another short distance walking test that has been widely used in the MS population to 
assess the walking performance is the 10mWT. The person is instructed to walk either at 
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a self-selected or at a fastest speed in a 10m course. The inter-rater and test-retest 
reliability have been found to be high for the 10mWT both at normal and fastest walking 
speeds (Vaney et al, 1996; Nilsagard et al, 2007; Paltamaa et al, 2005; Feys et al, 2014). 
It was reported that there is a strong correlation between the 10mWT and the 6MWT at 
both normal and fast speeds (Gijbels et al, 2012). Strong correlations were observed with 
measures of participation such as the Frenchay Activities Index (FAI) and accelerometer 
counts (Kierkegaard et al, 2011; Stellman et al, 2015), but only weak correlations were 
reported with self-reported fatigue (Morris et al, 2002). The 10mWT has demonstrated 
adequate responsiveness in both mildly disabled pwMS and in patients with EDSS range 
0 to 6 (Nilsagard et al, 2007; de Groot et al, 2006). However, many studies that have 
examined responsiveness of the 10mWT did not apply any interventions in the interim 
period, in order to record clinically meaningful changes (Paltamaa et al, 2008; Kempen et 
al, 2011; Freeman et al, 2013). These short distance walking tests (i.e. 10mWT, 30mWT, 
etc.) have various starting instructions (static vs dynamic) and pacing rhythms (normal vs 
fast). The differences in administration can affect the results of the assessments and 
therefore a more unified protocol would be useful to compare results among studies 
(Graham et al, 2008). 
Longer distance walking tests are commonly record the total distance walked as a measure 
of walking performance. The most widely used test is the 6MWT in which the person is 
asked to walk for six minutes at a maximal speed either in straight, square or ellipse course 
which involves turns (Goldman et al, 2008). The 6MWT has demonstrated excellent test-
retest and inter-rater reliability (Paltamaa et al, 2005; Fry et al, 2006; Goldman et al, 2008; 
Feys et al, 2014), with an MDC of 76.2m for pwMS with EDSS range 5-6.5 (Learmonth 
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et al, 2012) and an MDC of 88m for pwMS with mild to moderate disability (Learmonth 
et al, 2013a). It has been shown to have strong correlations with EDSS level and the MSFC 
and with self-reported measures such as the MSWS-12 (Goldman et al, 2008). Several 
studies have examined the responsiveness of the 6MWT and it was found that it is a 
sensitive tool to capture clinically meaningful changes over time (Paltamaa et al, 2008; 
Baert et al, 2013; Freeman et al, 2013). However, pwMS that experience severe fatigue 
and with moderate or severe disability levels, walking for six minutes can be exhausting 
and they might have to rest during the test. It has been suggested that the 6MWT is most 
likely a measure of walking endurance (Bethoux & Bennett, 2011). An alternative is the 
2-minute walk test (2MWT), in which the same protocol applies by walking at maximal 
speed for two minutes and the distance covered is recorded (Gijbels et al, 2011). Its 
psychometric properties have not been extensively documented in MS population, but few 
studies that have examined them reported good reliability and responsiveness to change 
after IVMP therapy or physical rehabilitation interventions but no MICD values have been 
reported (Filipovic et al, 2011; Baert et al, 2013; Feys et al, 2014). 
 
2.4.2.3 Quantitative gait analysis 
 
Walking performance tests are widely used and are simple in administration in clinical 
and research settings, but their main drawback is that they detect only deviations from 
normal walking (i.e. decreased walking speed or walking distance) and its variation over 
time without providing information on the gait pattern and thus possible underlying 
mechanisms (Bethoux & Bennett, 2011).  
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Three-dimensional gait analysis (3DGA) through motion capture systems has been 
considered the ‘gold’ standard in terms of quantitative gait analysis (Bethoux & Bennett, 
2011; Cofré Lizama et al, 2016) and it is one of the most common outcome measures used 
in MS population (Andreopoulou et al, 2018). The 3DGA utilizes camera systems to track 
marker trajectories of passive (e.g. Vicon, Oxford, UK) or active infrared emitting diode 
(e.g. Optotrak, NDI, Waterloo, Canada) markers that are placed on anatomical landmarks 
of the lower limbs. Many studies have reported gait deterioration based on kinematics 
changes even in minimally affected pwMS at an early disease stage (Martin et al, 2006; 
Sosnoff et al, 2012; Galea et al, 2017). However, the space and time requirements, cost of 
equipment and the complexity of data analysis have been reported as drawbacks for its 
use in a clinical setting for routine gait assessments (Bethoux & Bennett, 2011). A recent 
topical review on the use of gait analysis in pwMS suggested that gait measures obtained 
by 3DGA could potentially be used as sensitive biomarkers not only of mobility, but also 
of disease progression since they allow a better understanding of underlying mechanisms 
of walking disability that cannot be detected by conventional spatiotemporal parameters 
of gait (Cofré Lizama et al, 2016). However, evidence of the psychometric properties of 
3DGA in MS population is lacking (Andreopoulou et al, 2018).  
Another outcome measure that have been used in the MS population to quantify gait 
impairments is the GAITRite (CIR System, Inc, Havertown, PA). It consists of an 
instrumented walkway with sensors to identify footfall contacts, enabling the 
quantification of spatiotemporal parameters of gait (Cutlip et al, 2000). Spatiotemporal 
parameters measured by the GAITRite have shown a strong correlation with the T25FW 
and with EDSS (4-6), but only moderate correlation with the MSWS-12 (Sosnoff et al, 
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2011b). Further investigation of its reliability and responsiveness is needed, in order to 
potentially be used to capture changes in the context of rehabilitation or research practice.  
 
2.4.2.4 Outcomes of walking performance and measures of participation in daily life 
 
Pedometry and accelerometry have been used to detect movement by either counting of 
the steps or by monitoring movement in more dimensions. They have been utilized in 
studies with pwMS to provide an objective assessment of physical activity (Pearson et al, 
2004; Gosney et al, 2007; Motl et al, 2007). Motl et al. (2007) reported that the use for 
seven days of either an accelerometer or pedometer is a reliable measure (ICC=.93) to 
estimate physical activity in MS population, with a minimum of three days yielding an 
ICC of 0.80. Moreover, it has been demonstrated that habitual walking performance (i.e. 
amount of steps in a customary environment based on accelerometry) was significantly 
predicted by walking tests such as the 2MWT and the 6MWT (Gijbels et al, 2010). Further 
validation and examination of the responsiveness to changes have not been investigated 
in MS population (Bethoux & Bennett et al, 2011), which is of importance with regard to 
day-to-day variability in MS. 
 There is no ‘gold’ standard measure to assess walking performance in pwMS and is 
important that both clinical and patient perspectives are taken into account to evaluate 
function and disease status. Three-dimensional gait analysis is often considered the ‘gold’ 
standard to assess even minimal changes in walking performance and has been widely 
used in the MS. However, its psychometric properties has not yet been investigated in 
pwMS. It is of major importance that all outcome measures used to evaluate walking 
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performance are psychometrically sound in order to provide robust information to both 
clinician and researchers.  
 
2.4.3 Outcome measures of fatigue and fatigability in MS and psychometric properties 
 
Fatigue is one of the most debilitating symptoms in pwMS, with high prevalence rates as 
mentioned previously. However, there are challenges in the evaluation of fatigue because 
of the subjectivity and the multidimensionality of the symptom (Flachenecker et al, 2002). 
Perceived fatigue is measured through self-reported instruments where people rate or 
describe the impact or severity of their fatigue. Performance-based fatigability is assessed 
after a period of sustained level of physical performance (Kluger et al, 2013). 
The measurement of fatigability can be valuable for both clinical and research purposes. 
The majority of the studies evaluating fatigability have used either sustained maximal 
contractions of the thumb or lower limb muscles (de Haan et al, 2000; Ng et al, 2004; 
Andreasen et al, 2009), or by performing long distance walking protocols and measuring 
the performance in walking speed, the deceleration from the start to the end of the task 
and kinematic changes of the gait pattern (Phan-Ba et al, 2012; Sehle et al, 2014; 
McLoughlin et al, 2016). Nevertheless, a recent systematic review by Severijns et al. 
(2017) synthesized all the outcome measures and protocols that have been used so far to 
measure fatigability in pwMS. This review concluded that there are no standardized 
protocols to assess and comparing findings among studies assessing fatigability in this 
population and no psychometric studies have thus far been found (Severijns et al, 2017). 
Fatigue, on the other hand, is measured though self-reported questionnaires that have been 
developed. There are many generic and disease specific fatigue questionnaires and can 
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provide either a multidimensional or unidimensional assessment of fatigue. These 
questionnaires might measure different aspects or different theoretical constructs of 
fatigue, so in order to select the most appropriate a clinician or researcher must consider 
the underlying concept of fatigue that need to be captured, the psychometric properties of 
the instrument and the practical feasibility (Dittner et al, 2004; Kos et al, 2004). Table 2.3 
presents an overview of all the self-reported fatigue questionnaires that have been 
examined for their psychometric properties in pwMS and have been used to assess 
perceived fatigue in this population.  
Thus far, only two systematic reviews have evaluated the psychometric properties of self-
reported fatigue questionnaires in pwMS (Kos et al, 2004; Elbers et al, 2012). Elbers et 
al. (2012) reported that 20 questionnaires have been used in MS population and have been 
examined for their psychometric properties, with the most frequently used questionnaire 
being the Fatigue Severity Scale (FSS).  
One review, suggested the use of Fatigue Impact Scale (FIS) and Modified Fatigue Impact 
Scale (MFIS) for assessing self-reported fatigue (Kos et al, 2004). However, this study 
did not examine the methodological quality of the studies assessing the psychometric 
properties by standards guidelines (e.g. COSMIN) and the recommendations should be 
interpreted with caution. The other systematic review on psychometric properties 
recommended the use of the Fatigue Scale for Motor and Cognitive Function (FSMC) 
since it was found to have moderate level of evidence for internal consistency and 
structural validity and the Unidimensional Fatigue Impact Scale (U-FIS) that showed 
adequate reliability and structural validity in the MS population (Elbers et al, 2012).  
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Clinicians and researchers who wish to assess fatigue should consider whether a particular 
tool reflects the aspect of fatigue that they are interested in and it has sound psychometric 
properties. Future studies should consider investigating apart from fatigue and other 
contributing factors to fatigue such as mood, depression and sleep.   
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Table 2.3 Description of fatigue questionnaires that have been used in the MS population. 
Questionnaire  Construct assessed  Recall period Description  
CFQ Fatigue severity Last day It consists of 11 items measuring the severity of mental and 
physical fatigue. Each item is scored from 0 (less than usual) to 3 
(much more than usual), with higher scores representing high 
levels of fatigue   
CIS-20R Impact of 
fatigue/Fatigue severity  
Last 2 weeks Consists of 20 items and responses are based on a 7-point Likert 
type scale (1-7), with 1 ‘yes, that it is true’ to 7 ‘no, that is not true’ 
D-FIS Impact of fatigue Last day It is a unidimensional scale consisting of 8 items; rating is from 0 
‘no problem at all’ to 4 ‘extreme problem’  
EMIF-SEP Impact of fatigue Last month  It is the adapted French version of the FIS and is composed by 41 
items on 4-point Likert scale (1=it’s always false to 4 ‘it’s always 
true’)   
FAI Impact of 
fatigue/Fatigue severity  
Last 2 weeks It consists of 29 items on a 7-point Likert scale, with lower scores 
indicating less impact and severity of fatigue 
FDS Fatigue severity  Not specified This scale consists of 5 items rated in  a scale from 0-3; the total 
score ranges from 0-17 and the higher it is the greater the fatigue 
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Questionnaire  Construct assessed  Recall period Description  
    
FIS Impact of fatigue Last month It is a 40-item questionnaire with rating ranging from 0 ‘no 
problem’ to 4 ‘extreme problem’ 
FSMC Impact of 
fatigue/Fatigue severity 
General It consists of 20 items measuring mental and physical fatigue, with 
rating from 1 ‘does not apply at all’ to 5 ‘applies completely 
FSS Impact of 
fatigue/Fatigue severity  
Last week It consists of 9 items with 1 indicating ‘strongly disagree’ to 7 
indicating ‘strongly agree’ 
FSS-7 Impact of 
fatigue/Fatigue severity  
Not specified It is the same as the FSS after removing item 1 and item 2 from the 
original version 
FSS-5 Impact of fatigue Not specified It is the same as the FSS after removing item 1, item 2, item 6 and 
item 8 
MFI Impact of fatigue Lately It is 20-item questionnaire on a 5-point Likert scale, with higher 
scores indicating greater fatigue 
MFIS Impact of fatigue Last month It is a 21-item questionnaire that is divided in physical, cognitive 
and psychosocial subscales. The scoring ranges from 0 ‘never’ to 4 
‘almost always’ 
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Questionnaire  Construct assessed  Recall period Description  
    
MFSS Factors influencing 
fatigue 
Not specified It is a unidimensional questionnaire consisted of 6 items and is 
rated on 7-point Likert scale. Higher scores indicate greater fatigue 
NFI-MS Fatigue severity/Factors 
influencing fatigue 
Last 2 weeks It consists of 33 items which are rated on 4-point Likert scale 
ranging from 0 ‘strongly disagree’ to 3 ‘strongly agree’ 
PS-F Impact of fatigue  Last month It is a unidimensional scale consisted of 16 items; it is rated on 6-
point Likert scale and higher score indicates greater fatigue 
SOFI Fatigue severity Last 6 months It consists of 20 items, in which feelings of being tired are rated 
from 0 ‘not had such feelings at all’ to 6 ‘had such feelings to a 
very high degree’ 
U-FIS Impact of fatigue Last week  It is 22-item scale that is a modified version of the FIS; it is rated 
on a 4-point Likert scale with higher scores indicating greater 
fatigue 
WEIMUS Impact of fatigue Last 2 weeks It consists of 17 items rated on a 5-point Likert scale; the scale has 
cognitive and physical sub-scores, with higher scores indicating 
higher degree of fatigue  
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Questionnaire  Construct assessed  Recall period Description  
    
    
VAS Impact of 
fatigue/Fatigue severity  
Not specified Three VAS to assess impact of fatigue on daily life, self-care 
activities and household and occupation; the answer line of 10mm 
ranges from ‘no influence at all’ to ‘a lot of influence’  
Abbreviations: CFQ: Chalder Fatigue Scale; CIS-20R: Checklist Individual Strength Questionnaire; D-FIS: Daily Fatigue Impact Scale; EMIF-SEP: 
French adaptation of Fatigue Impact Scale; FAI: Fatigue Assessment Inventory; FDS: Fatigue Damage Spectrum; FIS: Fatigue Impact Scale; FSMC: 
Fatigue Scale for Motor and Cognitive Function; FSS: Fatigue Severity Scale; MFI: Multidimensional Fatigue Inventory; MFIS: Modified Fatigue 
Impact Scale; MFSS: Multiple Sclerosis-Specific Fatigue Severity Scale; NFI-MS: Neurological Fatigue Index; PS-F: Performance Scale Fatigue; SOFI: 
Swedish Occupational Fatigue Inventory; U-FIS: Unidimensional Fatigue Impact Scale; WEIMUS: Wurzburg Fatigue Inventory for Multiple Sclerosis; 
VAS: Visual Analogue Scale  
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2.5 Dual-task performance in MS 
 
As discussed in previous parts of this literature review, one of the benefits of the use of 
FES reported by pwMS themselves is that it reduces the mental effort of walking and that 
as a result less concentration is needed on the walking task (Bulley et al, 2015; (Miller) 
Renfrew et al, 2018). It has been suggested that postural control and cognition compete 
for a common pool of attentional resources and if one task is becoming more challenging, 
the available resources reach their limit and the performance in one or both tasks will 
deteriorate (Stins & Beek, 2012). Another theory, termed as bottleneck theory, assumes 
that due to limited resources there is a point in information processing that only one task 
can be performed at a time, causing a decline in the other while dual-tasking (Pashler, 
1994). The execution of a motor task simultaneous with a cognitive task is termed dual-
tasking and the cognitive-motor interference can be quantified by the dual-task cost 
(DTC), which is the percentage of change in performance from single to dual task (Yogev-
Selingmann et al, 2012). 
Cognitive tasks vary depending on demands and mental processes required to execute 
them. The majority of cognitive tasks that have been utilized in studies with MS 
population can be categorized in four domains. The definitions of these domains are based 
on a previous meta-analysis and include mental tracking, verbal fluency, discrimination 
and decision-making and working memory tasks (Al-Yahya et al, 2011). Mental tracking 
tasks are used to assess sustained attention and information processing, since they require 
to hold information in the mind while performing a mental manipulation process (e.g. 
serial digit subtraction and naming alternate letters of the alphabet) (Al-Yahya et al, 2011). 
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Verbal fluency tasks examine executive function and require word production 
spontaneously and under pre-specified conditions with a common example been the word 
list generation (Al-Yahya et al, 2011). Discrimination and decision-making tasks are 
associated with the measurement of attention and response inhibition and require selective 
attention to a particular stimulus with an appropriate response (e.g. Stroop test) (Al-Yahya 
et al, 2011). Lastly, working memory tasks are used to examine sustained attention and 
information processing speed, which require holding information in the mind that is 
available for processing for example the short-term memory recognition test (Al-Yahya 
et al, 2011).   
There is growing interest in the interaction between cognitive and motor function in MS 
research that reflects its clinical importance, since 65% of individuals with MS report to 
have cognitive deficits (Chiaravalloti & DeLuca, 2008). The majority of the studies 
examining cognitive motor interference (CMI) (i.e. decline in performance in a motor task 
when a cognitive task is performed concurrently) have utilized walking speed and other 
spatiotemporal parameters as the main outcome to detect changes in motor performance 
(Hamilton et al, 2009; Wajda et al, 2013; Wajda & Sosnoff, 2015). Monticone et al. (2014) 
examined the reliability and measurement error of spatiotemporal gait parameters in 
pwMS during dual-task conditions. Gait was evaluated on two different occasions with a 
motor-cognitive task (walk while a word list generation (WLG) task was administered) 
and a motor-motor task (walk while carrying a tray with glasses) and it was reported that 
all gait parameters had good to excellent ICCs, but with the gait parameters of pwMS 
being slightly more variable between tests than healthy individuals (Monticone et al, 
2014). 
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The majority of the literature focused on gait changes under dual-task conditions in pwMS 
with mild to higher EDSS scores. Only one study assessed gait performance in participants 
with CIS while performed a cognitive task (Kalron et al, 2010). It was been observed that 
gait parameters deteriorated even in this population when performing a cognitive task (i.e. 
modified WLG) compared to healthy individuals (Kalron et al, 2010). Several studies have 
utilized the WLG task while walking to examine CMI in pwMS (EDSS range: 2-6.5). 
Several authors reported that with the addition of this task, gait performance deteriorated 
(Sosnoff et al, 2011a; Wajda et al, 2013a; Wajda et al, 2013b; Motl et al, 2014). Other 
studies have found similar gait changes with the addition of a different cognitive task 
assessing mental tracking, such as alternating letters of the alphabet, serial 7 subtraction 
and counting backwards (Hamilton et al, 2009; Learmonth et al, 2014; Sandroff et al, 
2015; Allali et al, 2016; Etemadi, 2016; Wajda et al, 2016).  
Peruzzi et al. (2016) investigating the feasibility of a dual-task (DT) intervention program 
and pwMS underwent a six week virtual-reality (VR)-based treadmill training program. 
At baseline and at six weeks gait analysis was performed under single and dual-task 
conditions, with the serial 3 subtraction used as the cognitive task. It was observed that 
walking speed and stride length improved in the dual-task conditions after the intervention 
(Peruzzi et al, 2016). 
A recent meta-analysis synthesized the evidence for differences in CMI between pwMS 
and healthy individuals. There was a small effect size indicating a non-significant 
difference in CMI between pwMS and healthy individuals, even though there was 
decrease in the walking performance in pwMS compared to the healthy individuals 
(Learmonth et al, 2017). The findings of this meta-analysis are consistent with the general 
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understanding that, regardless of the health status, undertaking a cognitive and a motor 
task simultaneously will result in decreased performance of the motor or cognitive task or 
a combination of both (Al-Yahya et al, 2011; Hamacher et al, 2015).  
To our knowledge, although many studies have investigated dual tasking in pwMS, the 
influence of FES on the dual task cost has not been explored. In Chapter 6 the benefits of 
FES were explored under dual-task and fatiguing conditions in order to objectively 
document the effects of FES as perceived by pwMS. 
 
2.6 Summary and rationale of the overall aims of the thesis 
 
This background chapter has summarised and highlighted research findings and gaps in 
knowledge related to gait impairments and especially foot drop which is a key component 
of this thesis and reveals the following key points:  
 A variety of outcome measures have been used to measure the effects of 
interventions to treat foot drop but there is been no systematic review evaluating 
both the quality of the methodology and quality of the evidence of studies 
assessing the psychometric properties of these outcomes. 
 The psychometric properties of three-dimensional gait analysis, which is one of 
the most common outcomes to assess walking performance in MS, have not been 
established for the MS population. 
 Currently, there is no objective evidence of the ‘phenomenon/symptom’ of 
fatigable foot drop in people with low EDSS levels (< 3.5), i.e. whose daily 
walking performance is not affected. 
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 The most common outcome measures used to assess the effects of interventions to 
treat foot drop, do not always reflect the benefits of these interventions noticed by 
pwMS which are linked to benefits in real life situations as opposed to walking 
tests in a lab. Thus, future studies should focus on the effect of interventions to 
treat foot drop in more real life conditions such as those requiring dual tasking.  
 
Therefore, in accordance with the aforementioned bullet points, this PhD included the 
following research questions:  
Study 1 (Chapter 3) 
Research question 1: Which are the most frequently outcomes used to assess the 
effect of assistive technology to treat foot drop in pwMS? 
Research question 2: What is the quality of published evidence on the 
psychometric properties of the outcome measures identified?  
Research question 3: What is the level of evidence for the identified outcome 
measures?  
Contribution: In collaboration with my supervisors, I was responsible for the 
conception and design of the study, performed the database searches, screening 
and analysis and preparing and submitting the manuscript reporting the results of 
this study for publication in a peer-reviewed journal. 
Study 2 (Chapter 4) 
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Research question 1: What is the test-retest relative and absolute reliability of 
ankle kinematics and spatiotemporal parameters in two groups of pwMS with 
different level of walking impairments?  
Research question 2: What is the intra-session relative and absolute reliability of 
ankle kinematics and spatiotemporal parameters in two groups of pwMS with 
different level of walking impairments? 
Contribution: In collaboration with my supervisors, I have contributed to the 
conception and design of the study, data collection for the Group A, data analysis 
for both included groups and writing the study as an article for publication. 
Study 3 (Chapter 5) 
Research question 1: Can we objectively document gait deterioration, evidenced 
as foot drop, after a self-regulated exercise perturbation task in pwMS with 
minimal disability?  
Research question 2: Are there any differences in gait characteristics between this 
group of pwMS and a healthy age-matched control group?  
Contribution: Although this study was conceived an designed before prior to the 
start of my PhD, I was responsible for latter parts of ethical review (e.g. QMU 
ethics, amendments for NHS ethics), I was also responsible for all the data 
collection, data analysis and preparing the manuscript reporting the results of this 
study to be submitted in a peer-reviewed journal. 
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Study 4 (Chapter 6) 
Research question 1: What are the differences in the direct orthotic effect of FES 
under dual-tasking and fatiguing conditions?  
Research question 2: Is the dual-task cost of walking speed different between 
pwMS and an age-matched control group?  
Research question 3: How is fatigability affecting the gait characteristics in pwMS 
and a healthy age-matched control group while simultaneously performing a 
cognitive task?   
Contribution: In collaboration with my supervisors, I have contributed to the 
conception of the study, study design and acted as PI to gain NHS ethical approval, 
data collection and data analysis and preparing the manuscript reporting the results 
of this study to be submitted in a peer-reviewed journal. 
Taking all these into consideration, the overall aim of this PhD thesis was to explore foot 
drop, its presence in pwMS with different disability levels and the psychometric properties 
of outcomes used to evaluate walking impairments.  
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Chapter 3. Systematic review of the psychometric properties of 
walking performance measures  
 
3.1 Purpose of the chapter 
 
The purpose of this chapter is, through a systematic literature search, to identify all the 
outcome measures that have been used to assess the effects of assistive technology to treat 
foot drop. Further, to synthesize and evaluate the psychometric evidence of walking 
performance, effort of walking and lower limb function outcomes.  
 
3.2 Introduction  
 
One of the most common gait impairments is foot drop, which is the reduced dorsiflexion 
of the ankle during the swing phase of gait, potentially leading to trips or falls. Foot drop 
can be caused by weakness of the dorsiflexor muscles, impaired neural control causing 
co-contraction of agonist and antagonist muscles and increased tone in the plantarflexor 
muscles (Barret et al, 2009). In pwMS foot drop can also be caused by increased motor 
fatigability, which is described as the exercise-induced reduction in the ability of the 
muscles to produce force or power (Kluger et al, 2013). Two common interventions to 
treat foot drop are FES and AFOs. The most commonly used AFOs restrain the movement 
of the foot and thus reduce foot drop, but they do not allow active control of the ankle, 
which may result in an abnormal gait pattern (Bulley et al, 2015). On the contrary, FES 
involves electrical stimulation that is applied to the common peroneal nerve, eliciting the 
desired contraction to produce ankle dorsiflexion during the swing phase of gait. The 
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advantage of FES is that it facilitates a more normal gait pattern, increases walking speed 
and decreases the physiological cost of gait (Stein et al, 2006; Paul et al, 2008).  
The effects of FES and AFOs on walking performance is currently evaluated via a wide 
variety of outcome measures including, for example, timed walking tests (e.g. 6MWT, 
10mWT, T25FW) or patient or clinician reported instruments and rating scales [e.g. 
MSWS-12, HAI, Dynamic Gait Index (DGI)]. Instrumental motion analysis techniques 
are also used to objectively quantify the gait pattern. A comprehensive assessment of 
three-dimensional kinematics and kinetics can reveal minimal changes that cannot be 
observed visually (Bethoux & Bennett, 2011). For this reason, 3D gait analysis is widely 
used to discriminate between normal and abnormal gait patterns and to evaluate responses 
to interventions in a variety of populations, such as stroke (Stokic et al, 2009), cerebral 
palsy (Kainz et al, 2017a) and Parkinson’s disease (Roiz et al, 2010; Pistacchi et al, 2017).  
 The outcome measures used to assess the efficacy of interventions such as assistive 
technology to treat foot drop need to be valid, reliable and responsive to change. Several 
studies have evaluated the psychometric properties of outcome measures used to assess 
the effects of ankle foot orthoses and functional electrical stimulation to treat foot drop 
[e.g. Goldman et al. (2008), Stellman et al. (2015), Learmonth et al. (2012, 2013)]. 
However, no systematic review exists that has evaluated both the evidence and the 
methodological quality of studies describing the psychometric properties of such outcome 
measures.  
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We, therefore, aimed to (i) identify studies that evaluated the effects of ankle foot orthoses 
and functional electrical stimulation in pwMS and then (ii) synthesize the available 
psychometric evidence for the designated subset of, walking performance, effort of 
walking and lower limb function, outcome measures identified. In so doing, we hoped to 
augment the evidence-base available to optimize the appropriate selection of outcome 
measure(s) to evaluate the efficacy of assistive technology to treat foot drop in pwMS.  
 
3.3 Methods 
 
3.3.1 First search: overview of outcome measures  
The purpose of the first search of the literature was to identify those studies that assessed 
the effects of either FES or AFOs used to treat foot drop in pwMS. From these studies we 
identified the outcome measures used and the frequency of their use. 
3.3.1.1 Search strategy and study selection 
 
A comprehensive search of eight databases, including MEDLINE (1963-5/2017), 
CINAHL (1969-5/2017), EMBASE (1974-5/2017), SCOPUS (1963-5/2017), PsycINFO 
(1963-5/2017), AMED (1967-5/2017), SPORTDiscus (1963-5/2017) and Web of Science 
(1967-5/2017) was conducted in order to identify the articles that met the inclusion 
criteria. The search strategy included synonyms and keywords for functional electrical 
stimulation (e.g. ‘Functional Electrical Stimulation’, ‘foot drop stimulation’ and ‘common 
peroneal stimulation’) and ankle foot orthoses (e.g. ‘Ankle Foot Orthoses’ and ‘splints’) 
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and the population of interest (e.g. ‘multiple sclerosis’ and ‘demyelinating disease’). The 
full strategy can be found in Appendix 2.  
The inclusion criteria for this search were: a) studies that have assessed the use of FES or 
AFOs to treat foot drop in pwMS and b) studies that included outcome measures that 
evaluate function, walking performance, fatigue and QoL. The exclusion criteria were: a) 
studies that used other forms of electrical stimulation (i.e. not functional) and those that 
evaluated orthoses for other joints than the ankle, b) studies that were reviews (i.e. 
systematic, meta-analysis, etc.), conference abstracts and editorials and c) studies in 
languages other than English, Greek or Dutch.  
Two independent researchers (GA, MvdL) were involved in the screening of the articles 
for inclusion. After exclusion of irrelevant articles based on the titles and abstracts, the 
full-text of the remaining articles was examined for their eligibility. Reference lists of 
articles included in the review were searched for potentially relevant articles that were not 
retrieved in the original search. If any differences in opinion existed, consensus was made 
through discussion and a third reviewer (TM) was available if consensus between the 
primary two reviewers was not reached. From the eligible articles, we extracted the 
outcome measures that were employed to assess the effects of FES or AFOs and recorded 
the frequency of these measures being used.  
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3.3.2 Principal search: systematic review of the psychometric properties of outcome measures 
  
The second and principal search was conducted to identify studies that evaluated the 
psychometric properties of outcome measures that assess walking performance, effort of 
walking and lower limb function in pwMS.  
3.3.2.1 Search strategy and study selection 
 
A similar protocol for the second search was followed as the one described above. A 
comprehensive search of MEDLINE (1976-5/2017), CINAHL (1995-5/2017), SCOPUS 
(1999-5/2017), EMBASE (1974-5/2017), PsycINFO (1963-5/2017), AMED (1967-
5/2017), SPORTDiscus (1963-5/2017) and Web of Science (1967-5/2017) databases was 
conducted by combining the outcome measures of walking performance, effort of walking 
and lower limb function which were identified in the first search. The search strategy 
included keywords and synonyms of the population of interest (see first search), a subset 
of the identified outcome measures (e.g. ‘3D gait analysis’, ’10m walk test’, etc.) and a 
search filter for identifying studies evaluating measurement properties, developed by 
Terwee et al. (2009a). The full search strategy is included as an appendix (Appendix 3).  
The inclusion criteria for our second search were: studies that assessed the psychometric 
properties of a subset of the outcomes identified in the first search, namely those assessing 
walking performance, lower limb function and effort of walking. Although we 
acknowledge the importance of outcome measures such as QoL and fatigue, we decided 
to restrict the outcome measures in this review to those measures that are potentially 
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directly affected by the use of FES and AFOs. Further, the psychometric evidence for 
fatigue measures used in MS has been the subject of a previous review (Elbers et al, 2012). 
The exclusion criteria were: a) studies that were reviews (e.g. systematic and meta-
analyses), abstracts from conferences or editorials, and b) full texts in peer reviewed 
journals published in languages other than English, Greek or Dutch. The procedures used 
to select the final set of papers were the same as those described for the first search.  
 
3.3.3 Methodological quality  
 
The methodological quality of the studies identified in the second search was assessed 
using the COSMIN. We chose the COSMIN checklist since is used to obtain a score for 
the methodological quality of a study evaluating one or more measurement properties of 
a particular outcome measure (Mokkink et al, 2012; Terwee et al, 2012). The COSMIN 
checklist has been assessed for the inter-rater agreement and reliability of each item, with 
the percentage agreement being appropriate, but the kappa coefficients for each item being 
relatively low (Mokkink et al, 2010a). However, to overcome low inter-rater agreement 
in scoring items, we familiarized with the grading process and developed specific 
guidelines as recommended by the developers of COSMIN. The COSMIN-checklist 
consists of nine boxes (internal consistency, reliability, measurement error, content 
validity, structural validity, construct validity, cross-cultural validity and responsiveness) 
with each box including 5-18 items. The reviewer selects the measurement properties 
evaluated in the study and scores the specific item-lists with ‘poor’, ‘fair’, ‘good’ or 
‘excellent’ depending on the design and execution. The lowest score from the rated items 
determines the methodological quality of the measurement property (Mokkink et al, 
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2010b) (Appendix 4). Two reviewers (GA, MvdL) used the COSMIN checklist to rate the 
methodological quality of the measurement properties in all studies. Any disagreements 
in ratings were resolved through discussion.  
As previously mentioned, in order to be consistent in our ratings we developed guidelines 
for the rating of specific questions/items in each of the measurement properties in the 
COSMIN checklist (Appendix 5). For example, all studies that used the EDSS as a 
comparator instrument were rated under the measurement property of construct validity, 
even if the authors stated that criterion validity was assessed. The questions for missing 
items and how they were handled was scored as ‘not applicable’ for measures that were 
not self-reported scales. For studies assessing within-day test-retest reliability, the items 
for patients being stable and the time interval being appropriate were rated as excellent.  
The quality of the results of the psychometric properties of the outcome measures was 
assessed using the quality criteria by Terwee et al. (2007), which were recently revised by 
the authors (www.cosmin.nl, viewed online 2016). The quality of the results of the 
psychometric properties was rated as ‘positive’ (+), ‘indeterminate’ (?) or ‘negative’ (-) 
depending on the methods and results of the studies (Table 3.1). 
Table 3.1 Quality criteria for measurement properties (Terwee et al, 2007; www.cosmin.nl, 
viewed online 2016). 
Measurement 
property 
Rating* Criteria  
Reliability  
Internal consistency  + At least limited evidence for unidimensionality or positive 
structural validity AND Cronbach’s alpha(s) ≥ 0.70 and ≤ 
0.95  
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? Not all information for ‘+’ reported OR conflicting 
evidence for unidimensionality or structural validity OR 
evidence for lack of unidimensionality or negative 
structural validity  
- Criteria for ‘+’ not met 
Reliability  + ICC or weighted Kappa ≥ 0.70 
? ICC or weighted Kappa not reported 
- Criteria for ‘+’ not met 
Measurement error + SDC or LoA < MIC 
? MIC not defined 
- Criteria for ‘+’ not met 
Validity  
Construct validity 
(Hypothesis testing) 
+ At least 75% of the results are in accordance with the 
hypotheses 
? No correlations with instrument(s) measuring related 
construct(s) AND no differences between relevant groups 
reported 
- Criteria for ‘+’ not met 
Criterion validity  + Convincing arguments that gold standard is “gold” AND 
correlation with gold standard ≥0.70 
? Not all information for ‘+’ reported 
- Criteria for ‘+’ not met 
Responsiveness  
Responsiveness  + At least 75% of the results are in accordance with the 
hypotheses 
? No correlations with changes in instrument(s) measuring 
related construct(s) AND no differences between changes 
in relevant groups reported 
- Criteria for ‘+’ not met 
* + = positive rating; ? = indeterminate rating; - = negative rating 
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3.3.4 Data synthesis 
 
The overall level of evidence for each outcome measure was reported according to the 
recommendations of the Cochrane Back Review Group. This overall score was given in 
relation to the methodological quality of the study and the results of the measurement 
properties. The evidence was rated as ‘strong’ (consistent (positive) findings in multiple 
studies of good methodological quality or in one study of excellent methodological 
quality), ‘moderate’ (consistent (positive) findings in multiple studies of fair 
methodological quality or in one study of good methodological quality), ‘limited’ (one 
study of fair methodological quality), ‘conflicting’ (both positive and negative findings), 
‘unknown’ (only studies of poor methodological quality) (van Tulder et al, 2003). For 
instance, if the intra-rater reliability for a particular outcome measure had one study of 
poor quality and one of good quality showing positive results, the overall score was 
‘moderate’. Likewise, if there were four studies of fair methodological quality but only 
one with having a positive score for the quality of the results, the overall score was 
‘limited’.  
 
3.4 Results 
  
3.4.1 First search: overview of outcome measures  
 
After a systematic search of the eight databases, we retrieved 1393 titles for screening 
according to our inclusion criteria (Figure 3.1). We retained 34 articles and identified 27 
outcome measures evaluating lower limb function, walking performance, effort of 
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walking, fatigue and QoL. These outcomes measures were either self-reported measures 
(seven measures e.g. FSS, MSWS-12) or objective assessments (20 measures e.g. 6MWT, 
MSFC, spatiotemporal gait parameters). The most frequently used outcome measures 
were walking speed (mostly recorded over 10 meter distance), 3D gait kinematics and the 
Physiological Cost Index (PCI) (Figure 3.2).  
 
 
 
Figure 3.1 1. Preliminary search: identification of the outcomes measures that have been used to 
assess the effect of assistive technology for foot drop; 2. Principal search: studies evaluating the 
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psychometric properties of outcome measures of walking performance, effort of walking and 
lower limb function. 
 
 
Figure 3.2 Outcome measures identified in the preliminary search and the reported frequency of 
use.  
Abbreviations: MWP: measured walking performance; SRWP: self-reported walking performance; LLF: 
lower limb function; EoW: effort of walking; PF: perceived fatigue; spatiotemp. par.: spatiotemporal 
parameters; ROGA: Rivermead Observational Gait Analysis; EMG gait record: electromyography gait 
recording; mEFAP: modified Emory Functional Ambulation Profile; 10mWT: 10 meter Walk Test; T25FW: 
Timed 25 Foot Walk; 2MWT: 2 Minute Walk Test; 3MWT: 3 Minute Walk Test; 4MWT: 4 Minute Walk 
Test; 6MWT: 6 Minute Walk Test; MSFC: Multiple Sclerosis Functional Composite; MSWS-12: Multiple 
Sclerosis Walking Scale-12; HAI: Hauser Ambulation Index; CSRT: choice stepping reaction time; PCI: 
Physiological Cost Index; RPE: Rate of Perceived Exertion; ECW: energy cost of walking; FSS: Fatigue 
Severity Scale; SF-36: 36-Item Short Form Health Survey; COPM: Canadian Occupational Performance 
Measure; PIADS: Psychosocial Impact of Assistive Devices Scale; 9HPT: 9-Hole Peg Test; PASAT: Paced 
Serial Addition Test; MSIS-29: Multiple Sclerosis Impact Scale.  
 
3.4.2 Principal search: systematic review of the psychometric properties of outcome measures 
  
3.4.2.1 Description of included studies 
 
The systematic search of eight databases resulted in the identification of 2488 potentially 
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additional articles (Figure 3.1). Four studies (Hoogervost et al, 2002; Kragt et al, 2006; 
Goldman et al, 2013; Motl et al, 2014) were excluded at the full-text screening stage 
because they aimed at validating a previously reported MCID or cut-off points for a certain 
outcome measure and did not validate the outcome measure itself. Although of interest, 
the methodology of these studies is different from those reporting the psychometric 
properties of the outcome measures themselves and are therefore not appropriate to be 
assessed using the COSMIN checklist and Terwee criteria. In total, we included 41 articles 
reporting the psychometric properties of 10 outcome measures [MSFC, MSWS-12, 
spatiotemporal parameters, 10mWT, T25FW, 2MWT, 6MWT, RPE, peak oxygen uptake 
(VO2 peak) & reaction time/movement time (RT/MT)] which all have been used to assess 
the effects of assistive technology to treat foot drop. Using the COSMIN taxonomy the 
following measurement properties were evaluated: reliability was assessed in 18 studies 
[(intra-rater n=3; inter-rater n=3; test-retest n=14), 8 outcome measures], measurement 
error in four studies (six outcome measures) and internal consistency in six studies (one 
outcome measure). Hypothesis testing/construct validity was evaluated in 15 studies (nine 
outcome measures) and responsiveness was assessed in 15 studies (seven outcome 
measures). Most studies assessed the MSWS-12 (n=12), followed by the 6MWT (n=11) 
and the T25FW (n=11). The agreement between the two raters (GA & MvdL) in the items 
of all the measurement properties was 94.8% and for the final scores of each property the 
agreement was 94.7%. Upon discussion, any disagreement regarding the rating of the 
items or the total score of each property was resolved.  Studies included pwMS with RR, 
SP, PP and CIS with EDSS levels ranging from 0-8.5, with some studies not reporting this 
information (Kaufman et al, 2000; Hobart et al, 2003; Motl et al, 2011; Freeman et al, 
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2013; Toomey et al, 2013). The majority of the studies reported a mean of EDSS of four 
or more and five studies reported a mean EDSS of six (Vaney et al, 1996; Sosnoff et al, 
2011b; Coleman et al, 2012; Learmonth et al, 2012; Hobart et al, 2013). The sample size 
was 6796 in total for the 41 studies, with the number of females (n=2109) exceeding the 
number of males (n=972) and with some studies not reporting the gender of the 
participants (Cutter et al, 1999; Kaufman et al, 2000; Kragt et al, 2008; Motl et al, 2011). 
Table 3.2 presents an overview of the results together with the COSMIN rating and the 
rating of the quality of the results according to the revised Terwee criteria (Terwee et al, 
2007; Mokkink et al, 2010b; www.cosmin.nl, viewed online 2016). 
 
3.4.3 Methodological quality and strength of evidence 
 
3.4.3.1 Reliability 
 
The methodological quality of the studies was rated according to the COSMIN checklist 
as ‘good’ (n=3) (Cohen et al, 2001; Hobart et al, 2003; Learmonth et al, 2013a), as ‘fair’ 
(n=3) (Goldman et al, 2008; Motl et al, 2011; Larson et al, 2013) and ‘poor’ (n=12) (Vaney 
et al, 1996; Cohen et al, 2000; Kaufman et al, 2000; Schwid et al, 2002; Paltamaa et al, 
2005; Fry et al, 2006; Learmonth et al, 2012; Hobart et al, 2013; Toomey et al, 2013; Feys 
et al, 2014; Heine et al, 2015; Cleland et al, 2016). The main reasons for a lower score 
included not reporting the ICC or weighted Kappa, not describing the ICC model used, 
small sample size and the lack of an explicit statement that the repeated measurements 
were independent. Using the revised Terwee quality criteria (Terwee et al, 2007; 
www.cosmin.nl, viewed online 2016), the evidence for reliability in 13 studies (seven 
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outcome measures) (Cohen et al, 2000; Cohen et al, 2001; Hobart et al, 2003; Paltamaa et 
al, 2005; Fry et al, 2006; Goldman et al, 2008; Motl et al, 2011; Learmonth et al, 2012, 
Learmonth et al, 2013a; Larson et al, 2013; Toomey et al, 2013; Heine et al, 2015; Cleland 
et al, 2016) were rated as ‘positive’ and the remaining five (four outcome measures) 
(Vaney et al, 1996; Kaufman et al, 2000; Schwid et al, 2002; Hobart et al, 2013; Feys et 
al, 2014) were rated as ‘indeterminate’ because neither ICC nor weighted Kappa were 
reported. From the eight outcome measures that were evaluated for reliability (intra- & 
inter-rater, test-retest), seven of them demonstrated good and excellent values of ICC 
ranging from 0.86-0.96 and only for RPE the ICC values were moderate (0.706).  
 
3.4.3.2 Measurement error 
 
Of the four studies that evaluated measurement error (six outcome measures), the 
methodological quality of three (Paltamaa et al, 2005; Learmonth et al, 2012; Heine et al, 
2015) was rated as ‘poor’ due to a small sample size (n < 30) and due to testing conditions 
not being similar. The methodology in one study (Learmonth et al, 2013a) was rated as 
‘fair’ because it was unclear whether the patients were stable in the interim period. The 
quality of the results for measurement error in all four studies was rated as indeterminate 
(‘?’) because in none of the studies the Minimal Important Change (MIC) values was 
reported, which is required to interpret whether the measurement error is acceptable (de 
Vet et al, 2006a).   
 
3.4.3.3 Internal consistency 
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There were six studies that evaluated internal consistency. The methodological quality of 
four (Hobart et al, 2003; Motl et al, 2011; Engelhard et al, 2016; Mokkink et al, 2016) was 
rated as ‘excellent’, for one (Motl et al, 2008) it was rated as ‘good’ and one (Motl et al, 
2010) as ‘poor’ due to a small sample size. All six studies evaluated the MSWS-12 and 
were rated as positive (‘+’) for the quality of their results.   
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Table 3.2 Summary of the study characteristics, rating of the methodological quality using the COSMIN guidelines and rating of the quality of the 
results using the Terwee criteria (Terwee et al, 2007; Mokkink et al, 2010b; www.cosmin.nl, viewed online 2016). 
Author/Year Patient 
characteristics 
COSMIN 
Measurement 
Property 
Results Rating 
Methodological 
quality 
Quality of the 
results 
Choice reaction time & movement time (RT/MT) 
Apache et al 
(2002) 
n = 178 ,RR, SP,PP 
EDSS 0-6.5 
Hypothesis testing rs = 0.84 with EDSS Fair a + 
Apache et al 
(2005) 
n = 40, RR, SP 
EDSS median 4.5 
3 sessions in 1-year 
Responsiveness 
(no intervention) 
RT/MT mean change =16.6% (.1) Poor b ? 
 
MSFC 
Cohen et al 
(2000) 
n = 10, SP   
EDSS mean 5.2 
6 sessions (2 per day 
over 2 weeks) 
Reliability Intra-rater: ICC = 0.97 (session 4-5) 
Inter-rater: ICC = 0.96 (session 7-8) 
Poor c + 
Cohen et al 
(2001) 
n = 436, SP  
EDSS mean 5.2 
Reliability Intra-rater: ICC (over 4 sessions) = 0.87 Good d, e + 
Hypothesis testing   rs = -0.56  with EDSS   Fair o, q + 
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3 pre-baseline 
sessions over 28 days 
  Methodological 
quality 
Quality of the 
results 
      
Cutter et al 
(1999) 
n = 378, RR, SP 
EDSS 0-6.5  
3 annual sessions  
Hypothesis testing rs = -0.22 with EDSS Fair a, o ,q ? 
Responsiveness 
(no intervention) 
Average composite change Z-score:  
Baseline = -0.07 
1-year = -0.07 
2-year = -0.16 
Fair q ? 
 
Hobart et al 
(2004) 
n = 133, RR, SP,PP 
EDSS mean 3.1 
Hypothesis testing r = -0.64 with EDSS Good f, w + 
 
Kalkers et al 
(2001) 
n = 131, RR, SP,PP 
EDSS mean 3.1 
Hypothesis testing  rs = -0.25 with T2 lesion load 
rs = -0.24 with T1 lesion load 
Poor h ? 
 
Kragt et al 
(2008) 
n = 161, PP  
EDSS mean 5.0 
Responsiveness 
(no intervention)  
ES:  
EDSS = 0.23 
MSFC = 0.16 
Poor b ? 
 
Miller et al 
(2000) 
n = 300 
EDSS 0-8.5 
Hypothesis testing rs = -0.80 with HRQoL Poor h ? 
 
MSWS-12  
Baert et al 
(2014) 
n = 284, RR, SP,PP 
EDDS mean 4.8 
Responsiveness  AUC with Global Rating Scale:  
Whole group = 0.73  
Fair a + 
 82 
 
2 sessions (pre & 
post) 
(physical 
rehabilitation) 
EDSS≤4 = 0.64  
EDSS 4.5-6.5 = 0.77  
Filipović 
Grćić et al 
(2011) 
n = 49, RR  
EDSS mean 3.0 
2 sessions (pre & 
post) 
Responsiveness  
(IVMP for 
1month) 
SRM = 1.05 
ES = 1.02 
RE (%) = 82.4  
Fair a ? 
 
Freeman et al 
(2013) 
n = 70, RR, SP, PP 
3 annual sessions 
Responsiveness  
(no intervention) 
ES = -0.07 
SEM = 5.66 
r <0.35 with walking speed & RMI 
Fair j ? 
 
Hobart et al 
(2003) 
Community sample: 
n = 602 
2 sessions (10 days 
apart) 
Hospital-based 
sample:  
PP MS = 78 
Steroids = 54 
2 sessions (6 weeks 
apart) 
Internal 
consistency 
Community sample: Cronbach’s α = 0.97 
PPMS sample: Cronbach’s α = 0.97 
Steroids sample: Cronbach’s α = 0.94 
Excellent + 
Reliability  Community sample: Test-retest ICC = 0.94 Good d, e, k + 
Hypothesis testing  Steroids sample: rs = 0.65 with EDSS  Fair i, q + 
Responsiveness 
(steroid treatment) 
With EDSS:  
ES = 0.45 
SRM = 0.45 
RE = 0.31 
Fair m, q, t ? 
 
n = 82, RR, SP, PP Reliability  Test-retest: ICC(2,1) = 0.93 Good k, t + 
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Learmonth et 
al (2013) 
EDSS mean 3.5 
2 sessions (7 days 
apart) 
 
Measurement 
error 
SEM = 8; CV (5) = 27 
MDC95 = 22; %MDC95 = 53% 
Fair i, m, n ? 
 
McGuigan et 
al (2004) 
Community sample = 
149 
Outpatient sample = 
53  
RR, SP, PP  
EDSS mean 4.0 
2 sessions 
Hypothesis testing rs = 0.84 with EDSS Fair a, o, q ? 
 
Responsiveness 
(no intervention)  
Z-score = -2.87 Poor b ? 
 
Motl et al 
(2008) 
n = 133, RR, SP, PP  
EDSS mean 4.9 
1 session 
Internal 
consistency  
Cronbach’s α =.97 Good p, x + 
Hypothesis testing  rs = .77 with MSIS-29 (physical) 
rs = .36 with MSIS-29 (psychological) 
rs = .80 with EDSS 
Fair q + 
Motl et al 
(2010) 
n = 24, RR  
PDDS median 1.0 
1 session 
Internal 
consistency 
Cronbach’s α = .95 Poor c + 
Hypothesis testing With O2 cost of walking at:  
CWS, r = 0.64 
FWS, r = 0.61 
Poor c + 
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SWS, r = 0.64 
With O2 consumption: 
CWS, r = 0.24 
FWS, r = 0.14 
SWS, r = 0.44 
Motl et al 
(2011) 
n = 269, RR  
3 sessions over a year 
Internal 
consistency 
Cronbach’s α:  
Baseline = .96 
6-month = .97 
12-month =  .97 
Excellent + 
Reliability  Test-retest ICC(2):  
Across 6-months = .86 
Across 12-months = .87 
Fair i + 
Pilutti et al 
(2013) 
n = 268, RR, SP,PP 
PDDS median 3.0 
1 session 
Hypothesis testing rs = .72 with T25FW 
rs = -.75 with 6MWT 
Fair q + 
Mokkink et al 
(2016) 
n = 625, RR, SP, 
PP,PR, CIS 
EDSS median 3.5 
Internal 
consistency 
RMSEA = 0.078 
CFI = 1.000 
TLI = 0.999 
SRMR = 0.019 
Guttman’s lambda2 = 0.98 
Excellent + 
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Engelhard et al 
(2016) 
n = 293, RR, SP, 
PP,PR 
 
Internal 
consistency  
1D Rasch:  
BIC = 6112.5; AIC = 5933.7 
3D GRM: 
BIC = 5972.7; AIC = 5677.3 
Excellent + 
      
FAP/ Spatiotemporal parameters 
Sosnoff et al 
(2011) 
n = 13, RR, SP  
EDSS median 6.0 
1 session 
Hypothesis testing  FAP: 
rs = -0.82 with T25FW 
rs = -0.49 with MSWS-12 
rs = -0.81 with EDSS 
Poor c + 
Pilutti et al 
(2013) 
n = 268, RR, SP,PP  
PDDS median 3.0 
1 session 
Hypothesis testing Speed with T25FW: r = -.68 
Cadence with T25FW: r = -.50 
Speed with 6MWT: r = .67 
Cadence with 6MWT: r = .52 
Fair q + 
10mWT 
Feys et al 
(2014) 
n = 102, RR, SP,PP  
EDSS mean 4.6 
3 sessions within a 
day 
Reliability  Test-retest: 
Within-day variability (%) at usual speed: 
 -Community walkers (CW) = 22.6 
 -Limited CW = 26.6 
 -Most limited CW = 43.3 
Poor b ? 
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 Within-day variability (%) at fastest speed: 
-CW = 12.1 
-Limited CW = 23.4 
-Most limited CW = 38.4 
Freeman et al 
(2013) 
n = 70, RR, SP, PP  
3 annual sessions 
Responsiveness  
(no intervention) 
ES = 0.001 
r <0.35 with MSWS-12 & RMI 
Fair j ? 
 
Kempen et al 
(2011) 
n = 156 , RR  
EDSS mean 2.5 
6 sessions in 6 years 
Responsiveness 
(no intervention)  
AUC = 0.79 with MFWC6 
AUC = 0.86 with MFWC5 
AUC = 0.74 with MFWC4 
AUC = 0.82 with MFWC3 
Fair j + 
Paltamaa et al 
(2005) 
Test-retest n = 19 
Inter-rater n = 9 
RR, SP, PP  
EDSS 0-6.5 
2 sessions (1 week 
apart) 
Reliability  Test-retest: ICC = 0.91 
Inter-rater: ICC = 0.93 
Poor c + 
Measurement 
error  
Test-retest: SEM = 0.09m/s 
Inter-rater: SEM = 0.10m/s 
Poor c ? 
 
Paltamaa et al 
(2008) 
Baseline n = 120 
Follow-up n = 109 
RR, PP  
EDSS median 2.0  
Responsiveness 
(no intervention)  
AUC = 0.76 with EDSS 
MICdeterioration = -0.19 
 
 
Fair a + 
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3 sessions in 2years 
Stellman et al 
(2015) 
n = 28, RR, SP, PP  
EDSS mean 3.2 
1 session 
Hypothesis testing r = 0.61 with accelerometry Poor c + 
Vaney et al 
(1996) 
Reliability n = 25 
Responsiveness n = 
115 
EDSS mean 6.6 
5 sessions within-day 
Reliability  Test-retest: rs = -0.8 with RMI Poor c, u ? 
Responsiveness  
(physical & 
occupational 
therapy) 
Not adequate statistical information for 
responsiveness  
Poor y ? 
 
Timed 25-Foot Walk 
Baert et al 
(2014) 
n = 284, RR, SP,PP  
EDDS mean 4.8 
2 sessions (pre & 
post) 
Responsiveness 
(physical 
rehabilitation)  
AUC with Global Rating Scale: 
Whole group = 0.50  
EDSS≤4 = 0.64  
EDSS 4.5-6.5 = 0.45  
Fair a + 
Coleman et al 
(2012) 
n = 296, RR, RP, SP, 
PP   
EDSS mean 5.8 
4 sessions 
Responsiveness 
(dalfampridine 
treatment)  
rs = -0.39 with CGI 
MICD = 0.35 m/s 
Relative improvement = 17.2% 
Fair a + 
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Filipović 
Grćić et al 
(2011) 
n = 49, RR  
EDSS mean 3.0 
2 sessions (pre & 
post) 
Responsiveness 
(IVMP for 1 
month)  
SRM = 0.55 
ES = 0.27 
RE (%) = 68.3 
Fair a, t ? 
 
Hobart et al 
(2013) 
n = 533, RR, SP,PP  
EDSS mean 6.0 
9 sessions 
Reliability  Variability ranged from 10.03 – 11.44 Poor b ? 
Hypothesis testing  r = -0.20 to -0.43 with MSWS-12 Excellent + 
Kaufman et al 
(2000) 
n = 133, SP  
3 sessions (6 month 
period) 
Reliability Not adequate statistical information for 
reliability 
Poor b ? 
 
Responsiveness  
(no intervention) 
Not adequate statistical information for 
responsiveness 
Poor b, h ? 
 
Larson et al 
(2013) 
n = 36, RR  
EDSS mean 3.5 
2 sessions 1 week 
apart 
Reliability Test-retest ICC = 0.92 Fair c + 
Learmonth et 
al (2012) 
n = 24 
EDSS mean 6.02 
2 sessions 1 week 
apart 
Reliability  Test-retest ICC(2,3) = 0.94 
 
Poor c + 
Measurement 
error 
SEM = 4.56s 
MDC95 = 12.6s 
Poor c ? 
 
n = 82, RR, SP, PP  Reliability  Test-retest ICC(2,1) = 0.991 Good t + 
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Learmonth et 
al (2013) 
EDSS mean 3.5 
2 sessions (7 days 
apart) 
Measurement 
error 
SEM = 1s 
MDC95 = 2.7s 
% MDC95 = 36 
Fair i, m, n ? 
 
Schwid et al 
(2002) 
n = 63 
EDSS 0-6.5 
5 sessions 
Reliability  Test-retest reliability: 
95% CI: ± 16% of patients baseline score 
Poor b ? 
 
van Winsen et 
al (2010) 
n = 112, CIS, RR, SP, 
PP  
EDSS mean 4.5 
2 sessions (pre & 
post) 
Responsiveness 
(IVMP for 6 
weeks)  
Sensitivity (%) = 25 
Specificity (%) = 90 
LR+ = 2.50 
LR- = 0.83 
Fair a ? 
 
Jensen et al 
(2016) 
n = 105 
EDSS mean 5.6 
2 sessions 
Responsiveness 
(SR-Fampridine 
treatment)  
MCID = 1.3s 
%MCID = 14.2  
Poor h, y ? 
2-Minute Walk Test 
Baert et al 
(2014) 
n = 284, RR, SP, PP  
EDDS mean 4.8 
2 sessions (pre & 
post) 
Responsiveness 
(physical 
rehabilitation)  
AUC with Global Rating Scale:  
Whole group = 0.64  
EDSS≤4 = 0.74  
EDSS 4.5-6.5 = 0.60  
Fair a + 
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Feys et al 
(2014) 
n = 102, RR, SP,PP  
EDSS mean 4.6 
3 sessions within a 
day 
Reliability  Within-day variability (%):  
CW = 12.0 
Limited CW = 13.8 
Most limited CW = 26.3 
Poor b ? 
 
Filipović 
Grćić et al 
(2011) 
n = 49, RR  
EDSS mean 3.0 
2 sessions (pre & 
post) 
Responsiveness 
(IVMP for 1 
month)  
SRM = 0.89 
ES = 0.54 
RE (%) = 95.1 
Fair a ? 
 
Stellman et al 
(2015) 
n = 28, RR, SP, PP  
EDSS mean 3.2 
1 session 
Hypothesis testing r = 0.79 with accelerometry 
 
Poor c + 
6-Minute Walk Test 
Baert et al 
(2014) 
n = 284, RR, SP,PP  
EDDS mean 4.8 
2 sessions (pre & 
post) 
Responsiveness 
(physical 
rehabilitation)  
AUC with Global Rating Scale:  
Whole group = 0.68  
EDSS≤4 = 0.77  
EDSS 4.5-6.5 = 0.65 
Fair a + 
Feys et al 
(2014) 
n = 102, RR, SP,PP  
EDSS mean 4.6 
3 sessions within a 
day 
Reliability  Within-day variability (%):  
CW = 10.1 
Limited CW = 15.7 
Most limited CW = 28.7 
Poor b ? 
 
 91 
 
Freeman et al 
(2013) 
n = 70, RR, SP, PP  
3 annual sessions 
Responsiveness  
(no intervention) 
ES = 0.03 
 ‘general mobility’: r = 0.499 
Fair j ? 
 
Fry et al 
(2006) 
n = 12, RR, SP, PP  
EDSS mean 3.6 
2 sessions (1 week 
apart) 
Reliability  Test-retest ICC = 0.96 
 
Poor c + 
Goldman et al 
(2008) 
n = 40, RR, SP, PP  
EDSS 0-6.5 
3 sessions (in 4 
hours) 
Reliability  Test-retest: ICC = 0.94 
Inter-rater: ICC = 0.91 
Fair t + 
Learmonth et 
al (2012) 
n = 24 
EDSS mean 6.02 
2 sessions 1 week 
apart 
Reliability  Test-retest: ICC (2,1) = 0.96 Poor c + 
Measurement 
error 
SEM = 27.48m 
MDC95 = 76.2m 
Poor c ? 
 
Learmonth et 
al (2013) 
n = 82, RR, SP, PP  
EDSS mean 3.5 
2 sessions (7 days 
apart) 
Reliability  Test-retest: ICC(2,1) = 0.96 Good t + 
Measurement 
error 
SEM = 32m 
MDC95 = 88m 
% MDC95 = 20 
Fair i, m, n ? 
 
Paltamaa et al 
(2005) 
Test-retest n = 19 
Inter-rater n = 9 
Reliability  Test-retest: ICC = 0.96 
Inter-rater: ICC = 0.93 
Poor c + 
 92 
 
RR, SP, PP   
EDSS 0-6.5 
2 sessions (1 week 
apart) 
Measurement 
error 
Test-retest: SEM = 30.65 m 
Inter-rater: SEM = 35.85 m 
Poor c ? 
 
Paltamaa et al 
(2008) 
Baseline n = 120 
Follow-up n = 109 
RR, PP  
EDSS median 2.0  
3 sessions in 2 years 
Responsiveness 
(no intervention)  
AUC = 0.76 with EDSS 
MICdeterioration = -55.06 
 
 
Fair a + 
Stellman et al 
(2015) 
n = 28, RR, SP, PP  
EDSS mean 3.2 
1 session 
Hypothesis testing r = 0.68 with accelerometry 
 
Poor c + 
Toomey et al 
(2013) 
n = 8 
1 session(4assessors) 
Reliability  Inter-rater: ICC = 0.984  
 
Poor c + 
RPE 
Heine et al 
(2015) 
n = 31 RR, SP, PP 
EDSS mean 2.5 
2 sessions (1-3 weeks 
apart) 
Reliability  Test-retest: ICC = 0.706 Poor z + 
Measurement 
error 
SEM = 1.1 
SDCindividual  = 2.9 
SDCgroup = 0.52 
LoA = -2.9-2.9 
Poor z ? 
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Cleland et al 
(2016) 
n = 16 RR, SP, PP 
EDSS median 1.75 
2 sessions (6-10 days 
apart) 
Reliability  Test-retest: ICC = 0.870 Poor c + 
Hypothesis testing r = .691 with VO2 (L/min) 
r = .507 with VO2 (mL/kg/min) 
Poor c, h ? 
VO2 peak      
Heine et al 
(2015) 
n = 31 RR, SP, PP 
EDSS mean 2.5 
2 sessions (1-3 weeks 
apart) 
Reliability  Test-retest: ICC = 0.933 for VO2 peak (mLkg-
1min-1) 
Poor z + 
Measurement 
error 
VO2 peak (mLkg-1min-1):  
SEM = 1.7 
SDCindividual  = 4.6 
SDCgroup = 0.82 
LoA = -5.0-4.3 
Poor z ? 
      
 
COSMIN item rating: a: hypothesis vague or not formulated, possible to deduce; b: not appropriate statistical methods; c: small sample size; d: no 
description of ICC model used; e: assume that patients were stable in the interim period; f: expected magnitude of the correlations not stated; g: assumable 
that statistical methods were appropriate; h: no information about the psychometric properties of the comparator instruments; i: not clear how missing 
items were handled; j: unclear or not described what occurred in the interim period; k: assumable that measurements were independent; l: AUC or 
correlations not calculated; m: unclear if patients were stable; n: doubtful whether time interval was appropriate; o: poor description of the comparator 
instrument; p: no description of the % of missing data; q: some information on measurement properties or a reference; r: internal consistency not 
calculated for each subscale separately; s: no ICC, Spearman or Pearson’s correlations calculated; t: due to sample size; u: only correlations, not ICC 
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calculated; v: minimal number of hypothesis formulated a priori; w: expected direction of the correlations or differences not stated; x: not described but 
can be deduced how missing items were handled; y: unclear what was expected; z: test conditions were not similar 
 
 
Abbreviations: AIC: Akaike information criterion; AUC: Area under the curve; BIC: Bayesian information criterion; CFI: comparative fit index; CGI: 
Clinician Global Impression; CIS: Clinically Isolated Syndrome; CWS: comfortable walking speed; ES: effect size; FWS: faster walking speed; GPCM: 
generalized partial credit model; GRM: graded response model; HRQoL: Health-related Quality of Life; ICC: Intraclass Correlation Coefficient; IVMP: 
intravenous methylprednisolone therapy; LoA: limits of agreement; LR: Likelihood ratio; MDC: minimum detectable change; MIC: minimal important 
change; MICD: Minimally important clinical difference; MFWC: Modified Functional Walking Categories; PDDS: Patient Determined Disease Steps; 
PP: Primary Progressive; r: Pearson’s correlations; rs: Spearman coefficient; RE: relative efficiency; RMI: Rivermead Mobility Index; RMSEA: root 
mean square error of approximation; RR: Relapsing Remitting; SDC: smallest detectable change; SEM: standard error of mean; SP: Secondary 
Progressive; SRM: standardized response mean; SRMR: root mean square residual; SWS: slower walking speed; TLI: Tucker-Lewis index.
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3.4.3.4 Hypothesis testing/construct validity 
 
Fifteen studies assessed construct validity, with only one (Hobart et al, 2013) with an 
‘excellent’ methodological quality and one in which was rated as ‘good’ (Hobart et al, 
2004). The methodological quality of seven (Cutter et al, 1999; Cohen et al, 2001; Apache 
et al, 2002; Hobart et al, 2003; McGuigan et al, 2004; Motl et al, 2008; Pilutti et al, 2013) 
was rated as ‘fair’ either because the hypotheses were vague or due to limited information 
regarding the comparator instruments and its psychometric properties. The other studies 
(Miller et al, 2000; Kalkers et al, 2001; Motl et al, 2010; Sosnoff et al, 2011b; Stellman et 
al, 2015; Cleland et al, 2016) were rated as ‘poor’ due to a small sample size or the absence 
of information regarding the comparator instruments. Applying the Terwee quality criteria 
(Terwee et al, 2007; www.cosmin.nl, viewed online 2016), the quality of the results 
reported in 10 studies (Cohen et al, 2001; Apache et al, 2002; Hobart et al, 2003; Hobart 
et al, 2004; Motl et al, 2008; Motl et al, 2010; Sosnoff et al, 2011b; Hobart et al, 2013; 
Pilutti et al, 2013; Stellman et al, 2015) was rated as positive (‘+’) and in five studies 
(Cutter et al, 1999; Miller et al, 2000; Kalkers et al, 2001; McGuigan et al, 2004; Cleland 
et al, 2016) as indeterminate (‘?’) as the correlations presented were with unrelated 
constructs. The construct validity of seven of the studies reporting on six laboratory based 
measures and one self-perceived scale of walking performance used the EDSS as a 
comparator instrument. The comparator instrument in other studies were outcome 
measures such as the MSWS-12, Multiple Sclerosis Impact Scale-29 (MSIS-29), 
accelerometry and O2 cost of walking. Table 3.2 includes information regarding the 
comparator instruments and correlation coefficients presented in studies assessing 
construct validity. 
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3.4.3.5 Responsiveness  
 
Responsiveness was evaluated in 15 studies, with the methodological quality of nine 
(Cutter et al, 1999; Hobart et al, 2003; Paltamaa et al, 2008; van Winsen et al, 2010; 
Filipović Grćić et al, 2011; Kempen et al, 2011; Coleman et al, 2012; Freeman et al, 2013; 
Baert et al, 2014) rated as ‘fair’ and the remainder classed as ‘poor’ (Vaney et al, 1996; 
Kaufman et al, 2000; McGuigan et al, 2004; Apache et al, 2005; Kragt et al, 2008; Jensen 
et al, 2016). Most of the studies had a vague hypothesis or did not use appropriate 
statistical methods and this lowered their rating. Only four studies (Paltamaa et al, 2008; 
Kempen et al, 2011; Coleman et al, 2012; Baert et al, 2014) investigating the MSWS-12, 
10mWT, T25FW, 2MWT and 6MWT received a ‘positive’ rating and the remaining 11 
(Vaney et al, 1996; Cutter et al, 1999; Kaufman et al, 2000; Hobart et al, 2003; McGuigan 
et al, 2004; Apache et al, 2005; Kragt et al, 2008; van Winsen et al, 2010; Filipović Grćić 
et al, 2011; Freeman et al, 2013; Jensen et al, 2016) were rated as ‘indeterminate’ due to 
correlations with unrelated constructs or the lack of differences between relevant groups. 
Of the 15 studies evaluating responsiveness, only two studies (Paltamaa et al, 2008; 
Coleman et al, 2012) reported on the MCID (MIC) for the 10mWT, T25FW and 6MWT. 
 
3.4.4 Level of evidence – data synthesis 
 
The overall levels of evidence for the psychometric properties of each outcome measure 
are summarized in Table 3.3. It was found that the MSWS-12 has strong positive evidence 
for its internal consistency and test-retest reliability, moderate positive evidence for its 
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construct validity when compared to MSIS-29 and O2 cost of walking and limited positive 
evidence for its responsiveness. The MSFC showed moderate positive evidence for its 
intra-rater reliability and construct validity, while for the remaining measurement 
properties, including responsiveness, the evidence was ‘unknown’. For lower limb 
reaction/movement time, there was limited positive evidence for construct validity, but 
for responsiveness the evidence was ‘unknown’. Strong evidence was found for the 
construct validity of the T25FW while for responsiveness and for test-retest reliability the 
evidence was moderately positive. Spatiotemporal parameters were classed as having a 
limited positive level of evidence for construct validity. For the 10mWT the level of 
evidence for its responsiveness was moderately positive, while for the other measurement 
properties this was ‘unknown’. Limited positive evidence was found for the 
responsiveness of the 2MWT. For the 6MWT, the level of evidence for responsiveness 
and test-retest reliability was moderately positive, while the evidence for the inter-rater 
reliability was limited positive. The level of evidence for the measurement properties 
assessed for VO2 peak and RPE were all ‘unknown’.  
 
 
Table 3.3 Level of evidence for each outcome measure identified in the principal search. 
Outcome 
measure 
Internal 
consiste
ncy 
Reliability Measurement 
error 
Hypothesi
s testing 
Responsiv
eness Intra-
rater 
Inter-
rater 
Test-
retest 
        
RT/MT n/a n/a n/a n/a n/a + 
Limited 
? 
 
Unknown 
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MSWS-12 +++  
Strong 
n/a n/a +++ 
Strong 
?  
Unknown 
++ 
Moderate 
+ 
 Limited 
        
MSFC n/a ++ 
Moderate 
? 
Unkno
wn 
n/a n/a ++ 
Moderate 
?  
Unknown 
        
Spatiotempor
al parameters 
n/a n/a n/a n/a n/a + 
 Limited 
n/a 
        
10mWT n/a n/a ? 
Unkno
wn 
? 
Unknown 
?  
Unknown 
?  
Unknown 
++  
Moderate 
        
T25FW n/a n/a n/a ++ 
Moderate 
?  
Unknown 
+++  
Strong 
++  
Moderate 
        
2MWT n/a n/a n/a ? 
Unknown 
n/a ?  
Unknown 
+ 
 Limited 
        
6MWT n/a n/a +  
Limited 
++ 
Moderate 
?  
Unknown 
? 
 
Unknown 
++ 
 Moderate 
VO2 peak n/a n/a n/a ? 
Unknown 
?  
Unknown 
n/a n/a 
RPE n/a n/a n/a ? 
Unknown 
?  
Unknown  
?  
Unknown  
n/a 
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3.5 Discussion  
 
The first search of the present systematic review identified 27 outcome measures, 
assessing self-reported and objectively measured walking performance, self-perceived 
fatigue, effort of walking, QoL, balance, falls and lower limb function, that had been used 
in studies assessing the effects of assistive technology to treat foot drop in pwMS. The 
most frequently used measure was the 10mWT (n=19), followed by 3D gait kinematics 
(n=12) and PCI (n=10). Interestingly, although 3D gait kinematics was one of the most 
frequently used outcome measures to assess the effects of assistive technology to treat foot 
drop, its psychometric properties have not yet been reported for this specific population 
(Bethoux & Bennett, 2011). Similarly, there were no psychometric studies identified for 
PCI for the MS population. However, studies into the psychometric properties for 3D gait 
kinematics have demonstrated that 3D gait analysis is a reliable, valid and responsive tool 
for characterizing gait in stroke sufferers (Yavuzer et al, 2008), CP (Noonan et al, 2003; 
Kainz et al, 2017b; Nieuwenhuys et al, 2017) and many musculoskeletal disorders 
(Laroche et al, 2011; Bates et al, 2016). Similarly, the construct validity of the PCI has 
been assessed in the subacute stroke population and its reliability documented in children 
with cerebral palsy (Raja et al, 2007; Delussu et al, 2014).  
The second, and main, search for studies assessing the psychometric properties of the 20 
outcome measures related to walking performance, lower limb function and effort of 
walking identified in the first search, revealed 41 studies that evaluated only 10 of these 
twenty outcomes. Of those 10 measures, the MSWS-12 was found to have a strong level 
of evidence for its internal consistency and test-retest reliability and the T25FW for 
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construct validity. Moderate evidence was found for the test-retest reliability and 
responsiveness of the 6MWT and the responsiveness of the 10mWT.  
Short distance walking tests, such as the 10mWT and T25FW have been classified as 
reliable owing to ICC values of 0.7 and over. However, there are indications that walking 
speed, as measured over such short distances, may not be appropriate to assess the benefits 
of functional electrical stimulation for community walkers with relatively low levels of 
disability. For example, Miller et al. (2016) found that pwMS who walked faster than 
0.8m/s did not increase their walking speed in the T25FW with the assistance of functional 
electrical stimulation, while those with a slower walking speed than 0.8m/s did.  
De Vet et al. (2006b) distinguished two aspects of reliability, namely consistency (or 
relative reliability), which is assessed by the ICC and secondly measurement error (or 
absolute reliability), which is reported by measures like SEM, MDC and the LoA. 
Although ICC values are informative, these are greatly dependent on inter-subject 
variance in the outcome measure. The knowledge of the measurement error of a particular 
measure is essential for both researchers and clinicians when selecting a reliable outcome 
as both need to establish whether an “improvement” in a patient’s walking performance, 
with the use of assistive technology, is due to measurement error or a ‘true’ change as a 
result of the intervention (Bruton et al, 2000). This is best achieved via the implementation 
of MDC data, the value beyond which, in this instance, a difference between performance 
with and without assistive technology can be considered a true change. In our review, of 
the 18 studies evaluating ‘relative’ reliability, only four also reported the measurement 
error of six outcomes (MSWS-12, 10mWT, T25FW, 6MWT, RPE and VO2peak). The 
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MDC was reported to be 22 points, 2.7s and 88 meters for the MSWS-12, T25FW and 
6MWT respectively (Learmonth et al, 2013a). Paltamaa et al. (2005) reported an SEM of 
0.09 for the 10mWT that indicates an MDC95% of 2.4s. Heine et al. (2015) reported an 
SEM of 1.1 and 0.131 for RPE and VO2peak respectively, indicating an MDC95% of 3.04 
for RPE and 0.36 Lmin-1 for VO2peak. However, the strength of the results in these studies 
rated as ‘indeterminate’ because the MIC values were not reported. According to Terwee 
et al. (2009b) 81], the value of the measurement error needs to be considered in relation 
to MIC (also referred to as the MCID) values in order to determine whether the 
measurement error of an outcome measure is acceptable for use in research or clinical 
practice. If the measurement error is exceeding MIC, it is difficult to interpret whether the 
observed changes are clinically relevant and are not just because of measurement error (de 
Vet et al, 2006a; Terwee et al, 2009b). Another issue to consider is that patient-related 
factors, such as medications and comorbidities, can influence clinical outcome 
measurement findings by contributing to measurement error. Many people with MS using 
medications and have co-morbidities and symptoms such as fatigue, which may change 
over a period of several weeks or even days (Powell et al, 2017; Kasser et al, 2017). These 
factors are likely to affect outcome measures, both in test-retest reliability studies and 
clinical trials.  One of the items in COSMIN checklist for reliability and measurement 
error is: ‘Were patients stable in the interim period on the construct to be measured?’ For 
an ‘excellent’ score for this item authors need to provide evidence that the patients were 
stable. However, none of the papers, including those with repeated assessment over more 
than two weeks (Learmonth et al, 2013a; Heine et al, 2015), reported this evidence. 
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The methodological quality of the 41 studies rated according to the COSMIN criteria 
revealed that both the analysis and reporting of the psychometric properties of outcome 
measures is often inappropriate. For example, the methodological quality of 
responsiveness studies was often only rated as ‘fair’ and ‘poor’ because the hypotheses 
were not reported or because there was a lack of information regarding the comparator 
instruments (often EDSS) and their psychometric properties. Another potential 
problematic issue with evaluating responsiveness was that in eight of the 14 studies there 
was no intervention and the (often assumed) hypothesis was that pwMS would deteriorate 
over the time frame of the study, which ranged from one to two years.  
The comparator instrument in seven out of the 15 studies that evaluated validity was the 
EDSS, which has been widely accepted as a gold standard to measure disability in pwMS. 
However, its use as a gold standard to validate outcomes of walking performance may be 
less appropriate. The EDSS (Kurtzke, 1983) is a scale that was developed over 30 years 
ago and even though studies have reported high inter- and intra-rater reliability and high 
correlations for face validity (Goodkin et al, 1992; Sharrack et al, 1999), there are other 
studies raising issues regarding its reliability and objectivity and whether it  can be 
considered a ‘gold standard’ (Hobart et al, 2000; Cohen et al, 2012). 
It should be noted that the aforementioned methodological issues in the studies included 
in this review do not imply that the outcome measures are not appropriate but instead that 
more psychometric studies with higher methodological quality are needed. When planning 
studies to assess the psychometric properties of outcome measures, researchers should 
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consult standard guidelines such as COSMIN in relation to the selection of appropriate 
study design, statistical analysis and reporting of methods and results.  
To our knowledge, this is the first review that evaluated the evidence for the psychometric 
properties of walking performance related measures used to assess the effect of assistive 
technology in pwMS. We used standardized criteria to evaluate both the methodological 
quality (COSMIN) and quality of the results (Terwee et al, 2007; Terwee et al, 2012). To 
date, only two reviews have tried to highlight which are the most useful tools for walking 
assessment in pwMS. However, one was a narrative review of available outcome measures 
and offered little detail about psychometric properties (Bethoux & Bennett, 2011). The 
other was a topical review including some details of the psychometric properties of 
measures to assess walking disability, but which did not employ specific criteria to 
evaluate the evidence for their use (Kieseier & Pozzilli, 2012). Work has been published 
on the stroke population that evaluated, also using COSMIN criteria, the psychometric 
properties of walking performance measures (van Bloemendaal et al, 2012). This review 
concluded that most of the outcome measures were reliable and valid for use in the stroke 
population, but it was observed, similar to our findings, that there was a lack of evidence 
for the minimally important change and responsiveness. Two COSMIN reviews into the 
functional outcomes in the cerebral palsy population came to similar conclusions 
(Amman-Reiffer et al, 2014; Zanudin et al, 2017). 
This review has several limitations. Firstly, the COSMIN checklist was originally 
designed for patient-reported outcome measures and not for performance-based measures 
such as the majority of those included in our review. However, as there is no specific 
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checklist for performance-based measures we opted to use the COSMIN checklist since 
most of the items scored are also highly relevant to performance-based measures. 
Additional rules were specified for the ratings of items that were only applicable to 
patient-reported outcome measures. Moreover, another limitation might be that in our 
initial search we used only two interventions (i.e. AFOs and FES) to identify walking 
performance outcome measures, while studies reporting on other orthotic interventions 
may also have reported on walking outcomes. However, we believe that these two 
interventions were the most appropriate, since they are used widely to treat foot drop and 
the outcome measures used would be appropriate for that reason. Furthermore, only 
studies published in English, Greek or Dutch were included, which means that eligible 
studies in other languages will likely have been excluded. Finally, in the majority of the 
included studies, the mean EDSS was four or more and five studies involved participants 
with a mean EDSS of six. The responsiveness and reliability of walking performance 
measures in pwMS with EDSS > 4 may be different from those who are less affected by 
MS.  
 
3.6 Conclusion  
 
The present systematic review reported on the psychometric properties of outcome 
measures used to assess the effects of assistive technology to treat foot drop.  Forty-one 
studies were identified which reported information on the psychometric properties of only 
10 of the previously identified 20 measures related to walking performance. Strong levels 
of evidence were found for internal consistency and test-retest reliability of the MSWS-
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12 and the construct validity of the T25FW.  Moderate evidence was found for the test-
retest reliability and responsiveness of the 6MWT and for the responsiveness of the 
10mWT. None of the outcome measures that were evaluated for measurement error had 
an acceptable level of evidence for this measurement property. Our findings do not 
indicate that the existing outcome measures included in this review are poor, but that there 
is a need for more high quality studies evaluating the psychometric properties of these 
measures. Future research should (i) investigate the psychometric properties, and in 
particular measurement error and responsiveness, of a wider range of walking 
performance related measures and (ii) use standard guidelines such as the COSMIN to 
increase methodological quality enabling clinicians and researchers to select appropriate 
outcome measures to assess the effects of assistive technology to treat foot drop.  
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Chapter 4. Test-retest reliability and minimal detectable change of 
ankle kinematics and spatiotemporal parameters  
 
4.1 Purpose of chapter 
 
The purpose of this chapter is to describe the methodology, present and discuss the results 
of two studies reporting on relative and absolute reliability of the ankle kinematics and 
spatiotemporal parameters associated with walking in pwMS. These two studies report on 
the kinematics and spatiotemporal parameters of two groups of pwMS with a different 
level of walking impairments.  
 
4.2 Introduction  
 
The typical gait pattern in most pwMS is to walk slowly, with associated shorter stride 
length and prolonged double support phase (Benedetti et al, 1999; Givon et al, 2009; 
Kelleher et al, 2010; van der Linden et al, 2014b). Three-dimensional (3D) gait analysis 
is an established method to quantify and reveal even minimal gait disorders in a variety of 
populations. Increasingly, studies have incorporated 3D motion capture systems to record 
the gait kinematics of pwMS (e.g. Scott et al, 2013; Pau et al, 2014; McLoughlin et al, 
2016; Barr et al, 2017). 
Outcome measures, such as 3D gait kinematics, need to be reliable and responsive to 
changes, as both are essential psychometric characteristics for evaluating meaningful 
changes after clinical practice or research interventions (Hopkins, 2000). Variability in 
3D kinematics between sessions can be either due to ‘intrinsic’ factors, such as age and 
pathology or due to ‘extrinsic’ factors such as marker placement, data processing or 
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assessors’ experience. Consequently, it is important to identify the measurement error in 
order to avoid misinterpretation of the results, i.e. either meaningful changes to be missed 
or small changes to be considered meaningful (Schwartz et al, 2004; McGinley et al, 
2009). 
Chapter 3 reported on a recent systematic review regarding the psychometric properties 
of walking performance, effort of walking and lower limb function measures that have 
been used to evaluate assistive technology to treat foot drop in pwMS. This review 
included 41 studies reporting on the psychometric properties of ten outcome measures of 
walking performance (Andreopoulou et al, 2018). Eighteen studies investigated the 
reliability (intra-rater, inter-rater & test-retest) of eight outcome measures through ICC 
but only four studies reported on measurement error of six outcome measures by 
presenting SEM and MDC values. Interestingly, although 3D gait kinematics was one of 
the most frequent outcome measures to assess the effects of assistive technology to treat 
foot drop, no studies reporting on its psychometric properties were found for the MS 
population even though it is considered a ‘gold standard’ for the assessment of walking 
performance (Bethoux & Bennett, 2011).     
Although the psychometric properties of 3D gait kinematics might not have been 
extensively investigated in the MS population, these psychometric properties are well 
established in other populations [i.e. healthy, cerebral palsy (CP), stroke, etc.]. Table 4.1 
presents a summary of the studies reporting on relative and absolute reliability of ankle 
kinematics and stride parameters in healthy, stroke and CP populations. After a 
comprehensive literature search in PubMed and in relevant systematic reviews, twenty 
studies were identified (n=8 healthy, n=5 stroke, n=7 CP) which examined test-retest, 
 108 
 
intra-rater and inter-session reliability through ICC values (i.e. relative reliability or 
‘consistency’), while a few studies also reported on the measurement error, presented as 
MDC values. Most of the studies reported excellent ICC values for peak dorsiflexion (DF) 
in swing and angle ankle at initial contact (IC) apart from two studies on healthy 
individuals, one study in stroke patients for the ankle angle at IC and one study in CP 
population with  Gross Motor Function Classification System (GMFCS) level II. 
However, as discussed in Chapter 3, there is a lack of MS specific information on 3D gait 
kinematics. For that reason, it would be valuable to obtain relative and absolute reliability 
information for this specific group, since reliability may be dependent on the level of gait 
impairment and could differ among different patient populations and even among the same 
population with different disease progression. Furthermore, it is of importance to have 
reliable measures, and especially for ankle kinematics, that can objectively assess the 
effects of FES as a treatment for foot drop in pwMS. 
Therefore, the aim of this study was to examine two aspects of reliability in two groups 
of pwMS with different levels of walking impairment.  
• The first objective was to examine relative reliability which was assessed by the ICC. 
• The second objective was to examine absolute reliability (i.e. measurement error) of the 
ankle kinematics and spatiotemporal parameters. 
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Table 4.1 Summary of studies reporting on psychometric properties of ankle kinematics and gait speed in healthy, stroke and CP populations. 
Study  Participant characteristics [n, 
age (years), type]  
Type of reliability, session 
number, interval 
ICC MDC 
Healthy  
Fernandes et al, 
2016 
n = 23, age: 35  Test-retest reliability, 2 x 
sessions, interval: 7-11 days 
Peak DF:  
ICC = 0.77 
Peak DF:  
MDC = 3.9° 
Kadaba et al, 
1989 
n = 40, age range: 18-40 Test-retest reliability, 3 x 
sessions, interval: 1 week 
Ankle DF/PF: 
CMCleft = 0.937 
CMCright = 0.933 
– 
Kaufman et al, 
2016 
n = 10, age: 30 Inter-session reliability, 3 x 
sessions, interval: within 12 
months 
Medial inter-session 
error: 1.2° 
– 
Meldrum et al, 
2014 
n = 30, age: 30 Test-retest reliability, 2 x 
sessions, interval: 1 day – 1 
week  
Peak DF in swing: 
ICC = 0.44 
Ankle angle at IC: 
ICC = 0.49 
Gait speed:  
ICC = 0.89  
Peak DF in swing: 
MDC = 8.09° 
Ankle angle at IC: 
MDC = 8.26° 
Gait speed:  
MDC = 0.17m/s 
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Mentiplay & 
Clark, 2018 
n = 30, age: 23 Test-retest reliability, 2 x 
sessions, interval: 7 days 
Peak DF in swing: 
ICC = 0.78 
Peak DF in swing: 
MDC = 3.8° 
Maynard et al, 
2003 
n = 10, age: 39.2 Intra-rater reliability, 2 x 
sessions, interval: 1 week 
Ankle angle at IC:  
ICC = -0.10 
– 
Monaghan et al, 
2007 
n = 10, age: 28.5 Intra-rater reliability, 2 x 
sessions, interval: 1 week  
Ankle sagittal:  
ICC0%stance = 0.94 
ICC50%stance = 0.90 
ICC50%swing = 0.93 
– 
Wilken et al, 
2012 
n = 29, age: 24.7 Intrarater-intersession 
reliability, 2 x sessions, 
interval: 5 days 
Ankle DF: 
ICC = 0.82 
Ankle DF:  
MDC = 3.66° 
Stroke  
 
Caty et al, 2009 n = 10, age: 53.5 Inter-session reliability, 3 x 
sessions, interval: baseline 
(T0), 1 day (T1) & 1 month 
(T2) 
Peak DF in swing: 
ICCT0-T1 = 0.84 
ICCT0-T2 = 0.67 
Ankle Angle at IC: 
ICCT0-T1 = 0.64 
 
– 
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ICCT0-T2 = 0.44 
Correa et al, 
2017 
n = 20, age: 55.2  Test-retest reliability, 2 x 
sessions, interval: 2-7 days 
GDI (for one stride): 
ICCparetic = 0.69 
ICCnon-paretic = 0.80 
GDI (for one stride): 
MDCparetic = 9.4° 
MDCnon-paretic = 7.5° 
Devetak et al, 
2016 
n = 17, age: 54.9 Test-retest reliability, 2 x 
sessions, interval: 2-7 days 
GPS: 
ICCparetic = 0.92 
ICCnon-paretic = 0.93 
ICCoverall = 0.95 
GPS: 
MDCparetic = 2.3° 
MDCnon-paretic = 1.9° 
MDCoverall = 1.7° 
Kesar et al, 2011 n = 19, age range: 47-75 Between-session reliability, 
2 x sessions, interval: 20 
days 
Peak DF in swing:  
ICC = 0.941 
Ankle angle at IC:  
ICC = 0.893 
Peak DF in swing: 
MDC = 4.9° 
Ankle angle at IC:  
MDC = 7.0° 
Yavuzer et al, 
2008 
n = 20, age: 54.2 Test-retest reliability, 2 x 
sessions, interval: 2 hours 
Ankle DF in stance: 
ICC = 0.96 
Ankle PF in swing:  
ICC = 0.95 
– 
Cerebral palsy 
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Klejman et al, 
2010 
GMFCS I: n = 10, age: 6.6  
GMFCS II: n = 10, age: 8.1 
GMFCS III: n = 8, age: 7.3  
Test-retest reliability, 2 x 
sessions, interval: 1-2 weeks 
Peak DF in swing:  
ICCGMFCS I = 0.97 
ICCGMFCS II = 0.89 
ICCGMFCS III = 0.87 
Ankle angle at IC: 
ICCGMFCS I = 0.92 
ICCGMFCSII = 0.55 
ICCGMFCS III = 0.90  
Peak DF in swing:  
MDCGMFCS I = 7.8° 
MDCGMFCS II = 11.6° 
MDCGMFCS III = 11.4° 
Ankle angle at IC: 
MDCGMFCS I = 10.1° 
MDCGMFCSII = 11.6° 
MDCGMFCS III = 5.1° 
Mackey et al, 
2005 
n = 10, age: 9 Test-retest reliability, 2 x 
sessions, interval: 1 week 
Ankle DF/PF: 
CMCnormal = 0.98 
CMChemiplegic = 0.96 
– 
Miller et al, 1996 n = 5, children with CP 
n = 5, healthy children 
age range: 6-16 
Test-retest reliability, 5 x 
sessions, interval: NS 
Ankle DF/PF: 
ICCCP = 0.941 
ICChealthy = 0.598 
– 
Rasmussen et al, 
2015 
n = 18, age: 8 Intra-rater reliability, 2 x 
sessions, interval: 7-10 days 
GPS overall:  
ICC = 0.88 
GDI overall:  
ICC = 0.88 
GPS overall: 
MDC = 0.25° 
GDI overall:  
MDC = 10.80 
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Redekop et al, 
2008 
GMFCS I: n = 11, age: 7.0 
GMFCS II: n = 12, age: 8.2 
GMFCS III: n = 10, age: 10.0 
Intra-session reliability, 8 x 
trials, interval: NS 
Ankle angle at IC:  
ICCGMFCSI = 0.90 
ICCGMFCSII = 0.77 
ICCGMFCSIII = 0.88 
Gait speed: 
ICCGMFCSI = 0.76 
ICCGMFCSII = 0.83 
ICCGMFCSIII = 0.83 
Ankle angle at IC:  
MDCGMFCSI = 8.04° 
MDCGMFCSII = 3.71° 
MDCGMFCSIII = 4.21° 
Gait speed: 
MDCGMFCSI = 0.22m/s 
MDCGMFCSII = 0.22m/s 
MDCGMFCSIII = 0.28m/s 
Sorsdahl et al, 
2008 
n = 18, age range: 3-13 Test-retest reliability, 1 x 
session, interval: 25min 
Cadence: 
ICC = 0.95 
Cadence: 
MDC = 11.08steps/min 
Steinwender et 
al, 2000 
n = 20, children with CP 
n = 20, healthy children  
age range: 7-15 
Test-retest reliability, 3 x 
sessions, interval: 1 week 
Ankle DF/PF:  
CMCcp = 0.83 
CMCnormal = 0.87 
– 
 
Abbreviations: CMC:  Coefficient of Multiple Correlation; CP: Cerebral Palsy; DF: Dorsiflexion; GDI: Gait Deviation Index; GMFCS: Gross Motor Function 
Classification System; GPS: Gait Profile Score; IC: Initial Contact; ICC: Intraclass Correlation Coefficient; MDC: Minimal Detectable Change
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4.3 Methods  
 
4.3.1 Participants  
 
For the purpose of this study, the data of two groups of pwMS who participated in two 
different studies conducted at the QMU motion analysis laboratory were analyzed. 
The data collected for ‘group A’ are described in more detail in Chapter 5. This data 
collection was conducted by the PhD candidate and took place between 2017-2018. The 
eligibility criteria for this group were clinically definite MS according to the revised 
McDonald criteria, stable MS which meant no evidence of disease activity based on 
clinical and radiological findings, have minimal disability in no more than two functional 
systems (EDSS < 3.5), regularly take part in aerobic exercise (for at least 30 minutes twice 
a week) and aged between 18 and 80. The exclusion criteria were pregnancy or breast-
feeding and comorbidities such as neurological conditions other than MS, cardiovascular 
or respiratory diseases.    
Data collection for ‘group B’ took place in the period 2010-2011 by another researcher 
and were used for secondary analysis of the data. Participants were eligible if they were 
diagnosed with MS according to the revised McDonald criteria, experiencing foot drop 
during walking, being judged suitable for FES to treat foot drop by a clinical specialist 
physiotherapist and aged between 18 and 75. The exclusion criteria were any relapse in 
the past three months and patients who were pregnant or breast-feeding.  
  
4.3.2 Ethical opinion  
 
Both studies gained a favourable ethical opinion from NHS (National Health Service) 
Research Ethics Committee and Queen Margaret University Ethics Committee and NHS 
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Lothian Research and Development approval was sought before commencing the studies. 
All procedures were in accordance with the declaration of Helsinki regarding human 
experimentation.  
 
4.3.3 Recruitment process 
 
Participants in group A were recruited through the Anne Rowling Regenerative Clinic and 
the MS Therapy Centre Lothian, both based in Edinburgh, UK. Potential participants were 
identified by the MS specialist nurses and were given the Participant Information Sheet 
(PIS). Once they expressed an interest to take part, a visit was arranged to the Anne 
Rowling Clinic to meet with a consultant neurologist and co-investigator (Dr. Don Mahad) 
who explained the protocol in detail and answered any questions.  
All participants who were eligible and agreed to take part in the studies signed an informed 
consent form prior to commencing with the protocol.   
Participants for group B were recruited through a community NHS physiotherapy service 
based in Edinburgh, UK. People with MS who were considered suitable by their clinician 
for FES treatment were invited to take part in the study by giving them a PIS. People who 
agreed to take part in the study after reading the PIS, were contacted by the principal 
investigator (PI) to arrange the visits to QMU.   
 
4.3.4 Study procedures  
 
Both groups visited the motion analysis laboratory at Queen Margaret University and 
underwent 3D gait analysis assessment. Since the two groups involved participants taking 
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part in discrete studies, about seven years apart, the procedure of measurements for both 
groups is described separately.  
 
 
Figure 4.1 Flow diagram of the study design of Chapter 4. 
 
 
4.3.4.1 Group A 
 
Participants visited the laboratory on three occasions. The first visit consisted of 
measuring the anthropometric characteristics of the participants, recording of baseline gait 
kinematics during overground walking and habituation on the treadmill for the exercise 
task that they would have to complete in the second and third visit. The assessments in the 
second and third visits were identical. Walking kinematics of the participants were 
recorded before and after a 20 minute jogging/running on a treadmill. The protocol that 
this group completed is described in more detail in Chapter 5. For the purpose of this 
chapter, we used the kinematic variables derived from the gait analysis before the exercise 
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task from the second and third visit to calculate the test-retest reliability and the kinematic 
variables before the exercise task from the second visit for the intra-session reliability.  
 
4.3.4.2 Group B 
 
Participants were asked to visit the laboratory at least four times within a maximum of six 
weeks. All visits were separated by at least three days, but no more than 14 days. In each 
visit, participants underwent gait analysis assessment, along with the 6-min walk test and 
the 10-m timed walking test, the latter test was performed twice in each assessment. The 
10-m walk test and the gait analysis assessment were carried out with and without FES, 
within one session, while the 6-min walk test was performed either with or without FES 
in one session. The 6-min walk test and 10-m timed walking test were not used in the 
analysis for the present study. Gait analysis was carried out by first conducting the trials 
without FES, followed by the trials with FES.  
As previously reported (see section 4.3.1), this was a secondary analysis of the data 
collected in a previous study (Scott et al, 2013). For the purposes of the present study, i.e. 
to estimate the test-retest reliability, we used the data from the trials without FES from the 
first and second visit and for estimating intra-session reliability we used the trials without 
FES from the first visit. 
 
4.3.5 Gait analysis protocol (both studies) 
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The anthropometric characteristics that were measured were: body mass, height, leg 
length, knee width, ankle width and tibial torsion. These measurements are required for 
the calculation of the 3D position 
of the ankle, knee and hip joint 
centers by the Vicon Plug-in-Gait 
(Vicon Motion Systems, Oxford, 
UK). The gait analysis was 
undertaken using a 100Hz eight 
infra-red camera Vicon Nexus 
(version 1.8.5) computerized 3D 
motion capture system (Vicon 
Motion Systems, Oxford, UK). Passive 
reflective sphere markers of 9 or 14mm 
were placed on the lower limbs and pelvis of the participants according the Helen Hayes 
marker system (Kadaba et al, 1990). Markers were placed on the anterior superior iliac 
spines (ASIS) of each side and one on middle between the two posterior superior iliac 
spines (PSIS). For each leg, markers were placed on the lateral side of the thigh and tibia 
(wand markers), the knee marker on the lateral epicondyle of the femur just above the 
joint line in the center of the knee (walking trials only), the toe marker on the point 
between the second and third metatarsal heads, a marker on the middle of the lateral 
malleolus and the heel marker on the calcaneum in vertical alignment with the toe marker 
(Figure 4.2). A static trial (with the participant standing) was conducted first using a knee 
alignment device (KAD) to derive the orientation of the knee flexion/extension axis. After 
Figure 4.2 Anterior and posterior view of marker 
placement according to Helen Hayes marker 
system. 
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the static trial and the removal of the KADs, a standard reflective marker was placed on 
the lateral side of the knee as described above for the walking trials. Participants 
underwent gait analysis barefoot and were instructed to walk a distance of 7m across the 
laboratory, which consisted one trial, at their preferred self-selected walking pace. At least 
six trials were recorded using the Vicon motion analysis system. Participants were able to 
rest between trials if wished to do so. Similar to standard practice in clinical gait analysis, 
we chose the number of six walking trials to take into account variability and this number 
also allows trials to be discarded due to possible issues such as missing markers ( i.e. not 
visible by at last two cameras).   
 
4.3.6 Data analysis  
 
Pelvis and lower limb angles in sagittal, transverse and frontal planes were derived using 
the Vicon Plug-in-Gait software. Kinematic data for each of the six trials in each visit 
were time normalized so that every trial included one gait cycle (i.e. between two 
consecutive foot strikes) consisting of 51 data points. Polygon software (version 3.5.2) 
(Oxford Metrics Group, Oxford, UK) was used for reporting and graphically presenting 
the kinematic data for each trial. Through Polygon, kinematic and spatiotemporal data 
were extracted to Microsoft Excel files and then a custom-made program in Matlab 
R2014b (Mathworks, Natrick, USA) was used for further analysis. The peak dorsiflexion 
(DF) in the swing phase and the ankle angle at initial contact (IC) were derived for each 
of the six walking trials together with the spatiotemporal parameters (walking speed, step 
length, cadence). The average value of the joint angles (peak DF in swing and the ankle 
angle at IC) and step length was calculated from the six walking trials for the most and 
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the least affected legs for each of the two visits. The total walking speed and cadence were 
derived for both legs for each visit.  
The Gait Profile Score (GPS) (Baker et al, 2009) was also calculated for each walking 
trial for both visits and for each left and right leg separately and were summed to derive 
the total GPS score. The GPS is an index of overall gait pathology and is derived from the 
pelvis, hip, knee and ankle kinematics. The GPS in this study was calculated from the Gait 
Variable Scores (GVS) of the sagittal ankle angle, the foot progression angle, the sagittal 
knee angle, sagittal and frontal plane hip angle and pelvic angles in all planes. We 
excluded the hip rotation from the GPS score, as it has been documented that this angle is 
very sensitive to even small changes in marker placement and therefore exhibits large 
measurement error (Schwartz et al, 2004).  The GVS is the root mean square (RMS) 
differences over the whole gait cycle of an individual with MS and the average data of a 
healthy control group of similar age range. The healthy group consisted of eleven 
individuals (5 male, 6 female) and with an average age of 49.5 years (van der Linden et 
al, 2014b). The higher the GPS score, the higher the deviation from a normal gait pattern.   
 
4.3.6 Statistical analysis 
 
4.3.6.1 Test-retest reliability 
 
4.3.6.1.1 Consistency   
 
The relative reliability for peak DF in swing, ankle angle at IC, GPS and spatiotemporal 
parameters was calculated with the ICC (model 2,2) using a two-way mixed effects type 
of average measures for absolute agreement. We chose this type of ICC because repeated 
measurements (test-retest) cannot be regarded as randomised samples (Koo & Li, 2016). 
 121 
 
Intraclass correlation coefficient values ≥ 0.75 were as regarded as excellent level of 
practical and clinical significance for test-retest reliability, while ‘good’ was between 
0.60-0.74 and ‘fair’ between 0.40-0.59 (Shrout & Fleiss, 1979; Cicchetti, 1994).  
 
4.3.6.1.2 Agreement  
 
The absolute reliability for the aforementioned variables was determined by reporting the 
SEM, the MDC and the LoA.  
The SEM is related to an outcomes’ reliability, because it provides an indication of the 
variability among measurements (de Vet et al, 2006 (b)). It was determined with the 
following equation:  
SEM =  𝑆𝐷 ×  √(1 − 𝐼𝐶𝐶)  (1) 
where SD is the standard deviation from the first testing session.  
 
Minimal detectable change is important information for an evaluative instrument to 
provide to clinicians and researchers because it gives information of the cut-off point 
above which it can be regarded as ‘true’ change (de Vet et al, 2006) and was calculated 
using the equation:  
MDC95% = 1.96 × 𝑆𝐸𝑀 ×  √2  (2) 
 
Limits of agreement were quantified in this chapter for both groups by the Bland-Altman 
(B&A) plot. The B&A plot was developed in order to describe the agreement between 
two different instruments measuring the same outcome or the repeatability (precision) of 
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one instrument on repeated occasions (Bland & Altman, 1999). In order to do so, firstly 
by subtracting the mean of the first visit from the second visit the mean difference was 
calculated. The LoA were calculated according to the equation:  
         LoA =  𝑀𝑒𝑎𝑛 ± (𝑆𝐷 × 1.96)            (3) 
where, Mean is the average of the difference of the two visits and SD is the standard 
deviation of the difference between the two visits.  
 
4.3.6.2 Intra-session reliability  
 
4.3.6.2.1 Consistency  
 
The relative intra-session reliability (i.e. over the six trials) for peak DF in swing, ankle 
angle at IC, GPS and spatiotemporal parameters was calculated with the ICC (model 
2,2) using a two-way mixed effects type for average measures for absolute agreement. 
The ICC was calculated from the six walking trials of the first visit for both groups. As 
mentioned before, ICC values ≥ 0.75 were regarded as excellent, while ‘good’ were 
between 0.60-0.74 and ‘fair’ between 0.40-0.59 (Shrout & Fleiss, 1979; Cicchetti, 
1994). 
  
4.3.6.2.2 Agreement 
 
The absolute reliability for peak DF in swing, ankle angle at IC, GPS and spatiotemporal 
parameters was determined by calculating the SEM and MDC95% for these variables. For 
estimating the SEM and MDC95% values, the equations 1 and 2 were used respectively. 
The standard deviation of the first walking trial was used in the equations.  
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All mean, standard deviation (SD) and ICC values and B&A plots were calculated using 
SPSS 23 (IBM, Armonk, USA) and SEM and MDC95% calculations were determined 
with the use of Microsoft Excel 2007 (Microsoft Corp., Redmond, WA).   
 
 
 
4.4 Results  
 
Group A consisted of 21 highly active pwMS, with the data being collected by the 
researcher. Group B consisted of 28 pwMS who presented and were being treated for foot 
drop. This was a secondary analysis of previously collected data. The descriptive 
characteristics of the participants in group A and B can be seen in Table 4.2. 
 
 
 
Table 4.2 Participant characteristics of both groups. 
 Group A Group B p-value 
Female/Male, n 14/7 14/14 0.12 
Age, years 43.8 (10.9) 52.2 (10.1) 0.004 
EDSS range 1-3.5 4-6 -  
Height, m 1.71 (0.08) 1.69 (0.07) 0.27 
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Body mass, kg 72.6 (14.4) 78.2 (16.7) 0.10 
BMI, kg/m2 24.7 (4.4) 26.9 (4.3) 0.04 
Walking aid (none/ walking 
stick/stroller), n 
21/0/0 16/11/1 -  
 
Abbreviations: BMI: Body Mass Index; EDSS: Expanded Disability Status Scale; NA: not available 
 
4.4.1 Test-retest reliability  
 
4.4.1.1 Consistency   
 
Table 4.3 and Table 4.4 present the mean and standard deviation values from both visits 
of both groups respectively , ICCs [95% Confidence Intervals (CI)] between the two visits, 
and the SEM and MDC95% for all kinematic and spatiotemporal parameters. For group A 
all kinematic and spatiotemporal parameters exhibited ‘excellent’ ICC values. For group 
B, DF in swing, ankle angle at IC, walking speed, step length and cadence all exhibited 
‘excellent’ ICC values of  ≥ 0.75. ‘Good’ reliability was shown by the ICC values for the 
GPS of the most affected leg, while ICC values for GPS of the least affected leg indicated 
‘fair’ reliability.  
 
4.4.1.2 Agreement 
 
The agreement analysis showed that group B had higher SEM values than group A by ≈1° 
and higher MDC95% values by approximately ≈1°-5° for all the kinematic variables. Group 
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A also had lower SEM and MDC95% values for walking speed, step length and cadence 
(Table 4.3 & 4.4).  
 
Table 4.3 Test-retest reliability with mean (SD), ICC (95%CI), SEM and MDC95% for group A 
kinematic and spatiotemporal parameters. 
 Session 1 
Mean (SD) 
Session 2 
Mean (SD) 
p-value ICC (95% CI) SEM MDC95% 
DFMA (°) 7.9 (2.3) 8.1 (3.0) 0.30 0.862 (0.660-0.944) 0.85 2.4 
DFLA (°) 9.0 (2.5) 8.9 (2.8) 0.40 0.862 (0.657-0.944) 0.9 2.5 
ICMA (°) 0.9 (4.2) 1.7 (4.6) 0.06 0.919 (0.800-0.967) 1.21 3.4 
IC LA (°) 2.5 (3.9) 2.1 (5.2) 0.27 0.852 (0.635-0.940) 1.5 4.2 
GPSMA (°) 9.0 (1.4) 8.7 (1.1) 0.12 0.698 (0.274-0.876) 0.75 2.1 
GPSLA (°) 9.0 (1.1) 8.9 (1.6) 0.45 0.621 (0.039-0.848) 0.7 1.9 
WS (m/s) 1.25 (0.14) 1.26 (0.18) 0.36 0.833 (0.585-0.932) 0.06 0.16 
SLMA (m) 0.64 (0.07) 0.64 (0.08) 0.31 0.931 (0.830-0.972) 0.02 0.05 
SLLA(m) 0.64 (0.07) 0.63 (0.07) 0.24 0.909 (0.777-0.963) 0.02 0.06 
Cadence 
(steps/min) 
117 (7) 119 (9) 0.053 0.877 (0.698-0.950) 2 6 
 
Abbreviations: DFMA: peak dorsiflexion in swing of the most affected leg; DFLA: peak dorsiflexion in 
swing of the least affected leg; GPSMA: Gait Profile Score of the most affected leg; GPSLA: Gait Profile 
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Score of the least affected leg; ICMA: ankle angle at initial contact of the most affected leg; ICLA: ankle 
angle at initial contact of the least affected leg; ICC: Intraclass Correlation Coefficient; MA: most affected 
leg; MDC: minimal detectable change; LA: least affected leg; SEM: standard error of measurement; SLMA: 
step length of the most affected leg; SLLA: step length of the least affected leg; WS: walking speed.  
 
 
Table 4.4 Test-retest reliability with mean (SD), ICC (95% CI), SEM and MDC95% for group B 
kinematic and spatiotemporal parameters. 
 Session 1 
Mean (SD) 
Session 2 
Mean (SD) 
p-value ICC (95% CI) SEM MDC95% 
DFMA (°) 2.9 (6.7) 1.9 (6.5) 0.12 0.891 (0.761-0.951) 2.2 6.1 
DFLA (°) 7.5 (4.2) 6.4 (3.6) 0.04 0.823 (0.606-0.920) 1.8 4.9 
ICMA (°) -3.7 (6.9) -4.5 (5.6) 0.20 0.840 (0.647-0.928) 2.8 7.7 
ICLA (°) 1.8 (5.6) 1.1 (5.0) 0.23 0.773 (0.495-0.898) 2.7 7.4 
GPSMA(°) 9.1 (1.3) 8.8 (1.0) 0.18 0.636 (0.192-0.836) 0.8 2.2 
GPSLA (°) 9.5 (1.1) 9.2 (0.8) 0.09 0.489 (-0.105-0.767) 0.8 2.2 
WS (m/s) 0.77 (0.21) 0.81 (0.2) 0.10 0.831 (0.629-0.924) 0.08 0.23 
SLMA(m) 0.49 (0.09) 0.51 (0.09) 0.09 0.848 (0.666-0.931) 0.04 0.1 
SLLA (m) 0.47 (0.08) 0.49 (0.10) 0.15 0.742 (0.431-0.884) 0.04 0.1 
Cadence 
(steps/min) 
93 (16) 96 (14) 0.04 0.927 (0.835-0.968) 4 12 
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Abbreviations: DFMA: peak dorsiflexion in swing of the most affected leg; DFLA: peak dorsiflexion in 
swing of the least affected leg; GPSMA: Gait Profile Score of the most affected leg; GPSLA: Gait Profile 
Score of the least affected leg; ICMA: ankle angle at initial contact of the most affected leg; ICLA: ankle 
angle at initial contact of the least affected leg; ICC: Intraclass Correlation Coefficient; MA: most affected 
leg; MDC: minimal detectable change; LA: least affected leg; SEM: standard error of measurement; SLMA: 
step length of the most affected leg; SLLA: step length of the least affected leg; WS: walking speed.  
 
 
Limits of Agreement were for the two visits for both groups and the Bland-Altman plots 
were examined and are presented in Figures 4.2-4.6 for group A and Figures 4.7-4.11 for 
group B for all kinematic and spatiotemporal parameters.  
 
Figures 4.3 to 4.7 show the limits of agreement for group A and indicates that the limits 
of agreement for group A were narrower than those for group B for all kinematic and 
spatiotemporal parameters.  
For peak DF in swing (Figure 4.3) the mean difference was very close to zero with one 
outlier in both most and least affected legs.  
 
Figure 4.3 Bland & Altman plot of peak DF in swing (most and least affected leg) for group A. 
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─ 95% Limits of Agreement 
-- Mean difference 
DFMA: Peak dorsiflexion in swing of the most affected limb; DFLA: Peak dorsiflexion in swing 
of the least affected limb   
 
The limits of agreement of IC for the least affected leg were wider (-6.1-7.1°) than the 
most affected leg (-5.4-3.8°), but the participants were clustered around the mean 
difference compared to the most affected leg where they were more dispersed between the 
mean ± 1.96 x SD. 
 
 
Figure 4.4 Bland & Altman plot of IC (most and least affected leg) for group A. 
─ 95% Limits of Agreement 
-- Mean difference 
ICMA: Ankle angle at initial contact of the most affected limb; ICLA: Ankle angle at initial 
contact of the least affected limb  
 
Similar to the ankle kinematics, the limits of agreement for the GPS in group A were 
narrower (≈-2.5-2.5°) compared to group B.  
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Figure 4.5 Bland & Altman plot of GPS (most and least affected leg) for group A. 
─ 95% Limits of Agreement 
-- Mean difference 
GPSMA: Gait profile score of the most affected limb; GPSLA: Gait profile score of the least 
affected limb   
 
For both walking speed and cadence all values were between the limits of agreement apart 
from one outlier in each. The LoA were similar for walking speed in both groups, but 
smaller for cadence in group A. 
 
Figure 4.6 Bland & Altman plot of walking speed and cadence for group A. 
─ 95% Limits of Agreement 
-- Mean difference 
WS: Walking speed   
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There was a small negative deviation away from zero for step length in both legs, meaning 
that step length was higher in the second visit. A similar trend of dispersion was observed 
for both sides.  
 
Figure 4.7 Bland & Altman plot of step length (most and least affected leg) for group A. 
─ 95% Limits of Agreement 
-- Mean difference 
SLMA: Step length of the most affected limb; SLLA: Step length of the least affected limb   
 
Figure 4.8 to Figure 4.12 presents the limits of agreement for group B. Figure 4.8 shows 
that there are two outliers for peak DF in swing (i.e. difference between the visits of more 
than 1.96 x SD). It can also be seen that the limits of agreement are wider for the most 
affected leg (-7.1-9.0°) than for the least affected leg (-4.7-6.8°).  
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Figure 4.8 Bland & Altman plot of peak DF in swing (most and least affected leg) for group B. 
─ 95% Limits of Agreement 
-- Mean difference  
DFMA: Peak dorsiflexion in swing of the most affected limb; DFLA: Peak dorsiflexion in swing 
of the least affected limb   
 
For the ankle angle at IC there was the same trend as for DF in swing. For the least affected 
leg, all participants were concentrated around the mean difference of just above zero apart 
from two outliers. For the most affected leg, values were more dispersed but within the 
limits of agreement apart from one outlier. Limits of agreement were similar for both legs. 
 
 
Figure 4.9 Bland & Altman plot of IC (most and least affected leg) for group B. 
─ 95% Limits of Agreement 
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-- Mean difference 
ICMA: Ankle angle at initial contact of the most affected limb; ICLA: Ankle angle at initial 
contact of the least affected limb    
 
The limits of agreement for the GPS of both most and least affected legs were narrow (less 
than 3°). 
 
Figure 4.10 Bland & Altman plot of GPS (most and least affected leg) for group B. 
─ 95% Limits of Agreement 
-- Mean difference 
GPSMA: Gait profile score of the most affected limb; GPSLA: Gait profile score of the least 
affected limb   
 
For walking speed and cadence a trend was observed with participants walking slightly 
faster and with more steps/min in the first compared to the second visit. For both 
parameters, there was a central tendency around the mean with only one outlier for both 
parameters.  
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Figure 4.11 Bland & Altman plot of walking speed and cadence for group B. 
─ 95% Limits of Agreement 
-- Mean difference 
WS: Walking speed   
 
The limits of agreement for step length were narrow (≈-0.15-0.12m) with only two and 
one outliers for the most and least affected legs respectively.  
 
Figure 4.12 Bland & Altman plot of step length (most and least affected leg) for group B. 
─ 95% Limits of Agreement 
-- Mean difference 
SLMA: Step length of the most affected limb; SLLA: Step length of the least affected limb   
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4.4.2 Intra-session reliability  
 
4.4.2.1 Consistency  
 
The intra-session reliability (i.e. over six trials) was derived by calculating the ICC for the 
most and least affected legs for peak DF in swing, ankle angle at IC, GPS and 
spatiotemporal parameters. Both groups presented excellent consistency, with ICC values 
> 0.90 for all the kinematic and spatiotemporal variables (Table 4.5 & 4.6).   
 
4.4.2.2 Agreement 
 
For group A SEM values for peak DF in swing, ankle angle at IC and GPS were ranging 
between 0.1°-1.3°, with MDC values ranging from 0.3°-3.7° and were lower than what 
group B presented. The same pattern was for spatiotemporal parameters too, with group 
A presenting lower SEM and MDC95% values for walking speed, step length and cadence.  
 
Table 4.5 Intra-session reliability with mean (SD), ICC, 95% CI, SEM, MDC95% for Group A 
for the kinematic and spatiotemporal parameters. 
 Mean (SD) ICC (95% CI) SEM MDC95% 
DFMA (°) 7.8 (2.5) 0.949 (0.905-0.977) 0.7 1.9 
DFLA (°) 9.0 (2.6) 0.976 (0.954-0.989) 0.5 1.3 
ICMA(°) 1.2 (4.2) 0.986 (0.972-0.994) 0.6 1.5 
ICLA(°) 2.5 (4.4) 0.945 (0.897-0.975) 1.3 3.7 
GPSMA(°)  9.1 (1.4) 0.992 (0.986-0.997) 0.1 0.3 
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GPSLA(°) 8.9 (1.3) 0.980 (0.963-0.991) 0.2 0.5 
WS (m/s) 1.3 (0.2) 0.982 (0.965-0.992) 0.02 0.06 
SLMA (m) 0.64 (0.08) 0.982 (0.966-0.992) 0.01 0.03 
SLLA(m) 0.64 (0.07) 0.984 (0.971-0.993) 0.01 0.02 
Cadence (steps/min) 118 (8) 0.975 (0.953-0.989) 1 3 
 
Abbreviations: DFMA: peak dorsiflexion in swing of the most affected leg; DFLA: peak dorsiflexion in 
swing of the least affected leg; GPSMA: Gait Profile Score of the most affected leg; GPSLA: Gait Profile 
Score of the least affected leg; ICMA: ankle angle at initial contact of the most affected leg; ICLA: ankle 
angle at initial contact of the least affected leg; ICC: Intraclass Correlation Coefficient; MA: most affected 
leg; MDC: minimal detectable change; LA: least affected leg; SEM: standard error of measurement; SLMA: 
step length of the most affected leg; SLLA: step length of the least affected leg; WS: walking speed.  
 
Table 4.6 Intra-session reliability with mean (SD), ICC (95% CI), SEM, MDC95% for group B 
for the kinematic and spatiotemporal parameters. 
 Mean (SD) ICC (95% CI) SEM MDC95% 
DFMA (°) 2.9 (6.9) 0.989 (0.980-0.995) 0.7 1.9 
DFLA (°) 7.4 (4.4) 0.985 (0.972-0.993) 0.5 1.5 
ICMA (°) -3.7 (7.7) 0.961 (0.929-0.981) 1.4 4.0 
ICLA (°) 1.7 (6.3) 0.950 (0.910-0.976) 1.6 4.4 
GPSMA (°) 9.1 (1.4) 0.954 (0.916-0.978) 0.3 0.9 
GPSLA (°) 9.6 (1.3) 0.949 (0.909-0.975) 0.3 0.8 
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WS (m/s) 0.77 (0.2) 0.983 (0.969-0.991) 0.03 0.08 
SLMA(m) 0.50 (0.1) 0.961 (0.930-0.982) 0.02 0.05 
SLLA (m) 0.49 (0.1) 0.977 (0.956-0.989) 0.01 0.03 
Cadence 
(steps/min) 
89 (23) 0.995 (0.991-0.998) 2 5 
 
Abbreviations: DFMA: peak dorsiflexion in swing of the most affected leg; DFLA: peak dorsiflexion in 
swing of the least affected leg; GPSMA: Gait Profile Score of the most affected leg; GPSLA: Gait Profile 
Score of the least affected leg; ICMA: ankle angle at initial contact of the most affected leg; ICLA: ankle 
angle at initial contact of the least affected leg; ICC: Intraclass Correlation Coefficient; MA: most affected 
leg; MDC: minimal detectable change; LA: least affected leg; SEM: standard error of measurement; SLMA: 
step length of the most affected leg; SLLA: step length of the least affected leg; WS: walking speed.  
 
All kinematic variables in group B had higher SEM and MDC95% values than group A. 
All peak DF in swing and ankle angle at IC SEM values for group B were between 0.5°-
1.6° and GPS of 0.3°, with MDC95% values ranging from 1.74°- 4.31° and ≈ 0.80° 
respectively.  
 
4.5 Discussion 
 
The present study aimed to report on relative and absolute reliability of 3D ankle 
kinematics and spatiotemporal parameters in two groups of pwMS with different levels of 
walking impairment. These values were calculated through a test-retest design with a 
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period of seven to fourteen days between the two visits and also an intra-session design 
by using the six walking trials of the first visit.  
In Chapter 3 the gap of reliability indices for 3D gait kinematics in the MS population was 
highlighted, even though it is considered a ‘gold standard’ and is increasingly used to 
assess the effects of FES. This is the first study to report on such indices (i.e. ICC, SEM, 
MDC) for gait kinematics and spatiotemporal parameters in the MS population.  
Reliability is considered to be the extent to which the scores of an outcome on repeated 
measurements of participants that have not change in the interim period are the same under 
several conditions (e.g. over time, by different assessors, etc.) (de Vet et al, 2006). Relative 
reliability (i.e. consistency) in the present study was reported through ICC for a test-retest 
design and also during the same session (intra-session). Absolute reliability (i.e. 
agreement) was reported through SEM, MDC95% and Bland & Altman plots.  
 
4.5.1 Consistency  
 
Intra-class Correlations Coefficients were calculated for both groups for test-retest 
reliability and indicated good to excellent reliability for peak DF in swing, ankle angle at 
IC, GPS, walking speed, step length and cadence in both groups. The only exception to 
this was the GPS for group B which showed fair ICC values (≈0.48-0.63). The reliability 
of 3D gait kinematic and kinetic data have been explored in many studies in the healthy 
population. Similar to our findings, studies with healthy participants have shown good to 
excellent ICC values ranging from 0.77-0.93 for peak DF in swing and ankle angle at IC 
(Kadaba et al, 1989; Monaghan et al, 2007; Wilken et al, 2012; Fernandes et al, 2016; 
Mentiplay & Clark, 2018). However, other studies reported low ICC values for peak DF 
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in swing at ankle angle at IC (Meynard et al, 2003; Meldrum et al, 2014). Both of these 
studies reporting low ICCs (≈-0.10-0.44) had a small sample size and high standard 
deviation of each outcome, indicating inter-participant variability. 
For the spatiotemporal parameters, such as cadence, step length, walking speed and step 
width, we observed good to excellent ICC values in both groups. These findings are in 
accordance with studies in healthy populations which reported that these spatiotemporal 
parameters are reliable and highly repeatable (Meldrum et al, 2014). Although estimates 
of reliability for gait kinematics in pwMS have not been reported, a study by Sosnoff et 
al. (2015) examined the reliability of walking speed, cadence and step length. They 
reported that in a group of MS people with a varied disability level [Patient Determined 
Disease Steps (PDDS) range 0-6] there were excellent ICC values (0.91) for the 
spatiotemporal parameters which is similar to our findings for both groups.  
Reliability of kinematic variables has extensively been examined in the stroke population 
with studies reporting good to excellent ICC values indicating high test-retest reliability 
for peak DF in swing, ankle angle at IC and GPS (Yavuzer et al, 2008; Kesar et al, 2011; 
Devetak et al, 2016). On the contrary, one study indicated lower ICC values for most of 
the kinematic variables and especially for the ankle angle at heel strike (Caty et al, 2009). 
All studies presented in Table 4.1 with stroke population had a small sample size ranging 
from ten to twenty participants, with some studies reporting reliability values only for the 
paretic limb. Devetak et al (2016) examined ICC values for both limbs and found that the 
paretic limb had lower ICC values than the non-paretic. 
In children with cerebral palsy, sagittal kinematic parameters were found to have good to 
excellent reliability (Steiwender et al, 2000; Mackey et al, 2005; Redekop et al, 2008). 
 139 
 
When analysing the reliability for the GMFCS level separately, relative reliability in all 
kinematic variables was highest for children with GMFCS Level I (least impaired walking 
ability), with ICC values for GMFCS Level II and III ranging from moderate to high 
(≈0.55-0.90) (Redekop et al, 2008; Klejman et al, 2010). The reliability of cadence, 
walking speed, stride length, step length and single stance time were found to be excellent 
(ICC range 0.76-0.95) (Redekop et al, 2008; Sorsdahl et al, 2008), while step width had 
low ICC values indicating poor reliability (Sorsdahl et al, 2008). 
Intra-session reliability was also examined in the present study and we found excellent 
ICC values (> 0.92) for all kinematic and spatiotemporal parameters for both MS groups. 
There are few studies reporting on intra-session reliability, but all of them are in agreement 
with our findings showing excellent ICC values in different population groups 
(Steinwender et al, 2000; Monaghan et al, 2007; Yavuzer et al, 2008; Redekop et al, 2008; 
Kesar et al, 2011; Devetak et al, 20016). These findings of all studies, including ours, was 
expected and can be explained by the fact that compared to test-retest reliability in intra-
session reliability designs there is a decrease in the number of both extrinsic and intrinsic 
factors that could affect reliability such as marker placement and possible change in 
participants such as day-to-day variability especially in patient populations.   
 
4.5.2 Agreement  
 
Absolute agreement in the present study was examined through the indices of SEM, 
MDC95% and Limits of Agreement. For the test-retest design, the MDC95% values of peak 
DF in swing and ankle angle at IC were low (≈2.5ο) for the low EDSS group (group A), 
while for the high EDSS group (group B) SEM and MDC95% values were higher (4.9
ο-
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7.7ο). The same trend was also observed for GPS, walking speed, cadence and step length 
when comparing the two groups. The MDC95% values for our low EDSS group (group A) 
were similar to the values reported for the healthy population. Three studies with healthy 
participants reported MDC of ≈3.8ο for peak DF in swing (Wilken et al, 2012; Fernandes 
et al, 2016; Mentiplay & Clark, 2018). However, Meldrum et al (2014) found high 
MDC95% values for both peak DF in swing and ankle angle at IC of around 8°. 
Studies reporting on SEM and MDC values on kinematic and spatiotemporal parameters 
on stroke population and children with CP have similar findings as those in our group with 
higher EDSS (group B). The MDC values for stroke population have been reported to be 
of ≈2ο for the GPS, 4.9ο for peak DF in swing and 7ο for initial contact (Kesar et al, 2011; 
Devetak et al, 2016). In children with CP, the higher the GMFCS level, the higher the 
SEM and MDC values for all kinematic and spatiotemporal parameters (Redekop et al, 
2008; Sorsdahl et al, 2008; Klejman et al, 2010; Rasmussen et al, 2015). Hence, the results 
of our study and studies with different patient populations suggest that the more the 
walking pattern is impaired, the less reliable the measurement of gait kinematics will be. 
The association between gait variability and clinical walking indices in the MS population 
has been explored previously and it was found that people with higher EDSS (> 4.5) and 
using assistive devices had great variability in spatiotemporal parameters (i.e. step length, 
step time, etc.) than people with lower EDSS (Socie et al, 2013; Socie et al, 2014; Kalron, 
2016). 
Limits of agreement in our study were narrower for the minimally disabled group 
compared to the group with higher EDSS, which can be indicated by the increased 
variability in people with more impaired walking. Only two studies with healthy 
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population have reported on the limits of agreement for peak DF in swing, walking speed 
and cadence (Meldrum et al, 2014; Fernandes et al, 2016) and the results were similar to 
the minimally disabled group of MS. The limits of agreement should be interpreted with 
caution by clinicians, since there are no other MS or different patient group population 
data available to compare.   
The indices of SEM and MDC95% for the intra-session design were lower for both MS 
groups than for the test-retest design, which is in accordance with a study in stroke 
population (Kaser et al, 2011). There are not many studies examining the intra-session 
SEM and MDC values and that could potentially be because it is expected to have lower 
values than a test-retest reliability design since the number of extrinsic factors that could 
affect the repeatability is decreased.   
 
4.5.3 Limitations 
 
This study has some limitations that should be addressed in the future. Firstly, both groups, 
but especially group A, had small sample sizes. According to the COSMIN criteria the 
methodological quality of a study would be considered poor, if the sample size is less than 
30.  
Marker placement and analysis of the kinematics in the two groups were performed by 
two different researchers. This could introduce a form of an extrinsic error in the results 
when comparing the reliability indices between the two groups, i.e. the researcher placing 
the markers in group B may have had higher test-retest marker placement error, explaining 
somewhat the lower reliability for this group. However, both researchers for the two 
groups followed the same training protocol conducted by the same Director of the Gait 
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Lab, and similar number of practice sessions, including the assessment of within day test-
retest reliability of gait kinematic parameters for healthy participants.   
 
4.6 Conclusion  
 
The main objective of the present study was to determine relative and absolute reliability 
of 3D ankle kinematics and spatiotemporal parameters in two groups of pwMS with 
different levels of walking impairment.  
The results showed good to excellent ICC values of peak DF in swing, ankle angle at IC, 
GPS, walking speed, step length and cadence. The SEM and MDC95% values for each of 
the parameters were lower for the group with lower EDSS compared to the group with 
higher EDSS and that suggests that the higher the walking impairment the lower the inter-
session reliability. 
 The findings of this study provide clinicians and researchers with the indices of relative 
and absolute reliability for ankle kinematics in pwMS which can be applied to both clinical 
decision making and in the design of studies aimed at treating foot drop in people with 
MS.  
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Chapter 5. Gait characteristics in minimally impaired people with 
MS after an exercise task 
 
5.1 Purpose of the chapter 
 
The purpose of this chapter is to describe the methodology, and to present and discuss the 
findings of a study that was conducted to investigate the exercise-induced gait 
deterioration (as a measure of fatigability) in a highly physically active group of pwMS. 
The second aim of this study was to investigate whether the exercise-induced gait 
deterioration occurs in a healthy control group. 
 
5.2 Introduction 
 
As described in more detail in Chapter 2, gait impairments are a common symptom in 
pwMS with approximately 85% reporting experiencing walking difficulties at some stage 
throughout the disease course (Kelleher et al, 2010; Bethoux & Bennett, 2011). Walking 
impairments in relapsing remitting MS might be because of a relapse, which will 
frequently recover by leaving minimal or no permanent neurological deficit.  
Anecdotal reports in clinical practice indicate that a subset of pwMS, who are regularly 
engaged in exercise (i.e. jogging, running, etc.), often experience a transient phenomenon 
that often manifests as foot drop that resolves after cessation of exercise or a short period 
afterwards and the ability to walk and perform physical activities, such as running, returns 
to baseline. It is thought that this exercise induced transient phenomenon could be a sign 
of fatigability. At present, these transient periods of performance deterioration, or 
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fatigability, during exercise is largely put down to a rise in core body temperature in MS, 
which is known as Uhthoff’s phenomenon. It is considered as part of a temperature related 
neurological dysfunction when myelin or the protective fatty sheaths of nerve cells is 
damaged or lost (demyelinated) (Frohman et al, 2013). However, studies linking real-time 
core temperature changes with this reversible phenomenon are lacking.  
In order to explore how common it is for pwMS to experience transient foot drop, we 
conducted an audit. It was found that 33 out of 47 MS respondents (70%) reported 
experiencing this phenomenon with three reporting permanent foot drop and 11 not 
reporting any foot drop. The audit also showed that the most commonly activities 
associated with the self-reported foot drop were walking and running, and with foot drop 
appearing to be more evident and occurring earlier during faster speeds or when walking 
uphill (see details in section 2.3.3 and Appendix 1).   
Existing literature has demonstrated the presence of fatigability captured by gait kinematic 
changes. These studies have used protocols of prolonged walking until exertion or shorter 
walking tests (i.e. 6MWT) and reported exercise induced gait changes, evidenced as 
decrease in dorsiflexion at initial contact and at peak dorsiflexion in swing (Sehle et al, 
2011; McLoughlin et al, 2016; van der Linden et al, 2018). However, the EDSS of the MS 
population in these studies varied greatly ranged from 1.0 to 6.0, with the majority 4.0 or 
above (i.e. walking ability is affected) (McLoughlin et al, 2016; van der Linden et al, 
2018). To date, there has been no evidence whether exercise-induced deterioration occurs 
in pwMS with minimal neurological disability (EDSS < 3.0).  
Therefore, the aim of this study was to investigate the presence of exercise-induced 
deterioration of gait kinematics, thought to be sign of fatigability, in a group of pwMS 
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who have stable relapsing remitting MS, presented with minimal neurological disability 
(EDSS < 3.0).  
• The first objective was to investigate the differences in ankle kinematics and 
spatiotemporal parameters before and directly after a 20-minute treadmill run at a self-
selected speed and we hypothesised that the fatigability evidenced as foot drop was 
present in this group of pwMS after the exercise task. 
• The second objective was to find out whether this transient foot drop would be evident 
in an age-matched healthy control group and to explore the differences between the 
(unfatigued) gait kinematics of this group of pwMS and healthy controls. We hypothesised 
that the healthy control group would not exhibit this transient foot drop after the exercise 
task.  
• The third objective was to investigate the differences in exercise-induced gait 
deterioration between the second and third visit on the group of pwMS. It was 
hypothesised that there would be a similar pattern of gait deterioration in the group of 
pwMS between the two visits.  
• Finally, the fourth objective was to explore the association between the presence of 
exercise-induced deterioration of gait kinematics and changes in core temperature in a 
subgroup of pwMS. 
 
5.3 Methods 
 
5.3.1 Design  
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This was a pilot observational study with a pre-post design to measure exercise-induced 
gait deterioration, evidenced as foot drop in pwMS. The principal investigator (PI) for this 
study was a consultant neurologist from the Anne Rowling Clinic, Dr. Mahad, whose work 
in the laboratory using genetically manipulated mice with neuron specific mitochondrial 
respiratory chain enzyme defects indicated the role of neuronal metabolic changes in 
motor fatigability. Based on his laboratory work, this study was designed to investigate 
motor fatigability in the MS population. Data collection for this study took place from 
March 2017 until December 2018.  
 
 
Figure 5.1 Flow diagram of study design for Chapter 5. 
 
 
5.3.2 Participants 
 
Eligibility criteria required participants to be 18 years and over, have confirmed diagnosis 
of MS according the revised MacDonald criteria (Polman et al, 2011) and minimal 
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disability in no more than two functional systems (EDSS < 3). Further, in order to be 
eligible for inclusion, participants had to be regularly engaging in exercise for at least 30 
minutes continuously twice a week and be able to jog or run a mile without stopping. Only 
participants with stable MS were included in the study. Stable MS was defined as no 
evidence of disease activity based on clinical and radiological evidence within a two-year 
period prior to enrollment. Participants were eligible whether or not they were prescribed 
MS disease modifying therapy (DMT). 
The exclusion criteria were comorbidities such as neurological conditions other than MS, 
cardiovascular disease, respiratory disease such as asthma, metabolic disorders such as 
diabetes and thyroid disease, and peripheral vascular disease. In addition, people with a 
history of temperature sensitivity unrelated to exercise and those who were pregnant or 
post-partum were excluded from the study.  
For the healthy control group, eligibility criteria also required participants to be physically 
active (regularly engaged in exercise for at least 30min twice a week or more) and aged 
above 18. The exclusion criteria were similar to those in the MS group.  
Finally, contraindications for ingesting the thermistor capsule (VitalSense Core 
Tempereature Capsule, Equivital Inc., Cambridge) (see section 5.3.6.2) were: a) weight 
less than 36.3 Kg, b) diagnosed with diverticulitis, inflammatory bowel disease, gag reflex 
disorders, previously gastrointestinal (GI) surgery or hypo-mobility of the GI tract, c) 
undergo MRI while the thermistor capsule is still on the body, and d) having a cardiac 
pacemaker or implanted electronic medical device. All these contraindications are 
recommended by the manufacturer (Equivital Inc., Cambridge).  
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5.3.3 Ethical opinion  
 
Favourable ethical opinion was obtained from the National Health Service (NHS) 
Research Ethics Committee (South East Scotland Ethics Committee 02, REC reference 
number: 15-SS-0088) (Appendix 6) and Queen Margaret University Ethics Committee. 
Further, NHS Lothian Research and Development approval was also obtained before 
commencing with the study (Appendix 7). All procedures were in accordance with the 
declaration of Helsinki with regards to human participation. Participants could withdraw 
from the study at any point without giving any reason.  
 
5.3.4 Recruitment process 
 
People with MS with minimal neurological disability were recruited through the Anne 
Rowling Clinic (ARC), Edinburgh. The ARC is an outpatient MS service, where the 
patients are seen once a year by a neurologist consultant and every three to four months 
by MS specialist nurses. Patients are routinely asked about their lifestyle, including 
exercise, during their consultations. MS nurses and consultants mentioned the study to 
potentially eligible participants and if interested provided them with a PIS (Appendix 8). 
Potential participants were informed that their decision with regard to taking part in the 
study would not affect their usual medical care.  Potential participants were given two or 
more weeks to read the PIS and decide whether or not they were willing to take part in the 
study. Those that were willing to take part were invited to arrange a phone call or a visit 
to ARC to discuss the study with the PI and have the opportunity to ask questions in order 
to finalize their eligibility. Following the verbal consent to the PI, the first visit to the 
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motion analysis laboratory was arranged by the student where written informed consent 
(Appendix 9) was obtained after further explanation of the study.  
Healthy age matched control individuals were recruited through QMU and ARC by word 
of mouth. Those healthy individuals that expressed an interest were given the PIS and if 
they were willing to take part, a visit to QMU was arranged. The healthy control group 
also signed informed consent form prior to commencing the study protocol.  
 
5.3.5 Study protocol 
 
The study protocol required the participants with MS to visit the motion analysis 
laboratory at QMU on three occasions with one to three weeks in between each visit. Prior 
to arrival for the first visit, participants were sent four questionnaires by post and were 
asked to complete these and return them back to the student on the day of their visit. The 
questionnaires that were included were the Physical Activity Readiness Questionnaire for 
Everyone (PAR-Q+), FSMC, the FSS and a Foot Drop questionnaire developed for an 
audit (see details in section 5.3.6.5).  
 
5.3.5.1 Visit one 
 
Prior to commencing with the procedures, participants were explained the study aims and 
the tasks that they were going to be asked to perform.  
The aim of the first visit was for the participants to become familiar with the laboratory 
setting and exercising on a treadmill and for baseline 3D gait analysis. The first visit lasted 
no more than an hour.  
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The first step in the process was to perform the Nine-Hole Peg Test (9-HPT) one time 
with each hand and the T25FW that was performed twice. The next step was to measure 
anthropometric characteristics that are essential for the calculation of gait kinematics and 
these include body height and mass, leg length, knee and ankle width and tibial torsion. 
After the placement of the reflective markers (9mm) for the recording of the gait 
kinematics according to the Helen Hays marker set (Kadaba et al, 1990), participants were 
asked to stand still for five seconds with the KAD placed on the both knees so that a static 
reference trial would be captured. For more details about marker placement see details in 
section 4.3.5. After removing the KADs and placing the knee markers, a baseline gait 
analysis assessment followed which included six trials of barefoot walking over distance 
of around 7m at their usual comfortable walking pace. Prior to gait analysis, participants 
had a few walking trials to familiarise themselves with barefoot walking and markers 
attached to their pelvis and lower limbs.  
The final task for the first visit was for participants to become habituated to running on a 
treadmill. For this and any further visits to the gait laboratory that involved running on the 
treadmill, participants had to wear a harness (Wingman Harness, USA) that was attached 
to the ceiling in order to prevent any tripping or falling. When they felt ready the treadmill 
started at a low speed (0.5m/h) and the investigator increased the speed until the 
participants felt that they were running at their usual speed and which they could sustain 
for 20 minutes. This procedure lasted for 10 to 20 minutes depending on each individual 
and his/her confidence on running on a treadmill.  
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For those participants who had agreed to ingest the thermistor capsule in the second visit 
an appointment was arranged to hand over the thermistor so that participants could ingest 
it the night before this visit.  
  
5.3.5.2 Visit 2 
 
Participants were asked to attend the QMU motion analysis laboratory a second time about 
a week after their first visit. In the second visit, the same gait assessment as described for 
the first visit was performed. However, in the second and third visit this assessment was 
performed before and directly after an exercise task (see below).  
Those participants who had ingested the thermistor capsule were given a chest belt to wear 
under their t-shirts to which the EquivitalTM EQ02 LifeMonitor was attached in order to 
record the core body temperature data. Participants had to ingest the thermistor capsule 
the night before if their assessment was in the morning or in the morning if their 
assessment was in the afternoon.  
The exercise task comprised of jogging/running on 
the treadmill for 20 minutes at a self-selected speed 
that was perceived as their usual running speed 
(Figure 5.2). Participants wore a harness for safety 
reasons for the duration of the treadmill running 
task and were given five minutes for warm up and 
finding a speed that they were comfortable with 
prior to the 20-minute running task. They were 
informed that they could adjust the speed 
Figure 5.2 Participant performing the 
exercise task on the treadmill. 
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throughout the task and any changes in speed and the time this occurred were recorded. 
Participants were allowed to stop the test at any point during these 20 minutes, although 
they were encouraged to continue for as long as they could. Throughout the exercise task 
participants were asked to rate their perceived exertion, affective valence and perceived 
fatigue levels every four minutes. For rating the perceived exertion the Borg Scale was 
used which is a 15-point scale. Affective valence (pleasure/displeasure one feels) was 
rated through the Feeling Scale and perceived fatigue through a Visual Analogue Scale 
ranging from 0 (no fatigue at all) to 10 (maximum fatigue) (see details on these scales on 
section 5.3.6).  
Immediately after the completion of the 20-minute self-selected speed run, participants 
performed six walking trials during which the kinematics were recorded. As these trials 
required barefoot walking, participants removed their shoes and reflective markers were 
attached to their feet in a procedure that did not last more than three minutes. The position 
of the foot markers had been marked during the initial positioning, in order to assure that 
the markers would be placed in the same position after the removal of the shoes.  
At the end of the second visit participants were given a triaxial ActivPalTM activity monitor 
(PAL Technologies Ltd, Glasgow, UK) (see details in section 5.3.6.6) and were asked to 
wear this monitor for five days in order to record their daily physical activity. Participants 
were provided with written instructions and double sided skin friendly attachment gels 
(PAL-stickiesTM, PAL Technologies Ltd, Glasgow, UK) to attach the monitor to the front 
of their thigh. The instructions included details and pictures of how to attach the monitor 
(Appendix 10). Participants were allowed to remove the monitor at nighttime but were 
asked to note this on a form that was included in the instructions. The activity monitors 
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were returned to the student at the third and final visit to the gait lab or were posted back 
to the student in a stamped addressed envelope that was provided to them.  
  
5.3.5.3 Visit 3 
 
The final visit was mostly performed seven to ten days after the second visit or in a few 
cases later if participants could not attend earlier. In this visit, participants performed the 
same procedures as in the second visit. The same order of the tasks took place, with  
walking assessment followed by the exercise task and the walking assessment at the end. 
However, participants did not ingest the thermistor capsule again nor were asked to wear 
the activity monitors.  
 
5.3.6 Outcome measures 
 
5.3.6.1 Gait kinematics and spatiotemporal parameters 
 
Three-dimensional (3D) gait analysis is a widely used method for identification of even 
subtle changes on a patients’ walking pattern and is considered a ‘gold’ standard in terms 
of quantitative gait analysis. In the laboratory of QMU a 100Hz eight infra-red camera 
Vicon Nexus (version 1.8.5) computerized 3D motion capture system (Vicon Motion 
Systems, Oxford, UK) is installed and for details on this system, marker placement and 
gait analysis protocol please refer in Chapter 4 (section 4.3.5 and 4.3.6). Many studies 
have confirmed appropriate psychometric properties of 3D gait analysis, but as it was 
highlighted in the systematic review of Chapter 3, there was a lack of psychometric studies 
for 3D gait analysis in the MS population. In Chapter 4 we investigated the test-retest 
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reliability and the minimal detectable change of 3D ankle kinematics in two groups of 
pwMS with different levels of walking abilities.  
For each of the six walks before and after the exercise task, one gait cycle per walk was 
used for further analysis. Gait kinematics and spatiotemporal parameters were derived 
using the Vicon Plug-in-Gait software (Vicon Motion Systems, Oxford, UK) and a 
custom-written Matlab script. The average of the parameters of the six gait cycles for the 
most and least affected leg in the MS group and the left for the healthy control group was 
used for analysis. The most and least affected leg of the pwMS was decided after 
inspection of exercise-induced change in kinematics for each leg.  
The GPS (Baker et al, 2009) was also calculated for each walking trial for before and after 
the exercise task for each most and least affected leg separately. The GPS is an index of 
overall gait pathology and is derived from the pelvis, hip, knee and ankle kinematics and 
for more details of how this was calculated please refer to section 4.3.6. 
 
5.3.6.2 Core body temperature 
 
Core body temperature and how it increases during exercise in real-time is important 
information in MS research because of the potentially negative effect of the Uhthoff’s 
phenomenon on activities of daily life. The EQ02 Life Monitor records multi-parameter 
physiological data such as heart rate, respiratory rate, skin temperature and core 
temperature. We were interested in the core body temperature during the 20min of the 
exercise task. The use of VitalSense Core Temperature Capsule transmits every 15s real-
time data to the EQ02 Life Monitor. All the parameters recorded by the EQ02 Life 
Monitor have been examined for their psychometric properties in healthy population and 
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it was concluded that the monitor is a reliable and valid tool to record multi-parameter 
physiological data and in particular core body temperature data (Liu et al, 2013). 
The core body temperature data were used to address the fourth objective, which was to 
examine the association between the presence of exercise-induced gait deterioration and 
changes in core temperature.  
 
5.3.6.3 Perceived exertion 
 
The Borg Scale of Perceived Exertion (Borg RPE) is an indicator of an individual’s 
perception of the physical effort during exercise. It is a relative scale with range from 6 to 
20, with 6 being ‘no exerted at all’ and 20 ‘very, very hard’ (Borg, 1982) (Appendix 11). 
The Borg RPE scale is a widely used measure for prescribing and monitoring exercise 
intensity and has been found to be a reliable and valid measure in many populations such 
as MS, stroke and Parkinson’s disease. (Sage et al, 2013; Cleland et al, 2016; Penko et al, 
2017). 
In the present study, perceived exertion was recorded during the 20-minute exercise task 
at four-minute intervals and was used as a descriptive measure of the perceived intensity 
which participants the participants were exercising.   
 
5.3.6.4 Affective valence 
 
The Feeling Scale (FS) is used to measure the affective valence during exercise (i.e. 
pleasure-displeasure) (Appendix 12). It is an 11-point scale which ranges from very good 
(+5), neutral (0) to very bad (-5). Individuals are asked to rate how they feel at specific 
time points, since mood can fluctuate throughout an exercise task (Hardy & Rejeski et al, 
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1989).  As for perceived exertion, affective valence was recorded during the exercise task 
as a descriptor of how participants felt throughout the task.  
 
5.3.6.5 Perceived fatigue 
 
5.3.6.5.1 Fatigue Scale for Motor and Cognitive Functions (FSMC) 
 
The FSMC is a 5-point Likert-type scale assessing motor and cognitive fatigue and 
consists from 20 items ranging from 1 (does not apply at all) to 5 (applies completely) 
(Penner et al, 2009) (Appendix 13). It is divided in three sub-scales, with the total score 
presenting cut-off values of  ≥ 43 as mild fatigue, ≥ 53 as moderate fatigue and ≥ 63 as 
severe fatigue. For the cognitive sub-scale, a cut-off ≥ 22 represents mild cognitive 
fatigue, ≥ 28 moderate fatigue and ≥ 34 severe cognitive fatigue.  The third sub-scale for 
physical fatigue presents cut-off values of ≥ 22 as mild motor fatigue, ≥ 27 as moderate 
motor fatigue and ≥ 32 as severe motor fatigue. The sensitivity and specificity scores 
indicate good internal consistency and the scale has shown good convergent and 
discriminant validity (Penner et al, 2009). It has also been examined for cross-cultural 
validity in the Danish language, indicating that is a tool that can be used in the Danish MS 
population (Oervik et al, 2017).  
 
5.3.6.5.2 Fatigue Severity Scale (FSS) 
 
The FSS is a questionnaire evaluating the impact of fatigue, primarily on the physical 
domain, originally developed for MS and systemic lupus erythematosus. It consists of nine 
items and ranges from 1 (strong disagreement) to 7 (strong agreement) reflecting the 
severity of fatigue the past week (Krupp et al, 1989) (Appendix 14). The total score can 
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range from 9-63 and a score of less than the cut-off point of 36 indicates that the person 
might not suffer from fatigue. The psychometric properties of the FSS has been examined 
for the MS population and has been found to have good test-retest reliability, precision 
and strong association with other outcome measures indicating good construct validity 
(Krupp et al, 1989; Learmonth et al, 2013b) along with cross-cultural validity (Armutlu et 
al, 2007; Rietberg et al, 2010). 
Both the FSMC and the FSS were assessed in the present study in order to describe the 
level of self-reported fatigue.  
 
5.3.6.5.3 Visual Analogue Scale to evaluate fatigue severity (VAS-F) 
 
The VAS-F is a scale consisting of 18 items regarding subjective experiences of fatigue 
(Lee et al, 1991). In our study, we used the fourth item on the scale to evaluate fatigue at 
a specific point in time. Participants are asked to mark in a 10cm line ranging from 0 (not 
fatigued at all) to 10 (extremely fatigued). The scale with all the items has been found to 
be reliable in healthy individuals and people with sleep disorders (Lee et al, 1990) and 
also in the MS population (Kos et al, 2017). The VAS-F was recorded only during the 
exercise task, as perceived exertion and affective valence, in order to describe the overall 
self-reported experience of the participants during the treadmill task.  
  
5.3.6.6 Objective habitual physical activity  
 
ActivPALTM activity monitors provide a measure of objective habitual daily physical 
activity of an individual. It is attached in the front of the mid-thigh and it is small in size 
(35mm x 53mm x 7mm), which constitutes it unobtrusive. Participants wore the 
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ActivPALTM during waking hours except while showering and swimming for five days. 
The accelerometer senses limb position and acceleration activity, which translates in the 
time an individual spends standing, lying, transitions from sit to stand and step count. 
Moreover, the cadence of upright activities is recorded enabling to quantify the intensity 
of physical activities. The psychometric properties of ActivPALTM might not have been 
examined in the MS population, but have been examined in healthy (Dowd et al, 2012; 
Harrington et al, 2012) and other patient populations such as CP and stroke (Dahele et al, 
2007; Tang et al, 2013) indicating that is a reliable and valid tool to measure physical 
activity.   
Participants were asked to wear the ActivPALTM over five days and was used as a 
descriptive measure of their habitual physical activity. We reported the daily step count, 
but unfortunately we were not able to correct for wear time. Although a diary to record 
the time, during which the ActivPALTM was worn, was provided to the participants, a 
diary to record the time that they were wearing the, the majority of the participants did not 
record this information in the diary. 
 
5.3.6.7 Timed 25-Foot walk 
 
The T25FW is a short distance walking test assessing mobility function and it is one of 
the components of the Multiple Sclerosis Functional Composite (MSFC). The individual 
is instructed to walk a 25 foot distance as quickly as possible but safely twice. The score 
is the average of the two trials. The MSFC and the T25FW on its own have been 
extensively examined for their psychometric properties. The T25FW has shown to be a 
reliable, valid and responsive tool to examine walking capacity in the MS population 
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(Learmonth et al, 2012; Baert et al, 2014; Larson et al, 2013; Learmonth et al, 2013a; 
Andreopoulou et al, 2018).  
 
5.3.6.8 Nine Hole Peg test 
 
The 9HPT is a measure of manual dexterity and both dominant and non-dominant hands 
are tested. Individuals have to place and then remove nine pegs into nine holes as quickly 
as possible and the total time to finish the task is recorded. It is also one of the components 
of the MSFC. A recent systematic review summarized all the psychometric evidence of 
the 9HPT on the MS population. It is thought to be a ‘gold’ standard on measuring upper 
limb function and manual dexterity, since it has been found to be a reliable, valid, 
responsive and sensitive to changes outcome (Feys et al, 2017). 
 
5.3.6.9 Thermal perception 
 
A VAS scale for the perception of how heat is affecting participants when exercising was 
used. Individuals had to rate in a line from 0 to 10 how much they perceived that heat was 
affecting their exercise activities in their everyday life. Previous research has 
demonstrated good reproducibility and validity of the VAS scale for measuring thermal 
perception in healthy population (Davey et al, 2007; Leon et al, 2008). 
 
The T25FW, the 9HPT and the VAS for thermal perception were recorded only during 
the initial visit of the participants and were used only as descriptive characteristics of the 
participants, in order to gain more information about their abilities.  
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5.3.7 Statistical analysis  
 
In order to determine whether there was a difference between the pre- and post-exercise 
gait kinematic and spatiotemporal parameters in the MS group a paired t-test was carried 
out. The assumption of normality was checked and confirmed by visual inspection of the 
q-q plots and box plots of the data. A Shapiro-Wilks test was also performed, indicating 
that there was no violation in this assumption.  
Further, an independent t-test was carried out to analyse the difference between the change 
in the gait kinematic and spatiotemporal parameters (i.e. before-after the exercise task) 
between the MS and the healthy control group. This test was also employed to examine 
whether differences exist between the gait parameters between the groups before the 
exercise task. The assumption of normality was examined as described previously within 
groups and the homogeneity of variance was checked using the Levene’s test. There were 
no violations of these assumptions. The gait parameters that were analysed for both the 
MS and the healthy control group were the peak DF in swing, the ankle angle at initial 
contact, walking speed, cadence and step length.  
In order to analyse the presence of exercise-induced fatigability at an individual level, we 
also displayed the individual change values of peak DF in swing in relation to the 
MDC95%. The MDC95% values used in this study were derived from the test-retest 
reliability study that is described in Chapter 4.  
The other outcome measures, such as the fatigue questionnaires, the T25FW and 9HPT, 
the ActivPALTM data and the reported scales during the exercise task, were used as 
descriptive measures to characterise the population of interest.  
 
 161 
 
 
5.4 Results  
 
5.4.1 Participants 
 
A total of 17 pwMS with minimal disability (EDSS < 3) and who were physically active 
as set out in the inclusion criteria were recruited for this study. Two people withdrew from 
the study after their initial visit to QMU laboratory. The reasons for not continuing was 
personal issues for one and for the other not having enough time to commit to the 
subsequent visits. Table 5.1 presents the demographic characteristics of the 15 pwMS that 
completed the study. Further, 15 healthy individuals were also recruited and completed 
one visit to QMU with their demographic details also shown in Table 5.1.  
 
Table 5.1 Demographic characteristics for MS and healthy population presented as means (SD). 
 MS runners 
(n=15) 
Healthy control 
(n=15) 
Female/Male, n 9/6 8/7 
Age, years 42.0 (10.0) 41.8 (11.9) 
EDSS range 0.5-2.5 - 
RR/PP/SP, n 15/0/0 - 
Disease duration, years 16.5 (11.9) - 
T25FW, s 3.9 (1.0) - 
9HPT (Dominant/Non-Dominant), s 23.3/25.5 - 
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Daily step count (averaged over 5 
days), n 
11799 (4206)  
range: 3962-18832 
- 
FSMCtot (20-100) 45.5 (18.1) - 
FSMCcognitive (10-50) 22.3 (9.9) - 
FSMCphysical (10-50) 23.1 (8.9) - 
FSS (9-63) 28.6 (15.7) - 
 
Abbreviations: 9HPT: 9 Hole Peg Test; EDSS: Expanded Disability Status Scale; FSMC: Fatigue Scale 
for Cognitive and Motor Function; FSS: Fatigue Severity Scale; T25FW: Timed 25 Foot Walk; RR: 
Relapsing Remitting; PP: Primary Progressive; SP: Secondary Progressive 
 
The two groups were gender and age matched, with similar female to male ratio and 
average age in years. All the pwMS were diagnosed with relapsing remitting MS, with 
EDSS range of 0.5 to 2.5 and disease duration (i.e. first symptoms before confirmed 
diagnosis) of 16.5 years. All participants in the MS group (except one who twice a week 
was attending circuit gym classes) were frequent runners (at least twice a week). The 
healthy control group consisted of people who they ran at least three or more times a week. 
When inspecting the individual fatigue scores according to the cut-off values of the FSMC 
total score, two participants were experiencing mild fatigue, one participant moderate 
fatigue and four severe fatigue. Further, for the cognitive subscale of the FSMC three 
participants were experiencing moderate fatigue and three severe cognitive fatigue, whilst 
for the physical subscale one was experiencing mild physical fatigue, two participants 
reported moderate physical fatigue and four were experiencing severe physical fatigue. 
The individual scores of the FSS demonstrated that six of the participants were suffering 
from fatigue according to the cut-off values of the FSS [FSS < 36 (Krupp et al, 1989)].  
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The time interval between visits was approximately between to seven to fourteen days, 
with exception of three participants with interval from second to third visit been three to 
four weeks due to personal reasons (i.e. planned holidays and work).  
 
5.4.2 Pre-post exercise task gait changes in pwMS in the third visit 
 
Our first objective was to explore the differences between gait characteristics in pwMS 
before and directly after a 20-minute bout of treadmill running at a self-selected speed. 
There was a statistically significant difference between pre and post exercise peak DF in 
swing of the most affected limb of -1.5° [t(14)=2.703, p=0.017, 95% CI (0.32 2.76)] 
(Table 5.2). There were no other statistically significant differences in any other kinematic 
or spatiotemporal parameters between pre and post exercise walking trials (Table 5.2).  
 
Table 5.2 Gait kinematic and spatiotemporal characteristics of the MS group before and after a 
20-minute bout of treadmill running at a self-selected speed in the 3rd visit [Mean (SD)]. 
 Pre-run Post-run p-value 
Kinematic parameters 
DFMA (°) 7.7 (2.9) 6.2 (3.8) 0.017 
DFLA (°) 8.7 (2.7) 8.6 (2.7) 0.766 
ICMA (°) 0.4 (4.6) 0.2 (5.1) 0.624 
ICLA (°) 1.4 (5.6) 2.3 (5.8) 0.105 
GPSMA (°) 8.55 (1.1) 8.53 (1.0) 0.895 
GPSLA (°) 8.8 (1.4) 9.1 (1.3) 0.431 
Spatiotemporal parameters 
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WS (m/s) 1.29 (0.2) 1.31 (0.2) 0.447 
Cadence (steps/min) 118 (10) 119 (9) 0.324 
SLMA (m) 0.66 (0.08) 0.67 (0.09) 0.279 
SLLA (m) 0.65 (0.07) 0.65 (0.08) 0.849 
 
Abbreviations: DFMA: peak dorsiflexion in swing of most affected limb; DFLA: peak dorsiflexion in 
swing of least affected limb; GPSMA: gait profile score of most affected limb; GPSLA: gait profile score 
of least affected limb; ICMA: ankle angle at initial contact of most affected limb; ICLA: ankle angle at 
initial contact of least affected limb; SLMA: step length of most affected limb; SLLA: step length of least 
affected limb; WS: walking speed.  
 
At an individual level, six out of the 15 participants with MS showed a deterioration in 
peak DF in swing of the most affected limb that exceeded the MDC95% value (2.4°) (see 
Chapter 4) after a 20-minute of treadmill run at a self-selected speed (Figure 5.3). In Figure 
5.3 it is apparent that no one in the healthy control group presented any deterioration in 
peak DF in swing exceeding the MDC95% value, which could indicate that the deterioration 
after exercise in gait kinematics (i.e. evidenced as foot drop) is disease specific 
fatigability.  
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Figure 5.3 Pre-post exercise change in peak DF in swing of the MS (3rd visit) and healthy control 
group. Data are presented in relation to the MDC95% value (see Chapter 4). 
 
 
5.4.3 Gait differences between MS and healthy control group 
 
The table below illustrates the exercise characteristics of the third visit for the MS group 
and for the one visit of the healthy control group (Table 5.3). The average running speed 
during the 20-minute treadmill run was slower for the MS group compared to the healthy 
control group. Although these data are descriptive, they suggest that the healthy control 
group exerted themselves more than the MS group as denoted by the RPE scale and 
reached greater levels of fatigue.  
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Table 5.3 Basic description of the exercise task and self-reported response characteristics for the 
two groups. 
 MS (n=15) HC (n=15) 
Average Running Speed (m/s) 2.27 2.72 
Peak RPE (6-20) 14 17 
ΔRPE (6-20) 4.6 11 
ΔFeeling Scale (+5 to -5) 6.0 5.0 
ΔVAS Fatigue (0-10)  3.0 7.0 
 
Abbreviations: RPE: Rating of Perceived Exertion; VAS: Visual Analogue Scale.  
 
Table 5.4 presents the comparison between pre and post exercise gait characteristics in the 
healthy control group. As it can be seen from the table, unlike the MS group, there were 
no statistically significant differences in any of the kinematic parameters. Interestingly, 
there was a statistically significant increase after exercise in walking speed [t(14)=-3.552, 
p=0.003, 95% CI (-0.08 -0.02)], cadence [t(14)=-3.822, p=0.002, 95% CI (-4.3 -1.21)] and 
step length of the left limb [t(14)=-2.368, p=0.033, 95% CI (-0.02 -0.001)].  
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Table 5.4 Gait kinematic and spatiotemporal characteristics of healthy individuals before and 
after a 20-minute bout of treadmill running at a self-selected speed [Mean (SD)]. 
 Pre-run Post-run p-value 
Kinematic parameters 
DFL (°) 7.0 (2.2) 7.2 (2.7) 0.619 
DFR (°) 8.3 (1.9) 7.8 (2.5) 0.279 
ICL (°) 1.9 (3.0) 2.2 (3.4) 0.425 
ICR (°) 2.7 (2.7) 2.1 (4.1) 0.235 
Spatiotemporal parameters 
WS (m/s) 1.24 (0.16) 1.29 (0.18) 0.003 
Cadence (steps/min) 114 (10) 117 (10) 0.002 
SLL (m) 0.65 (0.05) 0.66 (0.05) 0.033 
SLR (m) 0.65 (0.05) 0.66 (0.06) 0.114 
 
Abbreviations: DFL: peak dorsiflexion in swing of left limb; DFR: peak dorsiflexion in swing of right 
limb; ICL: ankle angle at initial contact of left limb; ICR: ankle angle at initial contact of right limb; SLL: 
step length of left limb; SLR: step length of right limb; WS: walking speed.  
 
Another objective was explore any gait pattern differences between the two groups. As 
Table 5.5 shows, there was a statistically significant difference between groups in the pre 
and post exercise change in peak DF in swing. The MS group was characterised by a mean 
decrease of -1.5° compared to healthy controls with an increase of 0.2° [t(28)=-2.523, 
p=0.18, 95% CI (-3.15 -0.32)]. Interestingly, there were no statistically significant 
differences in any of the kinematic (i.e. notably the peak DF in swing) and spatiotemporal 
parameters between the MS and the healthy control group before the exercise task.  
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Table 5.5 Gait kinematic and spatiotemporal differences (post-pre exercise) between pwMS and 
healthy individuals. 
Difference (post-pre run) 
 MS (n=15) HC (n=15) p-value 
Kinematic parameters 
DFMA (°) -1.5 (2.2) 0.2 (1.5) 0.018 
DFLA (°) -0.1 (1.5) - 0.570 
ICMA (°) -0.2 (2.1) 0.3 (1.6) 0.380 
ICLA (°) 0.8 (1.8) - 0.770 
Spatiotemporal parameters 
WS (m/s) 0.02 (0.08) 0.05 (0.05) 0.181 
Cadence (steps/min) 1 (3) 3 (2.8) 0.043 
SLMA (m) 0.01 (0.04) 0.01 (0.02) 0.949 
SLLA (m) -0.001 (0.03) - 0.315 
 
Abbreviations: DFMA: peak dorsiflexion in swing of most affected limb; DFLA: peak dorsiflexion in 
swing of least affected limb; GPSMA: gait profile score of most affected limb; GPSLA: gait profile score 
of least affected limb; ICMA: ankle angle at initial contact of most affected limb; ICLA: ankle angle at 
initial contact of least affected limb; SLMA: step length of most affected limb; SLLA: step length of least 
affected limb; WS: walking speed.  
 
 
5.4.4 Individual analysis of self-reported and objective measures of fatigability for the 
MS group 
 
The participants of the MS group reported, through a foot drop audit, whether or not they 
experience transient foot drop and during which activities this phenomenon would occur. 
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It can be seen from the individual data in Table 5.6 that eight out of the fifteen pwMS 
reported experiencing transient foot drop, most commonly during running or walking and 
one participant during cycling. However, objectively, in the second visit a decrease in 
peak DF in swing exceeding the MDC95% value (2.4°) was only recorded in three out of 
the fifteen pwMS while in the third visit this was recorded in six out of fifteen and with 
one participant exhibiting a deterioration of DF in swing exactly of 2.4°. What is striking 
about this individual dataset in this table is that four pwMS who had reported that they do 
not experience transient foot drop exhibited a deterioration in their ankle kinematics with 
a decrease in peak DF in swing greater than the MDC95% either in one of the two or in 
both visits. Moreover, participants (five out of the eight) who had reported experiencing 
transient foot drop while exercising did not exhibit a deterioration in gait after the 20-
minute treadmill run at a self-selected speed in the third visit.  
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Table 5.6 Self-reported and objective measures of foot drop in the two visits for the MS group. 
Participants Reported 
foot drop 
Activities ΔDF° 
(post-pre 
run)  
2nd visit 
Average 
running 
speed 
(m/s) 
 (2nd visit) 
Peak RPE 
(2nd visit) 
ΔDF° 
(post-pre 
run)  
3rd visit 
Average 
running 
speed (m/s) 
(3rd visit) 
Peak 
RPE 
(3rd 
visit) 
EDSS 
PP1 No - -1.6 1.55 15 -0.5 1.63 16 1.5 
PP2 Yes Running -1.7 1.86 13 3.1 1.91 17 2.5 
PP4 No - 3.0 2.8 13 0.6 3.0 12 1.5 
PP5 Yes Running/cycling -2.2 2.75 13 -3.5 2.41 15 2.0 
PP6 Yes Running 0.2 2.86 17 -0.9 2.58 17 1.0 
PP9 No - -1.3 1.61 13 -3.3 1.86 11 2.0 
PP10 No - -3.0 - 15 -2.9 - 13 1.5 
PP12 No - -3.1 2.13 12 -0.8 1.86 12 1.0 
PP13 No - -1.8 2.63 13 -2.4 2.55 13 2.5 
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PP15 Yes NR 2.1 1.3 13 -4.4 1.41 12 1.0 
PP16 Yes Running/walking 0.5 2.72 14 1.2 2.63 13 1.5 
PP17 No - -1.8 2.86 14 -3.0 2.8 12 1.0 
PP19 Yes Running -1.9 2.0 17 0.2 2.19 16 1.5 
PP22 Yes Running/walking -7.5 2.27 13 -4.7 2.27 15 2.0 
PP23 Yes Jogging/walking -2.3 1.69 13 -1.8 1.33 15 2.5 
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Participants in both visits had similar self-reported responses in RPE, psychological affect 
and fatigue ratings and average speed over the 20-minute treadmill run, although it the 
third visit the speed was slightly higher.  
 
5.4.5 Core temperature changes and fatigability 
 
Another objective in this study was to explore the changes in the core temperature during 
the exercise task. During the second visit, six of the 15 pwMS consented to swallow an 
ingestible core temperature capsule in order to record the change in core temperature 
during the 20-minute treadmill run at a self-selected speed. This was done to gain some 
insight as to whether the change in core temperature would be associated with 
observations of fatigability throughout the exercise task. Table 5.7 presents core 
temperature change (ΔTcore), absolute end-task temperature (Peak Tcore), ΔRPE, Peak 
RPE, feeling scale, ΔVAS Fatigue and average speed during the exercise task for the three 
who exhibited a deterioration in peak DF in swing above the MDC95% and the three who 
did not exhibited such a deterioration. Even though these data is descriptive, these data 
indicate that the group exceeding the MDC95% value although selecting to run at a lower 
speed, had similar core temperature and self-reported RPE, psychological affect (FS) but 
a possibly slightly higher fatigue response during the exercise task.  
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Table 5.7 Description of self-reported response characteristics and core temperature during the 
exercise task of the 2nd visit for the MS group who took the thermistor capsule. 
Response characteristics DF > MDC95% (n=3) DF ≤ MDC95% (n=3) 
ΔDFMA (°) -2.2 0.5 
Average running speed (m/s) 2.19 2.5 
Peak Tcore (°) 38.2 38.4 
ΔTcore (°) 0.95 1.08 
Peak RPE (6-20) 15 17 
ΔRPE (6-20) 9 8 
Feeling Scale (+5 to -5) 2.8 3.1 
ΔVAS Fatigue 3.9 2.6 
 
Abbreviations: ΔDFMA: change in peak DF in swing of most affected leg; Tcore: core body temperature; 
RPE: Rating of Perceived Exertion; VAS: Visual Analogue Scale 
 
 
 
5.5 Discussion  
 
5.5.1 Pre-post exercise task gait changes in pwMS 
 
The first objective in this study sought to determine the presence of gait deterioration after 
a 20-minute treadmill run at a self-selected speed in highly active pwMS who were 
diagnosed with stable, relapsing remitting MS. The most important finding was the 
statistically significant decrease of peak DF in swing after the exercise task, with six out 
of the 15 pwMS showing a decrease in DF exceeding the MDC95% value. This finding is 
consistent with that of other studies that have investigated kinematic changes after a 
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6MWT in people whose daily walking ability is affected. The study of McLoughlin et al. 
(2016) found statistically significant decrease only in DF at initial contact, while the study 
of van der Linden et al. (2018) demonstrated a statistically significant decrease of both 
peak DF in swing and at initial contact. However, to our knowledge this is the first study 
that confirmed the presence of exercise gait deterioration in people with EDSS < 3.0. A 
20-minute treadmill running task was selected for the current study as it was thought that 
the 6MWT would not be sufficient demanding to elicit any gait changes in this highly 
physically active group.  
There is a great amount of literature investigating fatigability evidenced as a decrease in 
walking speed, the distance walked or in a few studies as a deterioration of gait kinematics 
over a certain exercise task. The exercise tasks that were most commonly used were the 
6MWT or longer distance walking protocols across a wide range of the disability spectrum 
in MS (EDSS range: 0-6.5) (Sehle et al, 2011; Phan-Ba et al, 2012; Dalgas et al, 2014; 
Leone et al, 2016; McLoughlin et al, 2016; van der Linden  et al, 2018). Thus far, no 
studies have evaluated fatigability evidenced as foot drop in highly active pwMS with 
minimal impairments. 
Another interesting finding was that we did not detect any statistically significant 
differences in spatiotemporal parameters (i.e. walking speed, cadence and step length) pre 
and post exercise task. There are conflicting findings in the literature reporting in 
spatiotemporal parameters after fatiguing protocols on pwMS. Some studies are in 
accordance with our findings and did not observe any changes in walking speed, cadence 
or step length after a 6MWT (Feys et al, 2013; McLoughlin et al, 2016). In the study by 
Feys et al. (2013) changes in spatiotemporal parameters after a 2MWT and a 6MWT were 
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investigated in three groups of pwMS with different level of walking ability. It was found 
that the least impaired group (EDSS range: 1.5-4.0) did not show changes in 
spatiotemporal parameters pre-post the fatiguing walking task. However, other studies 
have found either decrease in cadence (van der Linden et al, 2018) or increase in step 
length and step width after a fatiguing task (Sehle et al, 2011). These conflicting results 
among studies is likely to be associated with the different fatiguing protocols (i.e. 6MWT, 
walking until exhaustion, 20-minute treadmill run) and with the level of disability of the 
MS population that was included in those studies, with increased gait deterioration at 
higher EDSS levels.  
 
5.5.2 Gait differences between MS and healthy control group  
 
Another objective of the present study was to examine potential differences in (pre-
exercise task) gait kinematics and spatiotemporal parameters between the MS and a 
healthy control group. We found no statistically significant differences in any kinematic 
or spatiotemporal parameters of gait prior to the exercise task between the MS and the 
healthy control group.  
Previous research studies comparing the gait characteristics of healthy individuals and 
pwMS with minimal neurological disability (EDSS < 3.5) have reported ambiguous 
findings. Consistent with our findings of no changes (before the exercise task) in the 
spatiotemporal parameters was a single study that reported no significant differences in 
walking speed, step length and double support time between pwMS (EDSS range: 0-1.5) 
and healthy individuals (Nogueira et al, 2013). However, in contrast to our findings, most 
other studies demonstrated that pwMS with EDSS between 0 to 2.5 walked slower, with 
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associated decreased cadence, stride and step length and prolonged double support time 
(Benedetti et al, 1999; Martin et al, 2006; Kalron et al, 2011; Sosnoff et al, 2012). A recent 
meta-analysis summarizing the gait deficits in pwMS (EDSS range: 1-4.8) compared to 
healthy individuals found large effects of MS on walking speed [Standardised Mean 
Differences (SMD = 1.12)], stride (SMD = 1.27), step length (SMD = 1.15), double 
support (SMD = 0.85) and swing phase duration (SMD = 1.23) with all effect sizes 
increased when participants were asked to walk at faster speeds (Comber et al, 2017).  
Our findings also did not demonstrate any statistically significant differences in the pre-
exercise kinematic parameters between the MS and the healthy control group. 
Interestingly, these findings are not supported by other studies. A number of studies have 
investigated gait kinematic characteristics of pwMS that have minimal neurological 
deficits (EDSS < 2.5) and it was observed that compared to healthy individuals pwMS 
had a significant decrease in dorsiflexion at initial contact, at toe off and DF during the 
swing phase of gait (Benedetti et al, 1999; Martin et al, 2006; Nogueira et al, 2013). These 
conflicting findings between our results and the rest of the studies could be associated 
with the high physical activity status of our MS group compared to the MS population 
from the other studies. Even though pwMS in the other studies also had minimal 
neurological deficits (EDSS < 3) and were without any mobility impairments, our study 
population consisted of active pwMS that were exercising at least two or three times in a 
week. The association between physical activity level and walking performance in pwMS 
has been documented (Snook et al, 2009; Cavanaugh et al, 2011). For example, 
Cavanaugh et al. (2011) reported that pwMS without any mobility limitations (EDSS < 
4.0) accumulated an average of 8860 steps daily which is consistent with levels recorded 
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in the general adult population. The pwMS in our study however seem to be far more 
physically active with an average of over 11000 steps a day. One may speculate that a 
higher physical activity level and associated increased fitness levels may have led to the 
lack of even mild deterioration in gait kinematics in our participants (pre-exercise).    
An important finding was the significant decrease of peak DF in swing in pwMS compared 
to our healthy control group. This could be a sign of exercise-induced fatigability in the 
MS population that does not occur in the healthy individuals. It is likely that the cause of 
exercise-induced fatigability in MS is multifactorial. It has been suggested that fatiguing 
protocols in pwMS induce impaired central motor activation (Andreasen et al, 2009), 
while other studies reporting increased central activation during fatiguing exercises which 
could possibly reflect a compensation mechanism (Thickbroom et al, 2008). Thus, it could 
be that the observed deterioration of the gait parameters after fatiguing protocols is a 
reflection of the failure of these compensatory mechanisms. Further, another possible 
explanation for this significant decrease in peak DF in swing could be the Uhthoff’s 
phenomenon that is well known to trigger a number of symptoms in MS (Frohman et al, 
2013). The demyelination interferes with the transmission of the nerve impulses along the 
axons and even though there are compensatory mechanisms to restore the nerve impulse 
conduction in demyelinated axons, these axons are more susceptible to changes such as 
rise in core temperature (due to exercise) (Lassmann et al, 2012).  
 
5.5.3 Individual analysis of self-reported and objective measures of the second and third 
visit for the MS group  
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The results of this study indicated that the MS group in third visit had a significant 
decrease in peak DF in swing (≈1.5°) after completing the exercise task. What is 
interesting is that by observing the individual performance of each participant, in the 
second visit only three out of 15 exceeded the MDC95% value, while in the third visit six 
out of fifteen showed a worsening exceeding the MDC95%. What is more interesting is that 
in only two participants a decrease in peak DF in swing exceeding the MDC95% was 
observed in both the second and third visit. Several factors could explain this observation. 
Firstly, since participants had three visits, with the first visit consisting of habituation on 
running/jogging on the treadmill and the following two consisting of completing the same 
20-min treadmill run at a self-selected speed, there could be a certain amount of training 
effect which resulted in a slightly higher running speed on the exercise task in the third 
visit with possible associated worsening of the walking afterwards. An additional aspect 
that should be taken into account is the increasing motivation of the participants to 
increase their running speed since they were more accustomed and comfortable to put 
more effort in the exercise task than the previous visit, which as explained above could 
have led to more participants experiencing fatigability. Another possible explanation for 
the difference between the two visits is the within-day and day-to-day variability of gait 
parameters in pwMS, although evidence for this is conflicting. For example, Albrecht et 
al. (2001) reported marked day-to-day variability in individual maximum walking time 
and distance of unaided walking in pwMS with EDSS range from 4.0 to 5.5. A study by 
Feys et al. (2014) examined the within-day variability of gait parameters during short and 
long distance walking tests in a wider range of disability level among pwMS (EDSS range: 
0-6.5) demonstrated that there was greater within-day variability over shorter distance 
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walking tests and the variability increased proportionally with the disability level. 
Especially for the least impaired group the within-day variation of walking speed was far 
below 20% (Feys et al, 2014). However, Morris et al. (2002) reported that from morning 
to afternoon there was very little change in any of the spatiotemporal parameters in either 
MS or healthy populations, even though self-reported fatigue was increased in the 
afternoon in pwMS. Similarly, Crenshaw et al. (2006) reported that there were no 
significant changes of kinematic and spatiotemporal parameters variability in a group of 
pwMS from morning to afternoon after a 15min walk, even though self-reported fatigue 
was increased in the afternoon. The majority of these studies have investigated the within-
day variability, while the variability in detection of fatigability is between-day. Further, 
these studies, including our reliability study in gait kinematics and spatiotemporal 
parameters described in Chapter 4, have reported on the variability in gait characteristics 
and not in the exercise-induced change of gait characteristics.  
 
5.5.4 Perceived versus objectively recorded fatigability  
 
Another interesting finding in this group of pwMS was that in the third visit six out of the 
15 exhibited post-exercise reduction in peak DF in swing exceeding the MDC95%. Three 
out of the six had reported that were not experiencing transient foot drop while exercising, 
even though it was objectively documented with the reduction in peak DF in swing post-
exercise. This rather contradictory result might be due to the fact that these are highly 
physically active people and subtle changes could not be easily perceived, whilst with 3D 
gait analysis, as shown to be the ‘gold’ standard, even subtle differences can be recorded. 
On the other hand, five out of the fifteen had reported in the audit that they experience 
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‘transient’ foot drop while exercising, but this was not objectively documented. It is 
difficult to explain this result, but it might be related to the physical performance on the 
exercise task where the 20-min treadmill run might not have been long enough to elicit 
the phenomenon.  
 
5.5.5 Core temperature and self-response vs objectively measured characteristics 
 
A sub-analysis from the six participants that accepted to ingest the thermistor capsule for 
recording of the core temperature while performing the exercise task showed that the core 
temperature change was an increase of around ≈1.0°C. Similar to the thermal responses 
observed in our sub-group, studies have shown core temperature changes of ≈0.9±0.4°C 
after endurance exercise (Skjerbaek et al, 2012; Sandroff et al, 2016). However, these 
studies did not investigate changes in gait kinematics or spatiotemporal parameters. In this 
sub-group, three pwMS showed changes exceeding MDC95% and three of them did exhibit 
this worsening in peak DF in swing. Although because of the small sample size no 
inferential statistics could be performed, both groups seemed to demonstrate similar core 
temperature and self-reported RPE and fatigue rating responses. This might indicate that 
heat sensitivity per se was not a factor influencing the reduction in peak DF in swing. 
However, future studies should look into heat sensitive pwMS and exercise-induced gait 
changes and confirm or refute these preliminary findings.   
 
5.5.6 Limitations and future suggestions 
 
Some methodological considerations need to be addressed. Firstly, this experimental 
study had a small sample size and power calculation was not performed in order to detect 
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changes in gait characteristics. However, it is aimed to act as a pilot study in order to be 
able to calculate the sample size that would be needed to conduct a longitudinal multi-
centre trial. Further, another possible limitation that we could not control was that some 
of the participants could not attend the second and third session at the same time of the 
day. As mentioned earlier, the time of the day could have influenced the performance on 
the exercise task depended on the fatigue level of the individuals and subsequently have 
an effect on the walking ability prior and after the exercise task. Further, as only six out 
of fifteen agreed to ingest the thermistor capsule, our preliminary finding that a change in 
core temperature is not associated with the presence of fatigability measured as a reduced 
peak DF in swing needs to be confirmed in future investigations. Such investigations may 
also record the change in core temperature in healthy controls.   
Since this was a pilot study we used the data obtained to inform sample size calculations 
for future definitive studies based on the same primary outcome. Based on a calculation 
on g*power (Faul et al, 2017) with an effect size of 0.44 for the peak DF in swing, with 
80% power to detect statistical significance (p < 0.05) between pre-post measurements, a 
number of 33 participants will be needed.  
 
5.6 Conclusion  
 
The purpose of the current study was to investigate the presence and prevalence of 
exercise-induced fatigability, evidenced as deterioration in gait kinematics after an 
exercise-running task in stable, relapsing, highly physically active pwMS who presented 
with minimal or very mild neurological disability (EDSS < 2.5). A secondary aim was to 
compare before and after an exercise task the gait of these highly active pwMS with a 
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healthy control group who were also highly active. It was found that there is a significant 
decrease of peak DF in swing of the most affected limb in the MS group post-exercise. 
Inspecting the individual data of the MS group showed that six out of the 15 in the MS 
group showed reduced peak DF in swing exceeding the MDC95% value. However, unlike 
previous studies we did not observe any significant differences in the gait kinematics and 
spatiotemporal parameters in our participants with high levels of habitual physical activity 
compared with our healthy controls. Although highly speculative, this finding could 
indicate that high levels of physical activity protect against gait abnormalities. Future 
studies should consider investigating potential changes in other joints and planes, apart 
from sagittal ankle kinematics, which could possibly reveal different compensatory 
mechanisms for foot drop. As the focus of the present study was to examine fatigability 
evidenced as foot drop, we reported only sagittal ankle kinematics.  
Moreover, future studies should consider the use of a more standardized fatiguing task, so 
that the effort of all the participants can be relativised. Thus far, no standardised protocol 
is available to induce fatigability in pwMS, with lack of information on psychometric 
properties and comparison of different protocols. A standardised protocol should take into 
account the physical activity and disability level of pwMS and should be relativized 
according to each individual’s peak capacity.  
Finally, once a protocol that can reliably detect fatigability has been developed, this could 
potentially monitor longitudinally the worsening of gait kinematics after exercise-induced 
fatigability, through 3D gait analysis, since subtle changes in gait could possibly be used 
to detect changes in disease progression in this sub-patient population.  
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Chapter 6. The direct orthotic effect of FES on gait kinematics and 
walking speed in people with MS under dual-tasking and fatiguing 
walking conditions 
 
6.1 Purpose of the chapter 
 
The purpose of the present chapter is to investigate the direct orthotic effect of FES under 
a variety of walking conditions in people with MS who were prescribed FES to treat their 
foot drop. It was hypothesized that these walking conditions would simulate real life 
situations in which people have to focus on more than one task at the same time with and 
without exercise induced fatigability. And thus, the perceived benefits of the use of FES 
that pwMS have previously reported.    
 
6.2 Introduction  
 
As discussed previously, foot drop, i.e. the lack of dorsiflexion during the swing phase of 
gait is a common symptom in pwMS (Mount & Dacko et al, 2006). A common way to 
treat foot drop is through FES, where pre-tibial muscles are stimulated in order to produce 
ankle dorsiflexion. It has been reported that FES facilitates a more normal gait pattern and 
improves perceived quality of life (Stein et al, 2010). Many studies have investigated the 
direct orthotic effect of FES (FES off vs FES on) and reported an increased walking speed 
and a decrease in energy consumption cost (Taylor et al, 1999; Stein et al, 2010; Scott et 
al, 2013; Street et al, 2015). On the other hand, studies investigating the long-term 
(therapeutic) effect of FES to treat foot drop in pwMS, did not observe improvement over 
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time (Taylor et al, 1999; van der Linden et al, 2014a; Street et al, 2015), which might 
possibly be attributed to the progressive nature of the disease.  
Fatigue is an important factor that negatively affects the everyday life of pwMS. 
According to the taxonomy by Kluger et al (2013) there is a difference between 
perceptions of fatigue, which refers to the weariness and self-reported exhaustion, and 
fatigability, which is the exercise induced decline in the ability of the muscles to produce 
force or power regardless of whether the task can be sustained. To the best of our 
knowledge, only one study investigated how the use of FES affects fatigability-induced 
gait changes. The study by Barr et al. (2017) observed that an orthotic effect was not 
evident in the first use of FES, but after eight weeks of FES use there were positive effects 
on gait with the use of FES compared to without. However, in that particular study, the 
use of FES alone was not sufficient to overcome the deficits in gait related to fatigue after 
a 6MWT task.  
One of the benefits of the use of FES reported by pwMS themselves is that it reduces the 
mental effort of walking, as less concentration is needed on the walking task (Bulley et al, 
2015; (Miller) Renfrew et al, 2018). It has been suggested that postural control and 
cognition compete for a common pool of attentional resources and if one task is becoming 
more challenging, the available resources reach their limit and performance in one or  both 
tasks will deteriorate (Stins & Beek, 2012). The execution of a motor task simultaneous 
with a cognitive task is termed dual-tasking and the cognitive-motor interference can be 
quantified by the dual-task cost (DTC), which is the percentage change in performance 
from single to dual task (Yogev-Selingmann et al, 2012).  
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Several studies have indicated that while performing a cognitive task together with a 
walking task, pwMS exhibited deterioration in gait evidenced as reduced walking speed 
and associated reduced step length and increased double support time (Hamilton et al, 
2009; Wajda et al, 2013). The detrimental effect of the cognitive task on walking 
performance was observed to be more severe in pwMS with higher levels of disability 
(Sosnoff et al, 2011a), but was also evident in people with clinically isolated syndrome 
(Kalron et al, 2010).   
Although many studies have investigated dual-tasking in pwMS, the influence of FES on 
the dual-task cost and the orthotic effect of FES have not been explored. Miller et al. 
(2016) showed that, unlike patients with walking speeds lower than 0.8m/s, for those with 
higher walking speeds the use of FES does not induce an increase in walking speed during 
laboratory timed walking tests. However, subjectively, people with walking speeds faster 
than 0.8m/s, i.e. near normal walking speed, still report to benefit from the use of FES. In 
the current study, it was hypothesized that the benefit perceived in those people may be 
due to benefit of using FES when experiencing fatigability and/or when performing 
another task, i.e. when dual tasking.  
The aim of the present study was to investigate the direct orthotic effect of FES under 
conditions which may be more ecologically valid than a single task, short duration 
laboratory walking test conventionally used to investigate the effects of FES in gait. The 
current study compared three different conditions: 1) a single task walking condition 
without fatigability (task A), 2) a dual-task walking condition without fatigability (task B) 
and 3) a dual-task walking condition with fatigability (task C).  
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• The first objective was to explore the direct orthotic effect of FES in these three 
conditions on peak DF in swing and walking speed. We hypothesized that the direct 
orthotic effect of FES would be higher in task B compared to task A and also would be 
higher in task C compared to task A.  
• The second objective was to quantify the DTC of walking speed of task B of the MS 
group and to compare it with the DTC of a healthy age-matched control group. Based on 
other studies (i.e. Hamilton et al, 2009) it was hypothesized that the DTC of walking speed 
for the MS group would be at least 10%.  
• The final objective was to investigate the effect of fatigability (without the assistance of 
FES) measured as a deterioration in gait characteristics in task C (dual-task and exercise-
induced fatigability) compared to task B (dual-task only) in both groups. It was also 
hypothesized that gait deterioration would be greater in the MS compared to the healthy 
control group after inducing fatigability and performing a cognitive task. 
 
6.3 Methods 
 
6.3.1 Design  
 
This was a non-randomised experimental study to investigate the orthotic effect of FES 
under a variety of walking conditions in pwMS who experience foot drop. Data collection 
for this study started in August 2018 and is still ongoing until the sample size derived from 
the a priori power calculation is met.  
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Figure 6.1 Flow diagram of study design for Chapter 6. 
 
6.3.2 Participants 
 
Eligibility criteria required pwMS to have received clinically definite diagnosis of MS 
according to the revised McDonald criteria (Polman et al, 2011), be aged 18 years and 
over and to be characterized with moderate to severe disability according to EDSS (EDSS 
≤ 6.0). They should also be able to walk at least 100 meters with or without walking aids. 
Further, participants should be community walkers who experience foot drop diagnosed 
by a physiotherapist and were using FES to treat foot drop. Participants were excluded 
from the study if they had a clinically diagnosed relapse within the last month and had any 
musculoskeletal impairments and cardiopulmonary disorders that could affect their 
walking ability.  
In order to be eligible in the healthy control group, participants were aged 18 and over and 
were also ‘free’ from the diagnosis of any neurological disease or any other 
condition/injury that would affect their walking ability.  
 188 
 
 
6.3.3 Ethical opinion  
 
Favourable ethical opinion was obtained from the NHS Research Ethics Committee (West 
Midlands – Edgbaston Research Ethics Committee, REC Reference number: 
18/WM/0062) (Appendix 15) and Queen Margaret University Ethics Committee. 
Moreover, NHS Lothian Research and Development approval was obtained prior to 
commencing with the study (Appendix 16). All procedures were conducted in accordance 
with the Declaration of Helsinki with regards to human participation. Participants could 
withdraw from the study at any point without giving any reason.  
 
6.3.4 Recruitment process 
 
People with MS who use FES to treat foot drop were recruited from the MS Therapy 
Centre Lothian, the Anne Rowling Clinic and the Physiotherapy Department at Astley 
Ainsley Hospital, all based in Edinburgh. The specialist neurologists, physiotherapists and 
nurses from these centres identified potentially eligible participants. If people were 
interested to learn more about the study, a participant information pack was provided to 
them including a PIS (Appendix 17) and the self-report questionnaires [Multiple Sclerosis 
Neuropsychological Screening Questionnaire (MSNQ), foot drop questionnaire, FSMC & 
MSWS-12]. In the pack, we also included a stamped addressed envelope addressed to the 
PI (PhD student) and a form stating their agreement to be contacted by the PI. The 
potential participants were given at least two weeks to consider the information and 
contact the PI, their GP or other independent parties to decide whether they would take 
part. On receipt of the form and the screening questionnaires, the PI contacted those 
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eligible to take part in order to discuss the study protocol, answer any questions and where 
appropriate arrange the first study visit. On arrival at QMU motion analysis laboratory for 
the first visit, participants were asked to sign an informed consent form (Appendix 18). It 
was clearly stated that they could withdraw from the study at any point with no obligation 
to give any reason and without prejudice to their future care.  
The healthy control group of participants was age and gender-matched with the MS group 
and was recruited through word of mouth, through the QMU Moderator system and by 
advertisements in the recruitment centres (Appendix 19).  
 
6.3.5 Study protocol 
 
The study protocol required the participants in the MS group to visit the QMU motion 
analysis laboratory on two occasions.  
 
6.3.5.1 Visit one 
 
On arrival at the motion analysis laboratory, the study protocol was explained to the 
participants in detail and participants were given the opportunity to ask any questions. The 
next step was to sign the informed consent prior to commencing with any procedures. The 
purpose of this visit was to record anthropometric characteristics required for the 
processing of 3D gait analysis data, such as height, body mass, leg length, knee and ankle 
width and tibial torsion. If participants reported that they were experiencing difficulties 
with their use of FES, the PI would advise them 
to contact the physiotherapists at Astley Ainsley 
at the FES clinic for a follow-up appointment 
Figure 6.2 Stroop test 
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regarding their FES device. Finally, the Stroop test (Franzen et al, 1987), which they 
would have to perform on their second visit was explained. The Stroop test is an attention-
demanding task that ‘assesses the ability to inhibit cognitive interference which occurs 
when the processing of a stimulus affects the simultaneous processing of another attribute 
of the same stimulus’ (Stroop, 1935). In this test, participants were shown a word (‘blue’, 
‘yellow’, ‘red’ or ‘green’) written in a different colour (blue, yellow, red or green) and 
were instructed to state the colour of the text and ignore the meaning of the word itself 
(Figure 6.2). The font of the letters was large enough for the participants to read from a 
distance of seven meters and a new word was displayed every second. In this visit, 
participants performed a few practice trials to become accustomed with the protocol and 
to understand the task that they would be asked to perform in the next visit. This first visit 
lasted approximately one hour.   
 
6.3.5.2 Visit two 
 
The second visit to the motion analysis laboratory lasted approximately two hours. The 
purpose of this visit was to perform the walking (single and dual-task trials) and physically 
demanding procedures expected to induce fatigability to assess the direct orthotic effect 
of FES. On arrival, reflective markers were placed on the lower limbs and pelvis of the 
participants according to the Helen Hayes’ marker system (Kadaba et al, 1990). These 
small (9mm diameter) markers were attached using skin friendly double-sided tape, in 
order to allow the 8-camera 3D motion capture system (Vicon Motion Systems, Oxford, 
UK) to record the kinematic and spatiotemporal parameters of the lower limbs and pelvis 
(see details in section 4.3.5). The walking trials had to be performed barefoot and to ensure 
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that the foot switch from the FES device would still work we had to attach it with adhesive 
tape to the sole of the foot. Participants were given a few walking trials to familiarise 
themselves walking barefoot with the foot switch attached on the sole of the foot. 
Afterwards, participants were asked to complete a total of 24 short (approximately 7m) 
walking trials on three different conditions (see Table 6.1). The walking trials of the first 
and second condition (single-task vs dual-task) with FES on and off were counter-
balanced, so that a potential order effect was avoided. In order to do so, each trial was 
allocated a specific number and the sequence of the walking trials was decided by 
computer-generated randomization. Participants were allowed to rest between walks 
before (but not after) performing the fatiguing task.  
 
 
 
 
Table 6.1 The three different conditions in the study protocol. The order of trials with FES on 
and off were randomized.  
Condition  Walking trials 
Task A: single-task walking  Walking with FES on (4 trials) 
 Walking with FES off (4 trials) 
Task B: dual-task walking with the 
Stroop test 
 Walking with FES on (4 trials) 
 Walking with FES off (4 trials) 
Task C: dual-task walking with the 
Stroop test after induced fatigability  
 Walking with FES on (4 trials) 
 Walking with FES off (4 trials) 
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*The healthy control group performed all the conditions except those walking trials with FES on.  
 
After the completion of the walking trials of the first two conditions, the fatiguing task 
was performed. The fatiguing test that was chosen was the shuttle walk/run (SRT) test that 
was developed for children with CP at GMFCS level II (Verschuren et al, 2006). The 
initial plan was to use the Incremental Shuttle Walk Test (Singh et al, 1992) which is an 
incremental shuttle exercise test originally developed for patients with chronic obstructive 
pulmonary disease. However, the starting speed of that test was 1.80km/h with a 0.60km/h 
increase every minute, which after pilot testing was evident that the MS group would not 
be able to perform for more than a few ‘shuttles’. Hence, it was decided that the best 
method to induce fatigability in this population was the SRT at GMFCS level II since the 
initial speed is at 2km/h and the speed is increased by 0.25km/h every minute. The SRT-
II, comprised of 23 levels, requires participants to walk between two cones (10m distance) 
in time between two bleeps sounding from a CD player. Every minute, the time between 
the two bleeps is shorter hence participants were required to walk at a faster speed. The 
test was terminated if participants indicated that they could not continue with the test at 
the speed required. Furthermore, for safety reasons they were allowed to use their walking 
sticks and FES to complete the task. Directly after the termination of the SRT-II, 
participants performed the last eight walking trials (four with FES on and four with FES 
off) while performing the Stroop test.  
The participants in the healthy control group were asked to visit QMU motion analysis 
laboratory only for one session, in which all the procedures described above took place. 
At first, the purpose of the study was explained after which informed consent was taken. 
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Anthropometric measurements were recorded and participants were given the opportunity 
to practice with the Stroop test. This group performed the single and dual-task conditions 
in a counterbalanced order, as in the MS group, but of course without the walking trials 
with FES, hence performed a total of 12 walking trials.  
 
6.3.6 Outcome measures 
 
6.3.6.1 Gait analysis  
 
As described in the previous chapters of this thesis, 3D gait analysis is the ‘gold’ standard 
in terms of quantitative gait analysis and it has been widely used for quantifying gait 
changes in the MS population. In the present study, gait analysis was performed while 
participants performed 24 (MS group) or 12 (healthy control group) barefoot walking 
trials over a distance of about 7 meters. The most affected leg was defined as the leg for 
which they used FES to treat their foot drop. For the healthy control group we selected the 
left leg for comparison with the MS group, assuming there were no differences between 
left and right leg for the healthy group. For further details on marker placement and data 
processing please refer to Chapter 4 in sections 4.3.5 and 4.3.6. 
 
6.3.6.2 Fatigue Scale for Motor and Cognitive Function 
 
The FSMC is a self-reported questionnaire consisting of 20 items assessing motor and 
cognitive fatigue (Penner et al, 2009) (Appendix 13). Participants were asked to complete 
the FSMC once at the beginning of the study. For further details regarding the 
questionnaire, such as scoring and psychometric properties, please refer to Chapter 5, 
section 5.3.6.5.1.  
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6.3.6.3 Multiple Sclerosis Walking Scale  
 
The MSWS-12 consists of 12 items assessing the limitations to walking due to MS the 
past two weeks (Appendix 20). Each item is scored from 1 (not at all) to 5 (extremely) 
with the total score ranging from 12 to 60 and can be transformed to a percentage, with 
higher scores indicating greater impact on walking (Hobart et al, 2003). The psychometric 
properties of the MSWS-12 have been extensively examined. In Chapter 3, it was found 
that the MSWS-12 has a strong level of evidence for internal consistency, test-retest 
reliability and construct validity (see Andreopoulou et al, 2018). 
 
6.3.6.4 Multiple Sclerosis Neuropsychological Screening Questionnaire  
 
The MSNQ is a 15-item self-reported questionnaire with scores ranging from 0 (never, 
does not occur) to 4 (very often, very disruptive) for each item and with a value of 27 and 
above indicating cognitive impairment (Appendix 21). The MSNQ was designed as a 
screening tool that is easy and quick to administer by a nonprofessional and it is based on 
self-report observations over the past three months (Benedict et al, 2003). It has been 
found to be a reliable and valid tool for screening in the MS population (Benedict et al, 
2003; Nauta et al, 2018) and it has been translated in many languages (Sonder et al, 2012; 
Sejbæk et al, 2018).  
 
6.3.6.5 Hospital Anxiety and Depression Scale  
 
The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report measure 
divided in two subscales (depression and anxiety) (Appendix 22). The scoring for each 
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subscale can range from 0 to 21 and a score of 8 or above on either of the subscales can 
indicate possible anxiety or depression (Zigmond & Snaith, 1983). It is an easy and quick 
scale to administer and participants completed it once during the first visit. The HADS 
has been found to be a valid measure to detect depression and anxiety in the MS population 
and has been shown to have high sensitivity and specificity for both subscales (Watson et 
al, 2014; Patten et al, 2015). 
 
6.3.7 Statistical analysis  
 
6.3.7.1 Sample size calculation  
 
In the present study, sample size calculations estimated that 15 participants were needed, 
using a single group repeated measures ANOVA, to detect a statistical significant (p < 
0.05) difference between any of the three conditions with effect size of 0.33 and 80% 
power (overall F-test of difference between any of the three conditions). This was based 
on the primary outcome that was the direct orthotic effect of FES on ankle kinematics.  
 
6.3.7.2 Data analysis 
 
The initial plan of the descriptive and statistical analysis was as follows. Parametric 
assumptions of the gait data and walking speed would be checked. A Shapiro-Wilk test 
would be carried out, to explore the notion that the data are normally distributed. This 
would be also supported by visual inspection of the q-q plot and boxplot. For the primary 
question, to explore the orthotic effect of FES in three different conditions a one-way 
repeated measures ANOVA would be used. Partial eta2 would also be calculated to 
determine the effect size.   
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For the rest of the research questions, since only the walking conditions without FES 
would be used, paired or independent t-test or the non-parametric equivalent would be 
performed.  
Further, the median and the interquartile range (IQR) was reported for all of the outcomes. 
For our primary aim, to explore the direct orthotic effect of FES in the three conditions 
we calculated the effect size (Cohen’s d) on ankle kinematics and walking speed between 
Task A and Task B and also between Task A and Task C.  
For our second aim which was to compare the DTC of walking speed between the MS and 
the healthy control group we report the mean and standard deviation. The DTC of walking 
speed for both groups was calculated using the following formula:  
𝐷𝑇𝐶𝑤𝑠 =
𝑊𝑆 𝑠𝑖𝑛𝑔𝑙𝑒 𝑡𝑎𝑠𝑘 − 𝑊𝑆 𝑑𝑢𝑎𝑙 𝑡𝑎𝑠𝑘
𝑊𝑆 𝑠𝑖𝑛𝑔𝑙𝑒 𝑡𝑎𝑠𝑘 
 × 100 
 
For the final aim to investigate fatigability-induced changes in both groups, the median 
and IQR are reported for the conditions of dual tasking before and after the fatiguing 
(incremental shuttle) task (i.e. Task C vs Task B).   
 
 
6.4 Results  
 
6.4.1 Participants 
 
A total number of eight pwMS who were FES users and met the inclusion criteria were 
recruited for this study up to April 2019. One participant had to withdraw from the study 
after attending the first visit, due to an accident that affected her walking ability. Another 
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participant performed only three walking trials for each of the conditions instead of four, 
because of her walking difficulties. Further, seven healthy controls volunteered to take 
part, but due to issues with the recording of gait kinematics of two, only five were used 
for comparison with the MS group. Thus, seven pwMS and five healthy age-matched 
controls were used for analysis in the present study. All participants completed the study 
protocol without experiencing any adverse effects. As this sample size was below that of 
an appropriately powered study, no inferential statistical analysis was performed.  
 
 
Table 6.2 Demographic characteristics of MS and healthy groups presented as means (SD). 
 MS group (n=7) Control group (n=5) 
Female/Male, n 5/2 4/1 
Age, years 54.1 (10.4) 55.0 (11.6) 
EDSS range 4-6 - 
MSWS-12 (12-60) 46.6 (11.9) - 
MSWS-12 (%) 72.0 (24.9) - 
FSMCtot (20-100) 60.5 (4.6) 26.3 (8.5) 
FSMCcognitive (10-50) 26.7 (7.2) 13.0 (4.8) 
FSMCphysical (10-50) 33.8 (5.0) 16.3 (8.1) 
MSNQ (0-60) 20.1 (11.7) 14.7 (7.6) 
HADSdepression (0-21) 5.8 (2.6) 3.5 (2.9) 
HADSanxiety (0-21) 5.8 (3.9) 5.5 (3.7) 
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Abbreviations: FSMC: Fatigue Scale for Motor and Cognitive Function; HADS: Hospital Anxiety and 
Depression Scale; MSNQ: Multiple Sclerosis Neuropsychological Screening Questionnaire; MWSW-12: 
Multiple Sclerosis Walking Scale; PP: Primary Progressive; RR: Relapsing Remitting; SRT: Shuttle Run 
Test; SP: Secondary Progressive.  
 
The two groups had a similar female to male ratio and average age in years (Table 6.2). 
All the pwMS were currently FES users, with an EDSS range of 4 to 6. Based on the 
MSWS-12 scores, the walking ability of most pwMS was moderately affected with an 
average score of 72% indicating the most severe walking limitations. The MS group was 
suffering from severe physical fatigue (FSMCphysical  ≥ 32), but mild to moderate cognitive 
fatigue based on the FSMC sub-scales. Further, there were low average scores for 
cognitive impairment, depression and anxiety based on the MSNQ and HADS (Table 6.2). 
However, two of the participants in the MS group were exceeding the cut-off value of 27 
for the MSNQ. The healthy control group had low scores in all the questionnaires 
compared to the MS group and completed more shuttles in the SRT to induce fatigability.  
 
6.4.2 Direct orthotic effect of FES 
 
The main objective of the present study was to investigate the direct orthotic effect of FES 
during three different conditions. The first condition was to walk with FES on and off 
(Task A), the second condition was to walk with FES on and off while performing the 
Stroop test (Task B) and the third condition was to walk with FES on and off after 
completion of a fatiguing task while performing the Stroop test (Task C). Table 6.3 
presents the median and IQR of the ankle kinematic and spatiotemporal parameters over 
the three conditions. It is evident from this table that walking with FES-on resulted in an 
improvement in most gait parameters, i.e. a direct orthotic effect. Interestingly, in the 
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conditions A and B, on average, the ankle angle at initial contact was less (more plantar 
flexed) with the assistance of FES compared to no FES.  
The direct orthotic effect of FES was higher in both Tasks B and C compared to Task A 
(Table 6.4). As shown in Table 6.4, there was a small but positive effect size for the direct 
orthotic effect for peak DF in swing in both comparisons and for walking speed when 
comparing Task B and Task A, which indicates that that there was a benefit of FES as 
hypothesized. However, there was a small negative effect size for both orthotic effects of 
ankle angle at initial contact and walking speed when comparing Task C to Task A which 
is the opposite of our hypothesis, reflecting that there was no benefit of FES after the 
fatiguing task.  
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Table 6.3 Median (IQR) of gait kinematics and spatiotemporal parameters of the most affected leg in the three conditions (with FES off and FES on 
the MS group). 
 Task A Task B Task C 
 FES off FES on FES off FES on FES off FES on 
DFMA (°) 3.1 (10.1) 6.8 (7.2) 1.3 (11.8) 5.9 (6.3) 0.3 (9.4) 6.9 (6.1) 
ICMA(°) 1.0 (14.1) -0.1 (5.1) 1.1 (14.1) -0.3 (5.2) 0.3 (12.3) 0.5 (7.4) 
WS (m/s)  0.8 (0.67) 0.88 (0.6) 0.76 (0.59) 0.8 (0.45) 0.57 (0.41) 0.69 (0.4) 
Cadence (steps/min) 99 (65) 104 (51) 98 (67) 95 (46) 89 (48) 95 (48) 
SLMA (m) 0.47 (0.1) 0.50 (0.13) 0.43 (0.09) 0.48 (0.16) 0.45 (0.17) 0.45 (0.16) 
 
Abbreviations: DFMA: peak dorsiflexion in swing of most affected leg; ICMA: ankle angle at initial contact of most affected leg; IQR: Interquartile range; SLMA: 
step length of most affected leg; WS: walking speed.  
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Table 6.4 Direct orthotic effect of FES in the three conditions [presented as median (IQR) and effect size]. 
 Task A Task B Task C ES Task A/B ES Task A/C 
Orthotic effect DF (°) 3.7 (4.5) 4.2 (5.2) 4.2 (7.6) 0.12 0.10 
Orthotic effect IC (°) 4.6 (11.3) 5.1 (12.4) 4.9 (14.7) 0.04 -0.17 
Orthotic effect WS (m/s) 0.02 (0.07) 0.03 (0.13) 0.02 (0.05) 0.26 -0.09 
 
Abbreviations: DF: peak dorsiflexion in swing; ES: effect size; IC: ankle angle at initial contact; IQR: Interquartile range; WS: walking speed.  
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Figure 6.3 The direct orthotic effect on peak DF in swing between Task A (OrthoticFES) and Task B (OrthoticFESDT). Left: all MS participants 
included; Right: without participant PP3. 
 
 203 
 
   
 
             
Figure 6.4 The direct orthotic effect on peak DF in swing between Task A (OrthoticFES) and Task C (OrthoticFESDTFat). Left: all MS participants 
included; Right: without participant PP3. 
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Figure 6.5 The direct orthotic effect on initial contact. Left: between Task A (OrthoticFES) and Task B (OrthoticFESDT); Right: between Task A 
(OrthoticFES) and Task C (OrthoticFESDTFat). 
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Figure 6.6 The direct orthotic effect on walking speed. Left: between Task A (OrthoticFES) and Task B (OrthoticFESDT); Right: between Task A 
(OrthoticFES) and Task C (OrthoticFESDTFat). 
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Figures 6.3 to 6.6 presents the individual comparisons of the direct orthotic effect of FES 
between Task A/B and Task A/C for peak DF in swing, ankle angle at initial contact and 
walking speed. For peak DF in swing, six out of seven had a higher direct orthotic effect 
during the dual-task (Task B) compared to the single-task condition (Task A) whilst five 
out of seven had a higher direct orthotic effect after the fatiguing condition (Task C) 
compared to the single task condition (Figures 6.3 & 6.4). For DF in in swing there are 
two graphs in each condition, in order to highlight differences among participants with 
and without participant 3 who was an outlier. From Figure 6.5 we can see that four out of 
seven pwMS had a higher direct orthotic effect of ankle angle at initial contact at the dual-
task condition and only three out of seven after inducing fatigability. The individual 
graphs of the participants for the direct orthotic effect of walking speed showed that three 
out of seven pwMS had a higher effect during the dual-task condition and only for two 
out seven after completing the fatiguing task (Figure 6.6).  
 
6.4.3 Dual-task cost of walking speed  
 
Another aim of the present study was to investigate the DTC of walking speed (DTCWS) 
without the use of FES (Task B) in pwMS and to compare it with an age-matched healthy 
control group. Both groups had a positive DTCWS, with this positive percentage change 
indicating that there was a decrease in the walking speed from single to dual-task 
condition. However, it can be seen from the data in Table 6.5 that the DTCWS in the MS 
was considerably higher compared to the healthy control group. 
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Table 6.5 Percentage DTCWS of the MS and healthy control group (presented as means and 
SDs). 
 Participant type WS (m/s) WSDT (m/s) DTCWS (%) 
 MS (n=7) 0.77 (0.4) 0.67 (0.4) 12.4 (11.5) 
 HC (n=5) 1.26 (0.2) 1.20 (0.3) 4.6 (7.8) 
 
6.4.4 Fatigability induced gait changes under dual-task conditions 
 
Table 6.6 provides the medians (IQR) before and after completing the fatiguing task of 
the kinematic and spatiotemporal parameters of the two groups. It is apparent from this 
table that on average pwMS had slightly decreased peak DF in swing (1°) and ankle angle 
at initial contact (0.8°) after Task C compared to Task B. The healthy control group did 
not show any signs of fatigability since there was an increase on gait kinematics after 
exercise task. The healthy individuals had approximately ≈8° and ≈4° higher peak DF in 
swing and ankle angle at initial contact respectively compared to the MS group in both 
Task B and Task C. Further, the healthy control group walked faster, with increased 
cadence and step length in Task C and also compared to the MS group.  
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Table 6.6 Fatigability induced gait changes in kinematic and spatiotemporal parameters during dual tasking in pwMS (without FES) and healthy 
individuals (presented as medians and IQR). 
 Task MS (n=7) HC (n=5) 
DFMA (°) UnfatiguedDT 1.3 (11.8) 9.0 (5.5) 
FatiguedDT 0.3 (9.4) 9.2 (7.2) 
ICMA (°) UnfatiguedDT 1.1 (14.1) 3.7 (6.8) 
FatiguedDT 0.3 (12.3) 3.9 (9.2) 
WS (m/s) UnfatiguedDT 0.76 (0.59) 1.10 (0.49) 
FatiguedDT 0.57 (0.41) 1.24 (0.41) 
Cadence (steps/min) UnfatiguedDT 98 (67) 119 (25) 
FatiguedDT 89 (48) 128 (22) 
SLMA (m) UnfatiguedDT 0.43 (0.09) 0.60 (0.15) 
FatiguedDT 0.45 (0.17) 0.63 (0.12) 
 
Abbreviations: DFMA: peak DF in swing of most affected leg; DT: dual-tasking; ICMA: ankle angle at initial contact of most affected leg; SLMA: step length of the 
most affected leg; WS: walking speed.  
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6.5 Discussion 
 
6.5.1 Direct orthotic effect of FES under different conditions 
 
The first aim of the present study was to investigate the direct orthotic effect of FES 
under different conditions, which are assumed to be more ecologically valid and would 
thus replicate the real life environment. Thus far, seven pwMS have been recruited in 
the study and have completed: walking only trials (Task A), walking trials while 
performing the Stroop test (Task B) and walking with the Stroop test after a task 
inducing fatigability (Task C).  
Previous studies that have investigated the direct orthotic effect of FES on kinematic 
parameters, reported significant increases in peak DF in swing and at initial contact 
(Scott et al, 2013; van der Linden et al, 2014a; van der Linden et al, 2014b). Moreover, 
a recent meta-analysis reported a significant direct orthotic effect of FES on walking 
speed especially over short distance tests (Miller et al, 2017). 
Even though there is a great amount of literature investigating the direct orthotic effect 
of FES either on kinematic or spatiotemporal parameters, the novel element of the 
present study is the exploration of the direct orthotic effect of FES in pwMS who are 
simultaneously performing a cognitive task. This is of clinical significance, as it has 
been reported by many pwMS that one of the benefits of FES is that less concentration 
is needed while walking and that it is easier to perform two tasks (e.g. walking and 
talking) at the same time. 
Based on the qualitative studies by Bulley et al. (2015) and (Miller) Renfrew et al. 
(2018), we hypothesized that the direct orthotic effect of FES on ankle kinematics 
(peak DF in swing and ankle angle at IC) and spatiotemporal gait parameters would 
be  higher in dual tasking conditions (Task B and Task C) compared to single walking 
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condition (Task A). For the peak DF in swing this was indeed the case for six out of 
seven people in the MS group, although for none of the participants was this increase 
higher than the MDC95% (6.1°) derived from group B (EDSS range: 4-6) in Chapter 4 
(reliability study). None of the participants exceeded the MDC95% for initial contact 
(7.7°) reported in Chapter 4. For walking speed however, only three out of seven 
participants had a higher direct orthotic effect in both dual-task conditions (Task B and 
Task C) compared to the single task (Task A). A possible explanation for not finding 
a higher direct orthotic effect of FES in Task C compared to Task A in some of the 
participants might be that the action of FES was not sufficient to overcome the deficits 
due to local muscle fatigue.  
These findings agree with only one other study that examined gait changes after a 
6MWT and the effects of FES, which also reported that the action of FES alone was 
not sufficient to overcome the fatigability-induced gait changes after the fatiguing task 
(Barr et al, 2017). To the best of the author’s knowledge, there are no published studies 
reporting on the efficacy of FES under dual-tasking conditions nor under dual-tasking 
combined with fatigability-induced conditions in pwMS or any other populations.  
 
6.5.2 Dual-task cost of walking speed 
 
Another aim of the present study was to investigate the DTCWS in pwMS and a healthy 
control group. Our findings showed that the DTCWS was higher in pwMS (12.4%) 
compared to the healthy individuals (4.6%), indicating that the decrement in walking 
speed from single to dual tasking was higher in pwMS compared to the healthy control 
group. Further, our hypothesis based on previous studies that the MS group would 
exhibit a DTCWS of at least 10% was confirmed, since the DTCWS in our MS group 
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was 12.4%. The percentage change in our MS group is in accordance with work of 
other studies in this area. One of the first studies exploring dual tasking in pwMS 
during “walking while talking”, reported a DTC of walking speed of 10.7% for a 
titrated demand task and of 8.6% for a fixed demand task in a group of pwMS with 
mild to moderate disability level (Hamilton et al, 2009). In line with our findings, the 
majority of other studies exploring dual tasking in pwMS have reported a DTC of 
walking speed ranging from 11.8% to 15%. This is despite most of the studies 
employing a different cognitive task such as the modified word list generation and 
alternating letters of the alphabet (Sosnoff et al, 2011a; Learmonth et al, 2014; Motl et 
al, 2014; Coghe et al, 2018). Two studies also investigated the DTC of walking speed 
in pwMS and compared this with that in healthy individuals and reported higher DTC 
in pwMS (Hamilton et al, 2009; Coghe et al, 2018), similar to this study. Interestingly, 
the MS group in those two studies had mild disability level according to the EDSS, but 
they still reported statistically significant differences compared to healthy individuals.  
Despite the growing number of studies on DTC of gait in MS, there is no consensus 
on which cognitive task should be used to explore dual-task performance in pwMS. 
The selection of an appropriate cognitive task is important, since different cognitive 
tasks require different mental processes to execute them (Al-Yahya et al, 2011). A 
recent meta-analysis reported that the effect of cognitive-motor interference on motor 
performance was only significantly different between pwMS and healthy individuals 
during discrimination and decision-making tasks and not for example during mental 
tracking or verbal fluency tasks (Learmonth et al, 2017). 
 For that reason, we chose as a cognitive task the Stroop test, which is a discrimination 
and decision-making task and evaluates attention, working memory, processing speed 
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and cognitive flexibility (Stroop, 1935; Al Yahya et al, 2011). To the author’s 
knowledge only one study investigated cognitive-motor interference (CMI) in 
spatiotemporal parameters with the Stroop test in pwMS with mild disability (EDSS 
mean = 2.1) and reported a DTC of walking speed of 11.7% which was significantly 
higher compared to a healthy control group (DTC = 4.8%) (Coghe et al, 2018). 
Interestingly, in their systematic review into CMI in pwMS, Learmonth et al. (2017) 
concluded that CMI does not differ in magnitude under single and dual task conditions 
between groups of pwMS and healthy individuals (ES =0.08). However, this absence 
of difference in CMI between pwMS and healthy individuals could be attributed to the 
inclusion of a variety of different cognitive tasks in that meta-analysis, since the 
individual studies described above did report statistically significant differences in 
those two groups (e.g. Hamilton et al, 2009; Wajda et al, 2013). As there is a growing 
interest for the investigation of CMI in pwMS, and the underlying mechanisms, future 
research should consider the use of DT paradigms for rehabilitation purposes that 
could potentially positively impact the quality of life of pwMS. Only one study by 
Peruzzi et al. (2016), reported improvement in walking speed and stride length in dual-
task conditions after a virtual reality treadmill training program.  
 
6.5.3 Fatigability induced gait changes under dual-task conditions 
 
The third aim in the present study was to investigate gait characteristics after inducing 
fatigability between pwMS and healthy individuals while performing a cognitive task. 
Thus far, and to the best of our knowledge, no other studies have reported on gait 
changes after inducing fatigability and while simultaneously performing a cognitive 
task that potentially resembles conditions that pwMS experience in everyday life. A 
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study by Wolkorte et al. (2015) examined whether pwMS were more challenged by a 
dual-task compared to healthy individuals in fatiguing and less fatiguing conditions, 
but they were focused on maximal voluntary contractions of the index finger as a 
measure of fatigability and they did not examine gait changes.  
The present study found a small average decrease in ankle peak DF in swing (-1.0º) 
and ankle angle at initial contact (0.8º) in pwMS in the trials after the fatigability-
inducing task compared to those before. However, this decrease did not exceed the 
MDC95% of group B (the most impaired group), presented in Chapter 4, in any of the 
participants. Similar to our findings, studies investigating fatigability-induced gait 
changes in pwMS with similar disability level to ours (EDSS range: 3-6), reported a 
small decrease in peak DF in swing and ankle angle at initial contact after a 6MWT 
(McLoughlin et al, 2016; van der Linden et al, 2018). 
Interestingly, the healthy control group walked on average slightly faster (0.14 m/s), 
with associated increase in step length (0.03m) and cadence (9 steps/min) in the trials 
after the fatiguing task. This could possibly be explained by the post-activation 
potentiation effect (Sale, 2004). The healthy control group in Chapter 5 and the healthy 
control group in the study by McLoughlin et al. (2016) also presented the same 
phenomenon with increased walking speed, cadence and step length after an exercise 
task (i.e. 20 minute treadmill run and 6MWT respectively). However, the MS group 
did not present a similar increase in the spatiotemporal parameters, and it could 
possibly be explained by the disability of this group (EDSS 4-6).    
 
6.5.4 Limitations  
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The present study has several limitations. Primarily, the study was under-powered. 
Further, our inclusion criteria were possibly not specific enough, for example we 
included a participant who had FES on both legs (Participant 6) and one who used FES 
only for running as she did not have foot drop during walking (Participant 5). This 
resulted in large between participant variability in the outcome measures, which 
reduced the effect size. Further, when performing the SRT to induce fatigability, 
participants could terminate the test at any point with all but one terminating the test 
approximately three to four minutes after the start. Even though most participants 
reported that they could not continue due to foot drop or lack of balance, the time 
performing the fatiguing task might not be long enough to observe greater differences 
between Task B and Task C (without FES). Finally, participants performed the Stroop 
test over a 7m distance on the gait laboratory, which could have resulted in a learning 
effect of the cognitive task while performing 24 walking trials in total. We have tried 
to minimize this possible effect by counterbalancing the walking trials with and 
without the Stroop test before the fatiguing task, but in all trials after the fatiguing task 
the Stroop test was performed.   
 
6.6 Conclusion  
 
The present study set out to investigate the direct orthotic effect of FES on gait 
characteristics under a variety of walking conditions, such as walking while 
performing a cognitive task and walking after inducing fatigability with a simultaneous 
cognitive task. To the author’s knowledge, this is the first study to attempt to compare 
the direct orthotic effect of FES in different walking conditions in pwMS or any other 
neurological condition.  
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Secondary objectives were to examine the difference in DTCWS and fatigability 
measured as the deterioration in gait characteristics between pwMS and a healthy 
control group. Individual results indicated that for most participants the direct orthotic 
effect of FES was higher under dual-task conditions. However, the effect sizes for peak 
DF in swing, ankle angle at IC and walking speed between Task B and Task A were 
small (d=0.12; d=0.04; d=0.26 respectively). Similarly, small but positive effect size 
(d=0.1) was found for the comparison of the direct orthotic effect on peak DF in swing 
between Task C and Task A.  
Our hypothesis that the DTCWS for pwMS would be at least 10% was supported by our 
findings (DTCWS = 12.4%) and this was clearly higher than that found for the healthy 
control group (4.6%). After inducing fatigability there was a small decrease in the 
kinematic parameters and spatiotemporal parameters for the pwMS. Notwithstanding 
the relatively limited sample, this study offers valuable insights into the benefits of 
FES that pwMS report. In particular, that FES reduces the mental effort of walking. 
Further studies need to be carried out to investigate the benefits of FES under dual-
task conditions that will include a more homogeneous sample of pwMS and possibly 
under more demanding dual-task conditions. Further, more research is needed to 
examine dual-task performance in pwMS with the use of a standardized cognitive task 
in order to compare findings amongst studies.  
 
 
 
 
 
 216 
 
Chapter 7. Final discussion  
 
7.1 Purpose of the chapter  
 
The purpose of this final chapter is to synthesize the findings from the studies included 
in this thesis in an integrated discussion of the results and limitations. In the previous 
chapters, each study was discussed independently, but this final discussion will attempt 
to synthesize the findings in a broader context of existing literature.  
Firstly, a summary of all the key findings of each of the studies will be presented 
(section 7.2), followed by a synthesis of the findings in relation to the main focus of 
the present PhD that is investigation of walking impairments and especially foot drop 
in pwMS. Finally, methodological considerations, recommendations for future work 
and clinical implications will be presented throughout the chapter.  
 
7.2 Summary of the findings and linkage between the chapters 
 
The key findings from the chapters in this thesis are summarised in Table 7.1. The 
purpose of the systematic review (Chapter 3) was to evaluate the psychometric 
properties of outcomes measures used to examine the effect of assistive technology to 
treat foot drop in pwMS. One of the findings was the lack of psychometric evidence 
of 3D gait kinematics in the MS population, even though it was one of the most used 
outcome measures to evaluate walking performance with and without assistive 
technology. Thus in the next chapter (Chapter 4), the test-retest reliability of ankle 
kinematics and spatiotemporal parameters in two groups of pwMS with different level 
of walking impairment was examined. The SEM and MDC95% indices for ankle 
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kinematics derived from this study were then used to interpret the results of the study 
included in Chapter 5. This chapter focused on the objective measurement of fatigable 
foot drop (i.e. foot drop that recovers with rest) that is subjectively reported by highly 
physically active pwMS whose daily walking ability is not affected. The indices 
derived in Chapter 4 were also applied to interpret the results of the last study (Chapter 
6) that focused on a group of pwMS that had established (i.e. ‘fixed’) foot drop and 
were treated for this with FES. The main focus of this last study was to investigate the 
direct orthotic effect of FES under a variety of walking conditions, such as dual-tasking 
and exercise-induced fatigability, that were regarded more ecologically valid than 
short single task walking tests commonly used to assess the effect of FES.  
 
 218 
 
Table 7.1 Key findings of the four studies presented in this thesis. 
Chapter Key findings 
Chapter 3: Walking measures to evaluate 
assistive technology for foot drop in multiple 
sclerosis: A systematic review of 
psychometric properties. 
 Most frequently used outcomes measures to evaluate walking performance were 
walking speed (mostly recorded over 10m distance), 3D gait kinematics and the 
Physiological Cost Index.  
 No psychometric studies for 3D gait kinematics & PCI in MS population. 
 Moderate to strong evidence for the psychometric properties for MSWS-12, 
T25FW, 6MWT & 10mWT.   
Chapter 4: Test-retest reliability and minimal 
detectable change of ankle kinematics and 
spatiotemporal parameters in pwMS with low 
(< 3.5) and moderate to high EDSS (4-6). 
 Reliability was excellent (ICC values > 0.75) for ankle kinematics and 
spatiotemporal parameters. 
 GPS presented fair to moderate ICC values in both groups.  
 Smaller MDC95% values in the low EDSS group compared to the higher EDSS 
group.  
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Chapter 5: Deterioration of gait 
characteristics in minimally impaired pwMS 
after an exercise task.  
 Significant decrease in peak DF in swing for pwMS but no change in 
spatiotemporal parameters after a 20min run on a treadmill at a self-selected 
speed compared to the healthy control group. 
 Six out of the 15 pwMS had a decrease in peak DF in swing exceeding the 
MDC95% value, whilst no one on the healthy control group showed such a 
decrease.  
 Exercise-induced decrease in DF suggests a sign of onset of MS related 
fatigability.  
Chapter 6: The direct orthotic effect of 
functional electrical stimulation on gait 
kinematics and walking speed in people with 
 Walking with the assistance of FES resulted in an improvement in all the gait 
parameters and especially for peak DF in swing.  
 There was a small trend towards a higher direct orthotic effect for peak DF in 
swing during dual-task conditions (B and C) compared to single task (A) (ES 
Task A vs B = 0.12, ES Task A vs C = 0.10). 
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 MS under dual-tasking and fatiguing walking 
conditions simulating daily life. 
 The DTCWS was higher in the MS (12.4%) compared to the healthy group 
(4.6%).  
 There was a decrease in peak DF in swing and AAIC in pwMS after inducing 
fatigability without the use of FES. 
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7.3 Psychometric properties and outcome measures of walking performance 
 
7.3.1 Reporting standards on psychometric properties studies 
 
There are many guidelines to promote a robust study design and high quality reporting 
standards. For example, for randomised trials, the Consolidated Standards of Reporting 
Trials (CONSORT) aims to standardise the reporting of findings and to facilitate a 
transparent and complete reporting of the study methodology of randomised controlled 
trials (Schulz et al, 2010). The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) provides a guide to develop protocols for systematic review 
and meta-analyses (Moher et al, 2010). In Chapter 3, the systematic review was based on 
the COSMIN guidelines, which aim to provide an overview of the quality of an outcome 
measure (i.e. its psychometric properties) and support evidence-based recommendations 
for the selection of the most appropriate outcome measure for a specific purpose (Mokkink 
et al, 2010c). The COSMIN checklist was originally developed to rate the methodological 
quality of patient-reported outcome measures. However, the COSMIN developers have 
stated that systematic reviews on performance based measures can still be conducted 
based on the COSMIN guidelines, but some of the items on the checklist would need to 
be adapted to fit the reporting of the methodology (Mokkink et al, 2012). The COSMIN 
guidelines were updated on 2018 after we published our systematic review. One of the 
major changes that are included in the new guidelines is that studies rated as ‘poor’ (i.e. 
in the new guidelines are termed as ‘inadequate’) are no longer omitted from the rating of 
evidence. Previously, the ‘poor/inadequate’ studies were not taken into account in the 
evaluation of the overall quality of an outcome measure because the results of these studies 
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could be subject to bias. However, in the new guidelines these studies are included with 
the reasoning that all studies can be included but the quality of the evidence can be 
downgraded in the risk of bias assessment (Prinsen et al, 2018). Another major change is 
that items with regard to formulating hypotheses a priori for ‘hypothesis testing’ (i.e. 
construct validity) and responsiveness are removed, since it was concluded that the results 
from studies not reporting this information can still report appropriate correlations and the 
results are not necessarily biased. Finally, the item of adequate sample size has been 
removed from the boxes evaluating each measurement property to a later stage of the 
review process, because it is believed by the authors of the guidelines that even small but 
high quality studies can provide appropriate evidence of the measurement property 
evaluated. It is acknowledged that these changes of the guidelines could have impacted 
on our already published findings and conclusions. For example, a few studies in our 
systematic review were rated as ‘poor/inadequate’ due to either small sample size or 
because a priori hypotheses were not formulated. However, the overall level of evidence 
for each outcome measure would not be greatly affected, since the results of each study 
were also evaluated separately by the criteria for good measurement properties and were 
combined with the methodological quality to obtain an overall level of evidence for each 
outcome measure.  
The COSMIN taxonomy has been criticised for not including a domain for reliability of 
change score (i.e. ‘longitudinal reliability’) and for not supporting the use of MDC as an 
index for the domain of reliability of change scores (Polit, 2016).  However, the 
developers of COSMIN strongly support the use of MDC only as an index of measurement 
error, since it is calculated by the SEM (i.e. a parameter of measurement error) and this is 
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rarely based on an empirical assessment of the reliability of the change score (Mokkink et 
al, 2016). The COSMIN group continues to update the COSMIN tools, with the revised 
guidelines including a ten step process of performing a systematic review based on 
standards (i.e. referring to the design and statistical methods for evaluating the quality of 
studies on measurement properties) and criteria (i.e. what constitutes good measurement 
properties) (Prinsen et al, 2018).  
 
7.3.2 Evidence for psychometric properties of measures of walking performance in 
pwMS 
 
Walking ability is affected in many pwMS and there is a wide range of outcome measures 
evaluating walking in pwMS. In Chapter 3, 20 outcome measures were identified 
assessing walking performance, lower limb function and effort of walking in studies 
evaluating the effect of assistive technology in pwMS. However, only ten of these 
outcome measures were evaluated for their psychometric properties. This is of concern as 
it is essential for both clinicians and researchers to choose the most appropriate outcome 
in order to evaluate the effectiveness of an intervention such as FES to treat foot drop, 
which is the focus of this thesis. The selection of such an outcome should be based on its 
psychometric properties. By critically evaluating the evidence of studies on measurement 
properties of these walking performance outcomes using the COSMIN guidelines, we 
found strong levels of evidence for the internal consistency and test-retest reliability of 
the MSWS-12 and the construct validity of the T25FW. Moderate levels of evidence were 
found for test-retest reliability and responsiveness of both the T25FW and 6MWT. 
Interestingly, the 10mWT was the most frequent outcome measure used but only a 
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moderate level of evidence was found for responsiveness. However, this finding does not 
necessarily indicate that the 10mWT should not be used in clinical and research settings 
since it could have resulted from ‘poor’ methodological quality studies. However, this 
highlights the need for better design and planning of psychometric studies. Thus far, only 
two systematic reviews have reported on the outcome measures for the evaluation of 
walking performance in pwMS. Kieseier and Pozzilli (2012) reported on the psychometric 
properties of walking performance measures, but they did not assess the methodological 
quality of the included studies. The outcome measures were categorised as those assessing 
walking speed (e.g. T25FW, 10mWT, 30mWT), those evaluating walking distance (e.g. 
2MWT and 6MWT) and self-reported measures such as the MSWS-12. It was 
recommended that the T25FW was the most well characterised objective measure to be 
used in clinical settings, whilst longer timed or distance measures should be used to assess 
fatigability, distance limitations and functional capacity (Kieseier & Pozzilli, 2012). 
Bethoux and Bennett (2011) also recommended the T25FW along with the MSWS-12 to 
be suitable for routine evaluation of walking performance in the MS population due to its 
psychometric properties. However, the methodological quality of the studies included in 
these reviews was not taken into account in these recommendations. It is of importance to 
conduct high quality studies evaluating the psychometric properties of these outcomes. In 
particular, there is a need for studies providing indices like the minimal detectable change 
and minimal clinically important difference, both of which provide essential information 
to clinicians and researchers when interpreting score changes after an intervention.  
Even though in Chapter 3 it was highlighted that no studies had evaluated the 
psychometric properties of 3DGA in the MS population, a topical review emphasised its 
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importance for quantifying gait abnormalities, which could potentially allow for a better 
understanding of the underlying mechanisms of walking impairments that measures like 
spatiotemporal parameters cannot detect (Cofré Lizama et al, 2016). In order to address 
some of the gaps in the evidence for the measurement properties of 3DGA identified in 
Chapter 3, a test-retest reliability (i.e. absolute and relative reliability) study was 
performed in this thesis (Chapter 4). The study was focused on test-retest reliability of 
spatiotemporal parameters and especially ankle kinematics of pwMS, since foot drop is 
quantified by the decrease in dorsiflexion/increase in plantarflexion. Further, this study 
provided indices like SEM and MDC95% which provide essential information to clinicians 
and researchers. The test-retest reliability study included two distinct groups of pwMS 
(Group A: EDSS 0-3.5; Group B: EDSS 4-6). Participants in Group A were both 
minimally impaired by MS and highly physically active while participants in Group B 
used either an AFO or FES to treat their foot drop. Good to excellent ICC values for all 
kinematic and spatiotemporal parameters were found in both groups, with the SEM and 
MDC95% being lower for Group A compared to Group B. A higher variability in walking 
performance in pwMS with a higher level of walking impairment has been observed in 
other studies. For example, it has been shown that pwMS with EDSS > 4.5 and using 
assistive devices have great variability in spatiotemporal parameters than those who do 
not (Socie et al, 2013; Socie et al, 2014).  
Three-dimensional gait analysis systems utilise multiple cameras to track three-
dimensional trajectories of markers placed on anatomical landmarks (e.g. Vicon, 
Optotrak, etc.). These systems are considered the ‘gold’ standard for recording gait 
kinematics and 3DGA is often utilised to establish the construct validity of other measures 
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such as the Microsoft Kinect system that has emerged as a tool for movement analysis in 
clinical practice (Asaeda et al, 2018). However, Chapter 3 showed that EDSS is often used 
as the gold standard (or comparator) when assessing the criterion (or construct validity) 
of outcome measures used to assess walking performance. The EDSS is a scale that 
evaluates general disability and walking performance is taken into account only at EDSS 
of 4.0 and higher, which is important to bear in mind when the population of interest 
includes people with EDSS scores less than 4.0.  
Three-dimensional gait analysis outcomes and especially indices, which quantify the 
‘overall’ deficit in gait kinematics, such as the Gait Profile Score may be more appropriate 
comparators for clinical outcomes of walking performance. Although the reliability of the 
gait kinematic parameters has been assessed in other populations (e.g. Redekop et al, 
2008; Devetak et al, 2016), the study reported in Chapter 4 is the first to provide evidence 
of the reliability of gait kinematics in pwMS. Further work is needed to establish the 
psychometric properties of gait kinematics in pwMS other than reliability, such as the 
minimal clinically important difference (MCID). Knowledge of the MCID would assist 
the interpretation of studies exploring the long-term change in gait kinematics or those 
investigating the long-term effect of FES to treat foot drop.   
 
7.4 Gait deterioration and foot drop 
 
7.4.1 Foot drop in minimally impaired pwMS 
 
Consultant neurologists at the Anne Rowling Clinic in Edinburgh observed that it is not 
uncommon for highly physically active pwMS with EDSS < 2.5 to report that they 
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experience symptoms such as foot drop during relatively high intensity and/or long 
duration exercise bouts. These symptoms may affect walking ability during and directly 
after exercise but will disappear after a relatively short period of rest. Following these 
reports and reports of ‘fatigable foot drop’ in people who use FES (Bulley et al, 2015), we 
conducted an audit at the Anne Rowling Clinic which showed that 70% pwMS (33 out of 
47 respondents) reported experiencing transient foot drop that recovered following rest. 
Moreover, it was indicated from this audit that the most commonly reported activities that 
seem to induce this phenomenon were walking and running, while the average time until 
the initiation was 20 min (range: 2-60 min) and average distance covered until initiation 
was 1.6 miles (range: 0.5-4.5 miles). Thus, the aim of Chapter 5 was to attempt to 
objectively quantify this exercise-induced foot drop in highly physically active and 
minimally impaired (EDSS < 2.5) pwMS. The findings of the audit allowed us to 
hypothesize that for most participants a 20 min treadmill run at a self-selected speed would 
result into exercise-induced foot drop. Indeed, in the study described in Chapter 5 it was 
found that there was a statistically significant decrease in peak DF in swing in pwMS 
compared to healthy individuals after a 20-minute treadmill run, with six out of the 15 
pwMS showing a decrease in peak DF in swing exceeding the MDC95% (as derived in 
Chapter 4). However, it was observed that some of the participants who reported 
experiencing foot drop did not show any significant changes in kinematic parameters. A 
possible explanation for this might be that the test protocol used in this study was not 
demanding enough (i.e. too short or low intensity exercise task) for this highly physically 
active group of pwMS.   
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To our knowledge, the study described in Chapter 5 is the first study that investigated gait 
kinematics and spatiotemporal parameters after an exercise task that attempted to induce 
fatigability in highly physically active pwMS who did not experience any habitual gait 
dysfunction. Only a few studies have investigated changes in gait kinematics after 
inducing fatigability (i.e. after a 6MWT or walking on a treadmill until exhaustion), but 
the MS population in those studies had higher EDSS (EDSS > 3.5) (Sehle et al, 2011; 
McLoughlin et al, 2016).  
Another interesting finding of the study in Chapter 5 was that the pre-exercise gait 
characteristics in the highly physically active participants with MS did not differ from the 
age-matched healthy control group, contrary to findings in previous studies with pwMS 
with low EDSS. It is possible that the fact that the participants were all highly physically 
active could accounts for this difference in findings. Reporting the physical activity status 
of participants in studies investigating gait characteristics in pwMS with minimal or no 
walking impairment in daily life, would enhance the interpretation of the findings. Future 
studies should investigate transient foot drop in pwMS with EDSS scores < 3.5 but who 
are not highly physically active and thus may be a more representative sample. Further, 
this supports the notion that a more demanding task, such as the protocol used in this 
study, is needed in order to highlight changes in minimally impaired pwMS.  
In Chapter 5, fatigability was quantified as exercise-induced foot drop. A recent 
systematic review summarised existing protocols and outcome measures used to detect 
fatigability in the MS population (Severijns et al, 2017). It was found that most protocols 
used maximal single-joint isometric contractions, whilst walking protocols included the 
6MWT, walking on a treadmill until exhaustion and the T500mW (Severijns et al, 2017).  
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The majority of the studies, which used walking protocols to induce fatigability, quantified 
fatigability as the decrease in walking speed over time. However, a decrease in walking 
speed can also be the result of non-MS specific factors such as pacing and aerobic capacity 
(Dalgas et al, 2014). This study together with studies by McLoughlin et al. (2016) and 
Sehle et al. (2014) instead focused on gait kinematics where are more likely to reflect 
underlying MS specific neurological deficits. However, there is no standardised protocol 
in order to compare findings among studies, since each protocol is measuring different 
aspects of fatigability and future work should focus on investigating the psychometric 
properties of outcome measures used to assess fatigability in pwMS.  
Fatigability has also been investigated in different populations and similarly there are no 
standard protocols to assess fatigability in these populations either. For example, 
fatigability has been documented as changes in kinematic and spatiotemporal parameters 
after nine consecutive trials (over 10m) in stroke survivors (Boudarham et al, 2013), in 
myasthenia gravis as the distance covered in six 60s intervals of the 6MWT (Jordan et al, 
2017) and in older women as a decrease of maximum velocity of consecutive repetitions 
of sit-to-stand transfers (Lindemann et al, 2016).  
A potential factor that could have influenced the findings with regard to the presence of 
exercise-induced foot drop is the level and number of spinal lesions and the atrophy of the 
spinal cord in our MS group. A recent study by Sechi et al. (2019) reported that for pwMS 
with unilateral motor progression, the motor deficit may be attributable to a single critical 
corticospinal tract lesion. To the author’s knowledge, the correlation of spinal lesions with 
functional and walking performance outcome measures has not been widely examined. 
Only one study, by Cohen et al. (2012), reported that the upper cervical spinal cord volume 
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significantly correlated with EDSS, while there was lack of correlation between all brain 
and spinal cord lesions measures and the T25FW in a group of mildly disabled MS group 
with RRMS. In this case this might be explained by the fact that this group has no walking 
impairments. Another study also reported that the atrophy of the spinal cord is related to 
clinical disability as assessed with the EDSS (Lukas et al, 2013). However, the location 
and the number of lesions in the participants in the study were not investigated in Chapter 
5 as it was out with the scope of the overall aim of this thesis. However, the association 
between spinal lesions and walking related symptoms such as transient foot drop requires 
further investigation in order to gain an improved understanding of the underlying 
mechanisms of this exercise-induced phenomenon. Further work that could identify 
potential mechanisms of fatigability induced gait changes is through electromyography 
(EMG) for example of the tibialis anterior and the gastrocnemius muscles.  
 
7.4.2 The effect of FES to treat foot drop and dual-tasking in people with MS whose 
walking ability is impaired by fixed foot drop 
 
Even though there is a great amount of literature investigating the direct orthotic effect of 
FES on kinematic and/or spatiotemporal parameters, and usually over short 
distance/duration, the novel element of the study described in Chapter 6 is the exploration 
of the direct orthotic effect of FES on walking characteristics in pwMS who are 
simultaneously performing a cognitive task. 
Chapter 6 aimed to investigate the direct orthotic effect of FES under a variety of walking 
conditions that would be more ecologically valid and thus replicate activities of daily life 
in comparison to standard single task walking tests commonly used in research and 
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clinical practice. Participants were asked to perform walking trials under three conditions: 
1) single task walking, 2) walking with the addition of a cognitive task and 3) walking 
after inducing fatigability while simultaneously performing a cognitive task. The idea of 
this study was based on recent evidence of the experiences of the use of FES which 
suggests that one of the key perspectives that pwMS express is that they ‘do not have to 
concentrate as hard or think about every step they were taking’ when using FES (Bulley 
et al, 2015; (Miller) Renfrew et al, 2018). Even though there is a growing body of evidence 
on the effect of dual-tasking on gait parameters in pwMS, to our knowledge no other study 
has objectively examined and reported on the benefits of FES use under dual-tasking 
conditions. The results indicated that there was a small trend for higher direct orthotic 
effect of FES in peak DF in swing during the dual-task conditions (i.e. dual-task and dual-
task after induced fatigability) compared to single task condition (i.e. only walking) with 
a small but positive effect size (≈0.12). The DTC of walking speed in the condition without 
induced fatigue was 12.4%, while for the healthy control group was 4.6% which is similar 
to that found in previous studies investigating the DTC of walking speed compared to 
healthy individuals (e.g. Sosnoff et al, 2011a; Learmonth et al, 2014; Coghe et al, 2018). 
The sample size of the present study was less than required for an appropriately powered 
trial and thus we were not able to perform any inferential statistics. Hence, further 
appropriately powered trials are needed to confirm these findings. However, this study 
showed that the protocol was feasible in this population of pwMS and the results provide 
an initial insight into the potential benefits of FES which have not been explored before.  
There is evidence for the interaction of cognitive and motor functions in MS, with a 
growing interest in CMI that is the decline in the performance on the motor task while 
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performing a cognitive task simultaneously (Benedict et al, 2011; Motl et al, 2016). 
Nonetheless, a recent systematic review reported equivocal findings of studies 
investigating the DTC of walking speed and concluded that there is a minimal difference 
in CMI between pwMS and healthy individuals (Learmonth et al, 2017). It should be noted 
though, that the majority of the included studies had small sample sizes and more 
importantly used different cognitive tasks which makes it difficult to draw any conclusions 
since different test protocols examine different cognitive domains. The meta-analysis by 
Learmonth et al. (2017) suggested that discrimination and decision-making tasks to 
challenge motor control are most likely to highlight potential differences in CMI in pwMS 
compared to healthy individuals. For that reason, we decided to use the Stroop test as a 
cognitive task which is a discrimination and decision making task and is associated with 
the measurement of attention and response inhibition (MacLeod, 1991). Thus far, only 
one study investigated CMI on spatiotemporal parameters in pwMS with the use of the 
Stroop test and reported a DTC of walking speed of 11.7% for pwMS and 4.8% for the 
healthy control group (Coghe et al, 2018). Although similar to our findings, it should be 
noted that the MS group in that study consisted of mildly disabled pwMS (EDSS mean: 
2.1) whereas our group were moderately disabled (EDSS range: 4.0-6.0), suggesting that 
CMI is evident in mild MS compared to healthy individuals. Future studies should explore 
whether there is a correlation between CMI and disability status.  
The importance of dual-tasking in pwMS was also highlighted in a review by Motl et al. 
(2016) which suggested dual-task exercises as a promising intervention for improving 
walking and cognitive functions in pwMS. Although there is a growing body of literature 
highlighting the importance of exercise and cognitive interventions for rehabilitation 
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purposes in pwMS, the authors of this review concluded that there are no studies 
examining the efficacy of combining these two types of interventions on walking 
performance in pwMS, for example through dual-task exercises (Motl et al, 2016). Hence, 
the individual and combined effects of exercise and cognitive rehabilitation and their 
interaction on walking and cognitive performance need to be explored in future studies.  
 
7.5 Limitations and future work 
 
The present thesis has several limitations that should be considered in future studies. 
Firstly, the systematic review in Chapter 3 that reported on the evidence of the 
psychometric properties of self-reported and objective outcome measures of walking 
performance was based on the COSMIN guidelines that were developed for HR-PROMs 
and not for the type of performance-based measures included in the review in Chapter 3. 
However, the theoretical framework underpinning the development of COSMIN was 
applicable to both HR-PROMs and performance based outcome measures and the updated 
guidelines support the use of COSMIN on other measures apart from HR-PROMs with 
adapted methodology.  
 Chapter 4 examined the test-retest reliability of ankle kinematics and spatiotemporal 
parameters in two groups of pwMS with different level of walking impairments. The focus 
of the study was on the outcomes that can evaluate and quantify foot drop and that was 
the reason we examined test-retest reliability of the ankle kinematics. Nonetheless, and 
since they can provide important information of compensation strategies for foot drop in 
this population, future research should be undertaken to examine the reliability of the 
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kinematic parameters in other joints of the lower limbs (i.e. knee, hip and pelvis). 
Moreover, responsiveness of gait kinematics should also be examined since it is essential 
information for evaluating meaningful changes both in routine clinical practice and 
research interventions. Further, the sample size in both groups of pwMS would be 
considered small according to the COSMIN guidelines. However, in the updated 
guidelines the developers of COSMIN have removed the standard of ‘adequate’ sample 
size, since it was decided that small high-quality studies can still provide sufficient 
information on a measurement property and it is taken into account in a later phase when 
conclusions on the overall level of evidence of an outcome measure are drawn. 
The main weakness of the study in Chapter 5 was the exercise task that consisted of a 20 
minutes self-selected speed run on a treadmill. This exercise task was chosen based on the 
finding in our foot drop audit (see Appendix 1) that the average time until the onset of 
transient foot drop was 20 minutes. However, the chosen exercise task in  this study might 
not have been demanding enough for some of the participants, since we were not able to 
capture exercise-induced foot drop for some participants who reported experiencing this 
phenomenon. Another limitation is that the use of a treadmill limits the ecological validity 
and the clinical implementability of that specific exercise task. To develop a more 
comprehensive insight into fatigability in mildly disabled pwMS, additional studies will 
be needed. Those studies should consider the use of standardised clinical tests based on 
each participants’ functional ability such as the shuttle walk test, which is incremental and 
progressive and stresses the individuals to their maximal performance (Singh et al, 1992). 
 The main limitation in Chapter 6 was the small number of participants in both MS and 
healthy control groups and thus the study was not powered to detect any statistically 
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significant differences between the different conditions. The aim is to continue with 
recruitment until we reach the sample size derived from the a priori power calculation that 
was performed for this study. Further, because of the relatively broad inclusion criteria, a 
large variability among the participants was observed. For example, the population in the 
study consisted of a person using FES in both limbs and a person using FES only for 
running.  Stricter inclusion/exclusion criteria should be applied in future studies regarding 
the use of FES. Further work is required to gain a better understanding of CMI in pwMS 
and the perceived benefits of FES and this can be achieved by standardised use of 
cognitive tasks evaluating the same cognitive processes (i.e. discrimination and decision 
making tasks) so that the findings of studies can be comparable.    
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Chapter 8. Conclusion 
 
Walking impairments is one of the most debilitating symptoms in MS and especially foot 
drop although interestingly, its prevalence has not been reported in the literature. The 
overall aim of the present PhD thesis was to explore foot drop, its presence in pwMS with 
different disability levels and the psychometric properties of outcomes used to evaluate 
walking impairments. 
The systematic review summarised all self-reported and objective measures of walking 
performance used in studies that evaluated the effects of assistive technology in pwMS 
and evaluated the level of evidence for their psychometric properties. The findings of this 
review can guide clinicians and researchers to choose the most appropriate outcome 
measure for their needs based on the level of evidence of each outcome. This review also 
highlighted that there was a gap in the literature, with regard to the psychometric 
properties of 3D gait kinematics in pwMS. This finding resulted in our next study 
examining the test-retest reliability of ankle kinematics and spatiotemporal parameters 
and in two groups of pwMS with different levels of walking impairments. The findings of 
this reliability study helped to interpret the results in Chapter 5, which objectively 
documented gait deterioration evidenced as foot drop induced by an exercise task in highly 
active pwMS that could potentially be a sign of onset of fatigability. It was also used in 
Chapter 6 after inducing fatigability in pwMS that were FES users. Future studies are 
needed to explore the exercise-induced gait deterioration over time using more 
standardised exercise tasks so that participants are performing the same test each time 
without the issues of self-selecting speed and training effects. Further exploration is also 
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needed to unveil the potential value of gait analysis as a sensitive tool for disease 
progression. Gait analysis can record minimal changes and longitudinal follow-up of 
pwMS can reveal potential deterioration of mobility in early stages of the disease process, 
however its responsiveness has not been explored for pwMS. Finally, the last study 
(Chapter 6) was the first to investigate the benefits of FES under dual-tasking and 
fatiguing conditions in pwMS. Although the study was based on a small sample of 
participants, the findings suggest that there was a positive trend for the direct orthotic 
effect of FES under dual-tasking conditions compared to single-task conditions. Further 
investigations with appropriately powered study designs are required to determine the 
effectiveness of FES and also the CMI in this population with standardised cognitive tests 
that assess the same cognitive processes.  
In summary, the studies presented in this PhD have attempted to answer questions related 
to the level of psychometric evidence of walking performance measures in the MS 
population, as well as investigating foot drop in pwMS with different disability status. 
There are still many unanswered questions that the present thesis could not address, such 
as the underlying mechanisms of fatigability induced foot drop or the mechanisms of CMI 
in pwMS, but the project hopefully has shed some light on some of the issues and may 
ultimately positively impact the lives of pwMS.  
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Appendix 1:   Foot drop audit 
 
During annual clinical review of patients at the Anne Rowling Regenerative Medicine 
Clinic, we invited 80 ambulant pwMS to complete a short survey to explore their 
experience of exercise-related transient foot drop. Participants were included diagnosed 
with any subtype of MS and EDSS scores ranging from 0-5. Table 8 present the responses 
at each individual item of this questionnaire. Thirty-three of 47 respondents (70%) 
reported experiencing transient foot drop that comes during exercise, whilst three reported 
permanent foot drop and the remaining 11 did not report any foot drop. The most 
commonly reported activities associated with the onset of transient foot drop were walking 
(69%) and running (36%). The mean time for this to occur was 19 minutes of participation 
(range 2-60 minutes) or after approximately 1.65 miles. Based on the survey responses 
foot drop appears to be more evident, and occurs more quickly, during faster speeds of 
walking and running or walking uphill.  
 
Table 8 Audit questionnaire presented as number of answers (%) or mean (range). 
Questions Answers  
Q1. Do you experience temporarily ‘foot drop’ (after a certain 
period of walking or running or other type of activity? (n=47) 
Yes 
No, my foot drop  starts immediately when I start 
walking/exercising 
No, I don’t experience ‘foot drop 
 
 
33 (70%) 
3 (6%) 
11 (24%) 
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Q2. During which activity/activities do you experience this? (i.e. 
walking, running, cycling, driving) (n=36) 
Walking  
Running  
Cycling  
Other  
 
 
25 (69%) 
13 (36%) 
3 (8%) 
4 (11%) 
Q3. When do you start experiencing ‘foot drop’? (i.e. after how 
many miles or minutes?) (n=36)  
Minutes  
Miles  
 
 
19 (2 - 60) 
1.65 (0.5 - 4.5) 
Q4. Does foot drop force you to stop your activity or reduce the 
intensity (i.e. walking/running speed) (n=34) 
I have to stop and rest  
I have to slow down/change my activity 
 
 
16 (47%) 
18 (53%) 
Q5. How long does it take approximately until you feel the foot 
drop has disappeared and you are able to resume 
walking/exercising or the activity you were doing? (n=36) 
 
32 minutes (1-90) 
Q6. Do you think your foot drop comes on earlier if:  (n=36)  
You walk/run/cycle etc. faster 
You walk/run/cycle etc. uphill/upstairs 
You walk/run on uneven terrain/crowded streets 
Your feel more fatigued than usual before your activity 
 
23 (64%) 
21(58%) 
18 (50%) 
22 (61%) 
Q7. Do you think your foot drop comes on later if: (n=29) 
You walk/run/cycle etc.  slower 
You walk/run etc.  downhill/downstairs 
You walk/run etc. on a quiet, smooth level road 
Your feel less fatigued than usual before your activity 
 
18 (62%) 
10 (34%) 
12 (41%) 
17 (58%) 
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Appendix 2:   First search – overview of outcome measures 
 
CINAHL search strategy/15.4.2016/ 1969-2016 
 
S1. multiple sclerosis 
S2. demyelinating disease 
S3. demyelinating autoimmune disease 
S4. chronic progressive multiple sclerosis 
S5. secondary progressive multiple sclerosis 
S6. primary progressive multiple sclerosis 
S7. relapsing remitting multiple sclerosis 
S8. clinically isolated syndrome 
S9. demyelinating disorder 
S10. transverse myelitis 
S11. acute disseminated encephalomyelitis 
 
S12. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 
 
S13. functional electrical stimulation  
S14. foot drop stimulation 
S15. ankle foot orthosis 
S16. splints 
S17. electrical stimulation  
S18. orthosis 
S19. common peroneal stimulation 
S20. electric stimulation 
S21. peroneal nerve stimulation 
S22. orthotic devices 
S23. neuroprosthesis 
S24. lower limb orthosis 
 
S25. S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 
OR S23 OR S24  
 
S26. S12 AND S25 
 
 
MEDLINE search strategy/15.4.2016/1963-2016 
 
S1. multiple sclerosis 
S2. demyelinating disease 
S3. demyelinating autoimmune disease 
S4. chronic progressive multiple sclerosis 
S5. secondary progressive multiple sclerosis 
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S6. primary progressive multiple sclerosis 
S7. relapsing remitting multiple sclerosis 
S8. clinically isolated syndrome 
S9. demyelinating disorder 
S10. transverse myelitis 
S11. acute disseminated encephalomyelitis 
 
S12. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 
 
S13. functional electrical stimulation  
S14. foot drop stimulation 
S15. ankle foot orthosis 
S16. splints 
S17. electrical stimulation  
S18. orthosis 
S19. common peroneal stimulation 
S20. electric stimulation 
S21. peroneal nerve stimulation 
S22. orthotic devices 
S23. neuroprosthesis 
S24. lower limb orthosis 
 
S25. S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 
OR S23 OR S24  
 
S26. S12 AND S25 
 
SCOPUS search strategy /18.4.2016/1977-2016 
 
( ( ( TITLE-ABS-KEY ( multiple  sclerosis ) )  OR  ( TITLE-ABS-
KEY ( demyelinating  disease ) )  OR  ( TITLE-ABS-
KEY ( demyelinating  autoimmune  disease ) )  OR  ( TITLE-ABS-
KEY ( chronic  progressive  multiple  sclerosis ) )  OR  ( TITLE-ABS-
KEY ( secondary  progressive  multiple  sclerosis ) )  OR  ( TITLE-ABS-
KEY ( primary  progressive  multiple  sclerosis ) )  OR  ( TITLE-ABS-
KEY ( relapsing  remitting  multiple  sclerosis ) )  OR  ( TITLE-ABS-
KEY ( clinically  isolated  syndrome ) ) )  OR  ( ( TITLE-ABS-
KEY ( demyelinating  disorder ) )  OR  ( TITLE-ABS-
KEY ( transverse  myelitis ) )  OR  ( TITLE-ABS-
KEY ( acute  disseminated  encephalomyelitis ) ) ) )  AND  ( ( ( TITLE-ABS-
KEY ( functional  electrical  stimulation ) )  OR  ( TITLE-ABS-
KEY ( foot  drop  stimulation ) )  OR  ( TITLE-ABS-
KEY ( ankle  foot  orthosis ) )  OR  ( TITLE-ABS-KEY ( splints ) )  OR  ( TITLE-
ABS-KEY ( electrical  stimulation ) )  OR  ( TITLE-ABS-
KEY ( orthosis ) )  OR  ( TITLE-ABS-
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KEY ( common  peroneal  stimulation ) ) )  OR  ( ( TITLE-ABS-
KEY ( electric  stimulation ) )  OR  ( TITLE-ABS-
KEY ( peroneal  nerve  stimulation ) )  OR  ( TITLE-ABS-
KEY ( orthotic  devices ) )  OR  ( TITLE-ABS-
KEY ( neuroprosthesis ) )  OR  ( TITLE-ABS-KEY ( lower  limb  orthotics ) ) ) )  
 
 
Embase search strategy/15.4.2016/1974-2016 
 
1. multiple sclerosis/ 
2. demyelinating disease/ 
3. demyelinating autoimmune disease.mp. 
4. chronic progressive multiple sclerosis.mp. 
5. secondary progressive multiple sclerosis.mp. 
6. primary progressive multiple sclerosis.mp. 
7. relapsing remitting multiple sclerosis.mp. 
8. clinically isolated syndrome.mp. 
9. demyelinating disorder.mp. 
10. transverse myelitis.mp. 
11. acute disseminated encephalomyelitis.mp. or acute disseminated 
encephalomyelitis/ 
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
13. functional electrical stimulation.mp. or functional electrical stimulation/ 
14. foot drop stimulation.mp. 
15. ankle foot orthosis.mp. or ankle foot orthosis/ 
16. splints.mp. or splint/ 
17. electrical stimulation.mp. 
18. orthosis/ or orthosis.mp. 
19. common peroneal stimulation.mp. 
20. electric stimulation.mp. 
21. peroneal nerve stimulation.mp. 
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22. orthotic devices.mp. 
23. neuroprosthesis.mp. or neuroprosthesis/ 
24. lower limb orthosis.mp. 
25. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
26. 12 and 25 
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Appendix 3:   Principal search – systematic review of the psychometric 
properties of outcome measures  
 
CINHAL/MEDLINE 
 
1# Population  
multiple sclerosis OR demyelinating disease OR demyelinating autoimmune disease 
OR chronic progressive multiple sclerosis OR secondary progressive multiple sclerosis 
OR primary progressive multiple sclerosis OR relapsing remitting multiple sclerosis OR 
clinically isolated syndrome OR demyelinating disorder OR transverse myelitis OR 
acute disseminated encephalomyelitis 
2# Outcome measures  
(3D gait analysis OR kinematics) OR (6MWT OR 6 min walk test OR six minute 
walking test) OR (walking speed OR walking speed over 10m) OR (Physiological Cost 
Index OR PCI) OR (effort of walking OR RPE OR Rate of Perceived Exertion) OR 
GAITRite OR standing balance test OR choice stepping reaction time OR (oxygen 
consumption OR oxygen uptake) OR (energy cost of walking OR mechanical energy) 
OR (MSFC OR Multiple Sclerosis Functional Composite) OR (T25FW OR Timed 25 
Foot Walk) OR (mEFAP OR modified Emory Functional Ambulation Profile) OR 
(Rivermead Observational Gait Analysis OR ROGA) OROR falls diary OR (GAITRite 
FAP OR GAITRite Functional Ambulation Performance) OR Hauser Ambulation Index 
OR (2MWT OR 2 min walk test OR two minute walk test) OR (MSWS OR MS 
Walking Scale) OR (4MWT OR 4 min walk test OR four minute walk test) OR (3MWT 
OR 3 min walk test OR three minute walk test) OR EMG OR (stride parameters OR 
temporal parameters OR spatial parameters) 
 
 
3# Filter search 
 instrumentation* OR methods OR validation stud* OR comparative stud* OR 
psychometr* OR clinimetr* OR clinometr* OR (MH "Outcomes (Health Care)+") OR 
(MH "Treatment Outcomes+") OR (MH “outcome  
assessment”) OR outcome assessment OR outcome measure* OR observer variation OR 
(MH “Health Status Indicators”) OR (MH “reproducibility of results”) OR reproducib* 
OR (MH “discriminant analysis”) OR reliab* OR unreliab* OR valid* OR coefficient 
OR homogeneity OR homogeneous OR “internal consistency” 
 OR (cronbach* AND (alpha OR alphas)) 
 OR (item AND (correlation* OR selection* OR reduction*)) 
 OR agreement OR precision OR imprecision OR “precise values” OR test-retest OR 
(test AND retest)  
OR (reliab* AND (test OR retest))  
OR stability OR interrater OR inter-rater OR intrarater OR intra-rater OR intertester OR 
inter-tester OR intratester OR intra-tester OR interobserver OR inter-observer OR 
intraobserver OR intra-observer OR intertechnician OR inter-technician OR 
intratechnician OR intra-technician OR interexaminer OR inter-examiner OR 
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intraexaminer OR intra-examiner OR interassay OR inter-assay OR intraassay OR intra-
assay OR interindividual OR inter-individual OR intraindividual OR intra-individual OR 
interparticipant OR inter-participant OR intraparticipant OR intra-participant OR kappa 
OR kappa’s OR kappas OR repeatab* OR ((replicab* OR repeated) AND (measure OR 
measures OR findings OR result OR results OR test OR tests))  
OR generaliza* OR generalisa* OR concordance 
 OR (intraclass AND correlation*)  
OR discriminative OR “known group” OR factor analysis OR factor analyses OR 
dimension* OR subscale* 
 OR (multitrait AND scaling AND (analysis OR analyses))  
OR item discriminant OR interscale correlation* OR error OR errors OR “individual 
variability” 
 OR (variability AND (analysis OR values))  
OR (uncertainty AND (measurement OR measuring)) 
 OR “standard error of measurement” OR sensitiv* OR responsive*  
OR ((minimal OR minimally OR clinical OR clinically) AND (important OR significant 
OR detectable) AND (change OR difference)) 
 OR (small* AND (real OR detectable) AND (change OR difference))  
OR meaningful change OR “ceiling effect” OR “floor effect” OR “Item response 
model” OR IRT OR Rasch OR “Differential item functioning” OR DIF OR “computer 
adaptive testing” OR “item bank” OR “cross-cultural equivalence”) 
 
 
5# Combination 
1# AND 2# AND 3#  
 
 
SCOPUS  
 
1# POPULATION 
(TITLE-ABS-KEY(multiple sclerosis)) OR (TITLE-ABS-KEY(demyelinating disease)) 
OR(TITLE-ABS-KEY(demyelinating autoimmune disease)) OR (TITLE-ABS-
KEY(chronic progressive multiple sclerosis)) OR (TITLE-ABS-KEY(secondary 
progressive multiple sclerosis)) OR (TITLE-ABS-KEY(primary progressive multiple 
sclerosis)) OR (TITLE-ABS-KEY(relapsing remitting multiple sclerosis)) OR (TITLE-
ABS-KEY(clinically isolated syndrome)) OR (TITLE-ABS-KEY(demyelinating 
disorder)) OR (TITLE-ABS-KEY(transverse myelitis)) OR (TITLE-ABS-KEY(acute 
disseminated encephalomyelitis)) 
 
2#OUTCOME MEASURES 
(TITLE-ABS-KEY(3D gait analysis OR kinematics)) OR (TITLE-ABS-KEY(6MWT 
OR 6 min walk test OR six minute walk test)) OR (TITLE-ABS-KEY(walking speed 
OR walking speed over 10m)) OR (TITLE-ABS-KEY(Physiological Cost Index OR 
PCI)) OR (TITLE-ABS-KEY(effort of walking OR RPE OR Rate of Perceived 
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Exertion)) OR (TITLE-ABS-KEY(GAITRite)) OR (TITLE-ABS-KEY(standing balance 
test)) OR (TITLE-ABS-KEY(choice stepping reaction time)) OR (TITLE-ABS-
KEY(oxygen consumption OR oxygen uptake)) OR (TITLE-ABS-KEY(energy cost of 
walking OR mechanical energy)) OR (TITLE-ABS-KEY(MSFC OR Multiple Sclerosis 
Functional Composite)) OR (TITLE-ABS-KEY(T25FW OR Timed 25 Foot Walk)) OR 
(TITLE-ABS-KEY(mEFAP OR modified Emory Functional Ambulation Profile)) OR 
(TITLE-ABS-KEY(Rivermead Observational Gait Analysis OR ROGA)) OR (TITLE-
ABS-KEY(GAITRite FAP OR GAITRite Functional Ambulation Performance)) OR 
(TITLE-ABS-KEY(Hauser Ambulation Index)) OR (TITLE-ABS-KEY(2MWT OR 2 
min walk test OR two minute walk test)) OR (TITLE-ABS-KEY(MSWS OR MS 
Walking Scale)) OR (TITLE-ABS-KEY(4MWT OR 4 min walk test OR four minute 
walk test)) OR (TITLE-ABS-KEY(3MWT OR 3 min walk test OR three minute walk 
test)) OR (TITLE-ABS-KEY(EMG)) OR (TITLE-ABS-KEY(stride parameters OR 
temporal parameters OR spatial parameters)) 
 
3# FILTER/SENSITIVE 
instrumentation* OR methods OR validation stud* OR comparative stud* OR 
psychometr* OR clinimetr* OR clinometr* OR ( "Outcomes (Health Care)+") OR ( 
"Treatment Outcomes+") OR ( "outcome assessment") OR outcome assessment OR 
outcome measure* OR observer variation OR ( "Health Status Indicators") OR ( 
"reproducibility of results") OR reproducib* OR ( "discriminant analysis") OR reliab* 
OR unreliab* OR valid* OR coefficient OR homogeneity OR homogeneous OR 
"internal consistency" OR (cronbach* AND (alpha OR alphas)) OR (item AND 
(correlation* OR selection* OR reduction*)) OR agreement OR precision OR 
imprecision OR "precise values" OR test-retest OR (test AND retest) OR (reliab* AND 
(test OR retest)) OR stability OR interrater OR inter-rater OR intrarater OR intra-rater 
OR intertester OR inter-tester OR intratester OR intra-tester OR interobserver OR inter-
observer OR intraobserver OR intra-observer OR intertechnician OR inter-technician 
OR intratechnician OR intra-technician OR interexaminer OR inter-examiner OR 
intraexaminer OR intra-examiner OR interassay OR inter-assay OR intraassay OR intra-
assay OR interindividual OR inter-individual OR intraindividual OR intra-individual OR 
interparticipant OR inter-participant OR intraparticipant OR intra-participant OR kappa 
OR kappa's OR kappas OR repeatab* OR ((replicab* OR repeated) AND (measure OR 
measures OR findings OR result OR results OR test OR tests)) OR generaliza* OR 
generalisa* OR concordance OR (intraclass AND correlation*) OR discriminative OR 
"known group" OR factor analysis OR factor analyses OR dimension* OR subscale* 
OR (multitrait AND scaling AND (analysis OR analyses)) OR item discriminant OR 
interscale correlation* OR error OR errors OR "individual variability" OR (variability 
AND (analysis OR values)) OR (uncertainty AND (measurement OR measuring)) OR 
"standard error of measurement" OR sensitiv* OR responsive* OR ((minimal OR 
minimally OR clinical OR clinically) AND (important OR significant OR detectable) 
AND (change OR difference)) OR (small* AND (real OR detectable) AND (change OR 
difference)) OR meaningful change OR "ceiling effect" OR "floor effect" OR "Item 
Response Model" OR IRT OR Rasch OR "Differential item functioning" OR DIF OR 
"computer adaptive testing" OR "item bank" OR "cross-cultural equivalence" 
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EMBASE 
 
1# POPULATION 
1. multiple sclerosis/ 
2. demyelinating disease/ 
3. demyelinating autoimmune disease.mp. 
4. chronic progressive multiple sclerosis.mp. 
5. secondary progressive multiple sclerosis.mp. 
6. primary progressive multiple sclerosis.mp. 
7. relapsing remitting multiple sclerosis.mp. 
8. clinically isolated syndrome.mp. 
9. demyelinating disorder.mp. 
10. transverse myelitis.mp. 
11. acute disseminated encephalomyelitis.mp. or acute disseminated 
encephalomyelitis/ 
12.  1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 
 
2# OUTCOME MEASURES 
 (3D gait analysis or kinematics).mp. 
OR  
(6MWT or 6 min walk test or six minute walk test).mp 
OR (walking speed or walking speed over 10m).mp.  
OR  
 
(Physiological Cost Index or PCI).mp.  
 
OR  (effort of walking or RPE or Rate of Perceived Exertion).mp. OR 
 
GAITRite.mp.  
OR standing balance test.mp.  OR choice stepping reaction time.mp.  OR  (oxygen 
consumption or oxygen uptake).mp.  OR (energy cost of walking or mechanical 
energy).mp.  OR  (MSFC or Multiple Sclerosis Functional Composite).mp.  OR  (T25FW 
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or Timed 25 Foot Walk).mp.  OR  (mEFAP or modified Emory Functional Ambulation 
Profile).mp.  OR  (Rivermead Observational Gait Analysis or ROGA).mp. OR  
(GAITRite FAP or GAITRite Functional Ambulation Performance).mp.  OR  Hauser 
Ambulation Index.mp.  OR  (2MWT or 2 min walk test or two minute walk test).mp. OR  
(MSWS or MS Walking Scale).mp.  OR (4MWT or 4 min walk test or four minute walk 
test).mp.  OR  (3MWT or 3 min walk test or three minute walk test).mp. OR EMG.mp. 
OR (stride parameters or temporal parameters or spatial parameters).mp. 
 
 
3# FILTER/SENSITIVE 
('validation study'/ OR psychometr*.mp. OR clinimetr*.mp. OR ‘outcome assessment’/ 
OR outcome assessment*.mp. OR 'comparative study'/ OR outcome measure*.mp. OR 
'observer variation'/ OR 'observer variation'.mp OR 'reproducibility'/ OR 
reproducib*.mp. OR 'discriminant analysis'/ OR reliab*.mp. OR unreliab*.mp. OR 
valid*.mp. OR coefficient.mp. OR homogeneity.mp. OR homogeneous.mp. OR ‘internal 
consistency’.mp. OR (cronbach* AND (alpha OR alphas)) OR (item AND (correlation* 
OR selection* OR reduction*)) OR agreement.mp. OR precision.mp. OR 
imprecision.mp. OR ‘precise values’.mp. OR test-retest.mp. OR (test AND retest).mp. 
OR (reliab* AND (test OR retest)).mp. OR stability.mp. OR interrater.mp. OR inter-
rater.mp. OR intrarater.mp. OR intra-rater.mp. OR intertester.mp. OR inter-tester.mp. 
OR intratester.mp. OR intra-tester.mp. OR interobserver.mp. OR inter-observer.mp. OR 
intraobserver.mp. OR intra-observer.mp. OR intertechnician.mp. OR inter-
technician.mp. OR intratechnician.mp. OR intra-technician.mp. OR interexaminer.mp. 
OR inter-examiner.mp. OR intraexaminer.mp. OR intra-examiner.mp. OR 
interassay.mp. OR inter-assay.mp. OR intraassay.mp. OR intra-assay.mp. OR 
interindividual.mp. OR inter-individual.mp. OR intraindividual.mp. OR intra-
individual.mp. OR interparticipant.mp. OR inter-participant.mp. OR intraparticipant.mp. 
OR intra-participant.mp. OR kappa.mp. OR kappa*.mp. OR kappas.mp. OR 
repeatab*.mp. OR ((replicab* OR repeated) AND (measure OR measures OR findings 
OR result OR results OR test OR tests)).mp. OR generaliza*.mp. OR generalisa*.mp. 
OR concordance.mp. OR (intraclass AND correlation*).mp. OR discriminative.mp. OR 
‘known group’.mp. OR factor analysis.mp. OR factor analyses.mp. OR dimension*.mp. 
OR subscale*.mp. OR (multitrait AND scaling AND (analysis OR analyses)).mp. OR 
item discriminant.mp. OR interscale correlation*.mp. OR (error/ OR error.mp.) OR 
errors.mp. OR ‘individual variability’.mp. OR (variability AND (analysis OR 
values)).mp. OR (uncertainty AND (measurement OR measuring)).mp. OR ‘standard 
error of measurement’.mp. OR sensitiv*.mp OR responsive* OR ((minimal OR 
minimally OR clinical OR clinically) AND (important OR significant OR detectable) 
AND (change OR difference)).mp. OR (small* AND (real OR detectable) AND (change 
OR difference)).mp. OR meaningful change.mp. OR ‘ceiling effect’.mp. OR ‘floor 
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effect’.mp. OR ‘Item response model’.mp. OR IRT.mp. OR Rasch.mp. OR ‘Differential 
item functioning’.mp. OR DIF.mp. OR ‘computer adaptive testing’.mp. OR ’item 
bank’.mp. OR ‘cross-cultural equivalence’.mp.) 
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Appendix 4:   COSMIN checklist 
 
COSMIN checklist with 4-point scale 
Contact 
CB Terwee, PhD 
VU University Medical Center 
Department of Epidemiology and Biostatistics 
EMGO Institute for Health and Care Research 
1081 BT Amsterdam 
The Netherlands 
Website: www.cosmin.nl, www.emgo.nl 
E-mail: cb.terwee@vumc.nl 
 
 
 
Instructions 
This version of the COSMIN checklist is recommended for use in systematic reviews of measurement properties. With this version it is possible to calculate 
overall methodological quality scores per study on a measurement property. A methodological quality score per box is obtained by taking the lowest rating of 
any item in a box (‘worse score counts’). For example, if for a reliability study one item in the box ‘Reliability’ is scored poor, the methodological quality of that 
reliability study is rated as poor. The Interpretability box and the Generalizability box are mainly used as data extraction forms. We recommend to use the 
Interpretability box to extract all information on the interpretability issues described in this box (e.g. norm scores, floor-ceiling effects, minimal important change) 
of the instruments under study from the included articles. Similar, we recommend to use the Generalizability box to extract data on the characteristics of the 
study population and sampling procedure. Therefore no scoring system was developed for these boxes. 
 
This scoring system is described in this paper: 
 
 
Terwee CB, Mokkink LB, Knol DL, Ostelo RWJG, Bouter LM, de Vet HCW. Rating the methodological quality in systematic reviews of studies on 
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measurement properties: a scoring system for the COSMIN checklist. Quality of Life Research 2011, July 6 [epub ahead of print].
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Step 1. Evaluated measurement properties in the article 
 
 
 Internal consistency Box A 
 Reliability Box B 
 Measurement error Box C 
 Content validity Box D 
 Structural validity Box E 
 Hypotheses testing Box F 
 Cross-cultural validity Box G 
 Criterion validity Box H 
 Responsiveness Box I 
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Step 2. Determining if the statistical method used in the article are based on CTT or IRT 
 
 
Box General requirements for studies that applied Item Response Theory (IRT) models 
  excellent good fair poor 
 
1 
 
Was the IRT model used adequately described? e.g. One Parameter Logistic Model 
(OPLM), Partial Credit Model (PCM), Graded Response Model (GRM) 
 
IRT model 
adequately 
described 
 
IRT model not 
adequately 
described 
  
 
2 
 
Was the computer software package used adequately described? e.g. RUMM2020, 
WINSTEPS, OPLM, MULTILOG, PARSCALE, BILOG, NLMIXED 
 
Software package 
adequately 
described 
 
Software package 
not adequately 
described 
  
 
3 
 
Was the method of estimation used adequately described? e.g. conditional 
maximum likelihood (CML), marginal maximum likelihood (MML) 
 
Method of 
estimation 
adequately 
described 
 
Method of 
estimation not 
adequately 
described 
  
4 Were the assumptions for estimating parameters of the IRT model checked? e.g. 
unidimensionality, local independence, and item fit (e.g. differential item functioning 
(DIF)) 
assumptions of 
the IRT model 
checked 
assumptions of 
the IRT model 
partly checked 
assumptions of the 
IRT model not 
checked or unknown 
 
 
 
To obtain a total score for the methodological quality of studies that use IRT methods, the ‘worse score counts’ algorithm should be applied to 
the IRT box in combination with the box of the measurement property that was evaluated in the IRT study. For example, if IRT methods are used 
to study internal consistency and item 4 in the IRT box is scored fair, while the items in the internal consistency box (box A) are all scored as 
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good or excellent, the methodological quality score for internal consistency will be fair. However, if any of the items in box A is scored poor, the 
methodological quality score for internal consistency will be poor. 
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Step 3. Determining if a study meets the standards for good methodological quality 
 
 
 
Box A. Internal consistency 
  excellent Good fair poor 
1 Does the scale consist of effect indicators, i.e. is it based on a reflective model?     
Design requirements 
    
2 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
  
3 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced 
how missing items 
were handled 
Not clear how 
missing items 
were handled 
 
4 Was the sample size included in the internal consistency analysis adequate? Adequate sample 
size (≥100) 
Good sample size 
(50-99) 
Moderate sample 
size (30-49) 
Small sample 
size (<30) 
5 Was the unidimensionality of the scale checked? i.e. was factor analysis or IRT 
model applied? 
Factor analysis 
performed in the 
study population 
Authors refer to 
another study in 
which factor 
analysis was 
performed in a 
similar study 
population 
Authors refer to 
another study in 
which factor 
analysis was 
performed, but not 
in a similar study 
population 
Factor analysis 
NOT performed 
and no 
reference to 
another study 
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6 Was the sample size included in the unidimensionality analysis adequate? 7* #items and 
≥100 
5* #items and 
≥100 OR 6-7* 
#items but <100 
5* #items but 
<100 
<5* #items 
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7 Was an internal consistency statistic calculated for each (unidimensional) 
(sub)scale separately? 
Internal 
consistency 
statistic calculated 
for each subscale 
separately 
  Internal 
consistency 
statistic NOT 
calculated for 
each subscale 
separately 
8 Were there any important flaws in the design or methods of the study? No other important 
methodological 
flaws in the design 
or execution of the 
study 
Other minor 
methodological 
flaws in the design 
or execution of the 
study 
Other important 
methodological 
flaws in the 
design or 
execution of the 
study 
Statistical methods    
9 for Classical Test Theory (CTT), continuous scores: Was Cronbach’s alpha 
calculated? 
Cronbach’s alpha 
calculated 
Only item-total 
correlations 
calculated 
No Cronbach’s 
alpha and no 
item-total 
correlations 
calculated 
10 for CTT, dichotomous scores: Was Cronbach’s alpha or KR-20 calculated? Cronbach’s alpha 
or KR-20 
calculated 
Only item-total 
correlations 
calculated 
No Cronbach’s 
alpha or KR-20 
and no item- total 
correlations 
calculated 
11 for IRT: Was a goodness of fit statistic at a global level calculated? E.g. χ2, reliability 
coefficient of estimated latent trait value (index of (subject or item) separation) 
Goodness of fit 
statistic at a global 
level calculated 
 
Goodness of fit 
statistic at a 
global level NOT 
calculated 
 
NB. Item 1 is used to determine whether internal consistency is relevant for the instrument under study. It is not used to rate the quality of the study. 
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Box B. Reliability: relative measures (including test-retest reliability, inter-rater reliability and intra-rater reliability) 
 excellent Good fair poor 
Design requirements     
1 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
  
2 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced 
how missing items 
were handled 
Not clear how 
missing items 
were handled 
 
3 Was the sample size included in the analysis adequate? Adequate sample 
size (≥100) 
Good sample size 
(50-99) 
Moderate sample 
size (30-49) 
Small sample 
size (<30) 
4 Were at least two measurements available? At least two 
measurements 
  
Only one 
measurement 
5 Were the administrations independent? Independent 
measurements 
Assumable that the 
measurements 
were independent 
Doubtful whether 
the measurements 
were independent 
measurements 
NOT 
independent 
6 Was the time interval stated? Time interval 
stated 
 
Time interval NOT 
stated 
 
7 Were patients stable in the interim period on the construct to be measured? Patients were 
stable (evidence 
provided) 
Assumable that 
patients were 
stable 
Unclear if patients 
were stable 
Patients were 
NOT stable 
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8 Was the time interval appropriate? Time interval 
appropriate 
 
Doubtful whether 
time interval was 
appropriate 
Time interval 
NOT 
appropriate 
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9 Were the test conditions similar for both measurements? e.g. type of administration, 
environment, instructions 
Test conditions 
were similar 
(evidence 
provided) 
Assumable that 
test conditions 
were similar 
Unclear if test 
conditions were 
similar 
Test conditions 
were NOT similar 
 
10 Were there any important flaws in the design or methods of the study? No other important 
methodological flaws in the design or execution of the study 
 
Statistical methods 
11 for continuous scores: Was an intraclass correlation coefficient (ICC) calculated? ICC calculated 
and model or formula of the ICC is described 
 
 
 
 
 
 
 
ICC calculated but 
model or formula of 
the ICC not 
described or not 
optimal. 
Pearson or 
Spearman 
correlation 
coefficient 
calculated with 
evidence provided 
that no systematic 
change has 
occurred 
Other minor 
methodological 
flaws in the design 
or execution of the 
study 
 
 
Pearson or 
Spearman 
correlation 
coefficient 
calculated 
WITHOUT 
evidence provided 
that no systematic 
change has 
occurred or WITH 
evidence that 
systematic change 
has occurred 
Other important 
methodological 
flaws in the 
design or 
execution of the 
study 
 
No ICC or 
Pearson or 
Spearman 
correlations 
calculated 
12 for dichotomous/nominal/ordinal scores: Was kappa calculated? Kappa calculated Only percentage 
agreement 
calculated 
 
13 for ordinal scores: Was a weighted kappa calculated? Weighted Kappa 
calculated 
Unweighted Kappa 
calculated 
Only percentage 
agreement 
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calculated 
 
14 for ordinal scores: Was the weighting scheme described? e.g. linear, quadratic Weighting scheme 
described 
Weighting scheme 
NOT described 
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Box C. Measurement error: absolute measures 
 excellent Good fair poor 
Design requirements     
1 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
  
2 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced 
how missing items 
were handled 
Not clear how 
missing items 
were handled 
 
3 Was the sample size included in the analysis adequate? Adequate sample 
size (≥100) 
Good sample size 
(50-99) 
Moderate sample 
size (30-49) 
Small sample 
size (<30) 
4 Were at least two measurements available? At least two 
measurements 
  
Only one 
measurement 
5 Were the administrations independent? Independent 
measurements 
Assumable that the 
measurements 
were independent 
Doubtful whether 
the measurements 
were independent 
measurements 
NOT 
independent 
6 Was the time interval stated? Time interval 
stated 
 
Time interval NOT 
stated 
 
7 Were patients stable in the interim period on the construct to be measured? Patients were 
stable (evidence 
provided) 
Assumable that 
patients were 
stable 
Unclear if patients 
were stable 
Patients were 
NOT stable 
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8 Was the time interval appropriate? Time interval 
appropriate 
 
Doubtful whether 
time interval was 
appropriate 
Time interval 
NOT 
appropriate 
 
 
299 
 
 
9 Were the test conditions similar for both measurements? e.g. type of administration, 
environment, instructions 
Test conditions 
were similar 
(evidence 
provided) 
Assumable that 
test conditions 
were similar 
Unclear if test 
conditions were 
similar 
Test conditions 
were NOT 
similar 
10 Were there any important flaws in the design or methods of the study? No other important 
methodological 
flaws in the design 
or execution of the 
study 
 Other minor 
methodological 
flaws in the design 
or execution of the 
study 
Other important 
methodological 
flaws in the 
design or 
execution of the 
study 
Statistical methods     
11 for CTT: Was the Standard Error of Measurement (SEM), Smallest Detectable 
Change (SDC) or Limits of Agreement (LoA) calculated? 
SEM, SDC, or 
LoA calculated 
Possible to 
calculate LoA from 
the data presented 
 
SEM calculated 
based on 
Cronbach’s 
alpha, or on SD 
from another 
population 
 
 
 
 
Box D. Content validity (including face validity) 
  excellent Good fair poor 
General requirements     
1 Was there an assessment of whether all items refer to relevant aspects of the Assessed if all  Aspects of the NOT assessed if 
 construct to be measured? items refer to construct to be all items refer to 
  relevant aspects measured poorly relevant aspects 
  of the construct to described AND of the construct 
  be measured this was not taken to be measured 
   into consideration  
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2 Was there an assessment of whether all items are relevant for the study Assessed if all Assessed if all Assessed if all NOT assessed if 
 population? (e.g. age, gender, disease characteristics, country, setting) items are relevant items are relevant items are relevant all items are 
  for the study for the study for the study relevant for the 
  population in population in population in small study population 
  adequate sample moderate sample sample size (<5) OR target 
  size (≥10) size (5-9)  population not 
     involved 
3 Was there an assessment of whether all items are relevant for the purpose of the Assessed if all Purpose of the NOT assessed if  
 measurement instrument? (discriminative, evaluative, and/or predictive) items are relevant instrument was all items are 
  for the purpose of not described but relevant for the 
  the application Assumed purpose of the 
    application 
4 Was there an assessment of whether all items together comprehensively reflect the Assessed if all 
 
No theoretical NOT assessed if 
 construct to be measured? items together foundation of the all items 
  comprehensively construct and this together 
  reflect the was not taken into comprehen- 
  construct to be consideration sively reflect the 
  measured  construct to be 
    measured 
5 Were there any important flaws in the design or methods of the study? No other important 
 
Other minor Other important 
  methodological methodological methodological 
  flaws in the design flaws in the design flaws in the 
  or execution of the or execution of the design or 
  study study execution of the 
    study 
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Box E. Structural validity 
  excellent Good fair poor 
1 Does the scale consist of effect indicators, i.e. is it based on a reflective model?     
Design requirements 
    
2 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
  
3 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced 
how missing items 
were handled 
Not clear how 
missing items 
were handled 
 
4 Was the sample size included in the analysis adequate? 7* #items and 
≥100 
5* #items and 
≥100 OR 5-7* 
#items but <100 
5* #items but 
<100 
<5* #items 
5 Were there any important flaws in the design or methods of the study? No other important 
methodological 
flaws in the design 
or execution of the 
study 
 
Other minor 
methodological 
flaws in the design 
or execution of the 
study (e.g. rotation 
method not 
described) 
Other important 
methodological 
flaws in the 
design or 
execution of the 
study (e.g. 
inappropriate 
rotation method) 
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Statistical methods    
6 for CTT: Was exploratory or confirmatory factor analysis performed? Exploratory or 
confirmatory factor 
analysis performed 
and type of factor 
analysis 
appropriate in view 
of existing 
information 
Exploratory factor 
analysis 
performed while 
confirmatory 
would have been 
more appropriate 
No exploratory or 
confirmatory factor 
analysis performed 
7 for IRT: Were IRT tests for determining the (uni-) dimensionality of the items 
performed? 
IRT test for 
determining 
(uni)dimension- 
ality performed 
 
IRT test for determining 
(uni)dimension- ality NOT 
performed 
 
 
 
Box F. Hypotheses testing 
 excellent Good fair Poor 
Design requirements     
1 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
  
2 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced 
how missing items 
were handled 
Not clear how 
missing items 
were handled 
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3 Was the sample size included in the analysis adequate? Adequate sample 
size (≥100 per 
analysis) 
Good sample size 
(50-99 per 
analysis) 
Moderate sample 
size (30-49 per 
analysis) 
Small sample 
size (<30 per 
analysis) 
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4 Were hypotheses regarding correlations or mean differences formulated a priori 
(i.e. before data collection)? 
Multiple 
hypotheses 
formulated a priori 
Minimal number of 
hypotheses 
formulate a priori 
Hypotheses vague 
or not formulated 
but possible to 
deduce what was 
expected 
Unclear what 
was expected 
5 Was the expected direction of correlations or mean differences included in the 
hypotheses? 
Expected direction 
of the correlations 
or differences 
stated 
Expected direction 
of the correlations 
or differences NOT 
stated 
  
6 Was the expected absolute or relative magnitude of correlations or mean 
differences included in the hypotheses? 
Expected 
magnitude of the 
correlations or 
differences stated 
Expected 
magnitude of the 
correlations or 
differences NOT 
stated 
  
7 for convergent validity: Was an adequate description provided of the comparator 
instrument(s)? 
Adequate 
description of the 
constructs 
measured by the 
comparator 
instrument(s) 
Adequate 
description of 
most of the 
constructs 
measured by the 
comparator 
instrument(s) 
Poor description 
of the constructs 
measured by the 
comparator 
instrument(s) 
NO description of 
the constructs 
measured by the 
comparator 
instrument(s) 
8 for convergent validity: Were the measurement properties of the comparator Adequate Adequate Some information No information 
 instrument(s) adequately described? measurement Measurement on measurement on the 
  properties of the properties of the properties (or a measurement 
  comparator Comparator reference to a properties of the 
  instrument(s) in a instrument(s) but study on comparator 
  population similar not sure if these measurement instrument(s) 
  to the study apply to the study properties) of the  
  population Population comparator  
    instrument(s) in  
    any study  
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    population  
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9 Were there any important flaws in the design or methods of the study? No other important  Other minor Other important 
  methodological methodological methodological 
  flaws in the design flaws in the design flaws in the 
  or execution of the or execution of the design or 
  study study (e.g. only execution of the 
   data presented on study 
   a comparison with  
   an instrument that  
   measures another  
   construct)  
Statistical methods     
10 Were design and statistical methods adequate for the hypotheses to be tested? Statistical Assumable that Statistical Statistical 
  methods applied statistical methods methods applied methods applied 
  appropriate were appropriate, NOT optimal NOT 
   e.g. Pearson  appropriate 
   Correlations   
   applied, but   
   distribution of   
   scores or mean   
   (SD) not   
   Presented   
 
 
 
 
Box G. Cross-cultural validity 
 excellent Good fair poor 
Design requirements     
1 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
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2 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced how 
missing items were 
handled 
Not clear how 
missing items 
were handled 
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3 Was the sample size included in the analysis adequate? CTT: 7* #items 
and ≥100 
IRT: ≥200 per 
group 
CTT: 5* #items and 
≥100 OR 5-7* 
#items but <100 
IRT: ≥200 in 1 
group and 100- 
199 in 1 group 
CTT: 5* #items 
but <100 
IRT: 100-199 per 
group 
CTT: <5* #items 
IRT: (<100 in 1 
or both groups 
4 Were both the original language in which the HR-PRO instrument was developed, 
and the language in which the HR-PRO instrument was translated described? 
Both source 
language and 
target language 
described 
  Source 
language NOT 
known 
5 Was the expertise of the people involved in the translation process adequately 
described? e.g. expertise in the disease(s) involved, expertise in the construct to be 
measured, expertise in both languages 
Expertise of the 
translators 
described with 
respect to 
disease, 
construct, and 
language 
Expertise of the 
translators with 
respect to disease 
or construct poor or 
not described 
Expertise of the 
translators with 
respect to 
language not 
described 
 
6 Did the translators work independently from each other? Translators 
worked 
independent 
Assumable that 
the translators 
worked 
independent 
Unclear whether 
translators worked 
independent 
Translators 
worked NOT 
independent 
7 Were items translated forward and backward? Multiple forward 
and multiple 
backward 
translations 
Multiple forward 
translations but 
one backward 
translation 
One forward and 
one backward 
translation 
Only a forward 
translation 
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8 Was there an adequate description of how differences between the original and 
translated versions were resolved? 
Adequate 
description of how 
differences 
between 
translators were 
resolved 
Poorly or NOT 
described how 
differences 
between 
translators were 
resolved 
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9 Was the translation reviewed by a committee (e.g. original developers)? Translation Translation NOT   
  reviewed by a reviewed by 
  committee (such) a 
  (involving other Committee 
  people than the  
  translators, e.g.  
  the original  
  developers)  
10 Was the HR-PRO instrument pre-tested (e.g. cognitive interviews) to check Translated Translated Translated Translated 
 interpretation, cultural relevance of the translation, and ease of comprehension? instrument pre- instrument pre- instrument pre- instrument NOT 
  tested in the target tested, but unclear tested, but NOT in pre-tested 
  population if this was done in the target  
   the target population  
   Population   
11 Was the sample used in the pre-test adequately described? Sample used in 
 
Sample used in 
 
  the pre-test the pre-test NOT 
  adequately (adequately) 
  described described 
12 Were the samples similar for all characteristics except language and/or cultural Shown that Stated (but not Unclear whether Samples were 
 background? samples were shown) that samples were NOT similar for 
  similar for all samples were similar for all all 
  characteristics similar for all characteristics characteristics 
  except language Characteristics except language except language 
  /culture except language /culture /culture 
   /culture   
13 Were there any important flaws in the design or methods of the study? No other important 
 
Other minor Other important 
  methodological methodological methodological 
  flaws in the design flaws in the design flaws in the 
  or execution of the or execution of the design or 
  study study execution of the 
    study 
 
 
311 
 
 
 
 
Statistical methods   
14 for CTT: Was confirmatory factor analysis performed? Multiple-group 
confirmatory factor 
analysis performed 
Multiple-group confirmatory factor 
analysis NOT performed 
15 for IRT: Was differential item function (DIF) between language groups assessed? DIF between 
language groups 
assessed 
DIF between language groups 
NOT 
assessed 
 
 
Box H. Criterion validity 
 excellent Good fair poor 
Design requirements     
1 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
  
2 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced 
how missing items 
were handled 
Not clear how 
missing items 
were handled 
 
3 Was the sample size included in the analysis adequate? Adequate sample 
size (≥100) 
Good sample size 
(50-99) 
Moderate sample 
size (30-49) 
Small sample 
size (<30) 
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4 Can the criterion used or employed be considered as a reasonable ‘gold standard’? Criterion used can 
be considered an 
adequate ‘gold 
standard’ 
(evidence 
provided) 
No evidence 
provided, but 
assumable that the 
criterion used can 
be considered an 
adequate ‘gold 
standard’ 
Unclear whether 
the criterion used 
can be considered 
an adequate ‘gold 
standard’ 
Criterion used 
can NOT be 
considered an 
adequate ‘gold 
standard’ 
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5 Were there any important flaws in the design or methods of the study? No other important 
methodological 
flaws in the design 
or execution of the 
study 
Other minor methodological 
flaws in the design or 
execution of the study 
Other important 
methodological 
flaws in the 
design or 
execution of the 
study 
Statistical methods    
6 for continuous scores: Were correlations, or the area under the receiver operating 
curve calculated? 
Correlations or 
AUC calculated 
 
Correlations or 
AUC NOT 
calculated 
7 for dichotomous scores: Were sensitivity and specificity determined? Sensitivity and 
specificity 
calculated 
 
Sensitivity and 
specificity NOT 
calculated 
 
 
Box I. Responsiveness 
 excellent Good fair poor 
Design requirements     
1 Was the percentage of missing items given? Percentage of 
missing items 
described 
Percentage of 
missing items 
NOT described 
  
2 Was there a description of how missing items were handled? Described how 
missing items 
were handled 
Not described but it 
can be deduced 
how missing items 
were handled 
Not clear how 
missing items 
were handled 
 
3 Was the sample size included in the analysis adequate? Adequate sample 
size (≥100) 
Good sample size 
(50-99) 
Moderate sample 
size (30-49) 
Small sample 
size (<30) 
4 Was a longitudinal design with at least two measurement used? Longitudinal 
design used 
  
No longitudinal 
design used 
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5 Was the time interval stated? Time interval 
adequately 
described 
  
Time interval 
NOT described 
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6 If anything occurred in the interim period (e.g. intervention, other relevant events), 
was it adequately described? 
Anything that 
occurred during the 
interim period (e.g. 
treatment) 
adequately 
described 
Assumable what 
occurred during the 
interim period 
Unclear or NOT 
described what 
occurred during the 
interim period 
 
7 Was a proportion of the patients changed (i.e. improvement or deterioration)? Part of the 
patients were changed (evidence provided) 
NO evidence 
provided, but 
assumable that part 
of the patients were 
changed 
Unclear if part of 
the patients were 
changed 
Patients were 
NOT changed 
 
Design requirements for hypotheses testing 
 
For constructs for which a gold standard was not available: 
 
8 Were hypotheses about changes in scores formulated a priori (i.e. before data 
collection)? 
Hypotheses 
formulated a priori 
Hypotheses vague or 
not formulated but 
possible to deduce 
what was expected 
Unclear what 
was expected 
 
9 Was the expected direction of correlations or mean differences of the change 
scores of HR-PRO instruments included in these hypotheses? 
Expected direction of 
the correlations or 
differences stated 
Expected direction 
of the correlations 
or differences NOT 
stated 
 
10 Were the expected absolute or relative magnitude of correlations or mean 
differences of the change scores of HR-PRO instruments included in these 
hypotheses? 
Expected 
magnitude of the 
correlations or 
differences stated 
Expected 
magnitude of the 
correlations or 
differences NOT 
stated 
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11 Was an adequate description provided of the comparator instrument(s)? Adequate 
description of the 
constructs 
measured by the 
comparator 
instrument(s) 
 Poor description 
of the constructs 
measured by the 
comparator 
instrument(s) 
NO description of 
the constructs 
measured by the 
comparator 
instrument(s) 
12 Were the measurement properties of the comparator instrument(s) adequately 
described? 
Adequate 
measurement 
properties of the 
comparator 
instrument(s) in a 
population similar 
to the study 
population 
Adequate 
measurement 
properties of the 
comparator 
instrument(s) but 
not sure if these 
apply to the study 
population 
Some information 
on measurement 
properties (or a 
reference to a 
study on 
measurement 
properties) of the 
comparator 
instrument(s) in 
any study 
population 
NO information 
on the 
measurement 
properties of the 
comparator 
instrument(s) 
13 Were there any important flaws in the design or methods of the study? No other important 
methodological 
flaws in the design 
or execution of the 
study 
 
Other minor 
methodological 
flaws in the design 
or execution of the 
study (e.g. only 
data presented on a 
comparison with an 
instrument that 
measures another 
construct) 
Other important 
methodological 
flaws in the 
design or 
execution of the 
study 
Statistical methods     
14 Were design and statistical methods adequate for the hypotheses to be tested? Statistical 
methods applied 
appropriate 
 
Statistical 
methods applied 
NOT optimal 
Statistical 
methods applied 
NOT 
appropriate 
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Design requirement for comparison to a gold standard     
 
For constructs for which a gold standard was available: 
    
15 Can the criterion for change be considered as a reasonable gold standard? Criterion used can 
be considered an 
adequate ‘gold 
standard’ 
(evidence 
provided) 
No evidence 
provided, but 
assumable that the 
criterion used can 
be considered an 
adequate ‘gold 
standard’ 
Unclear whether 
the criterion used 
can be considered 
an adequate ‘gold 
standard’ 
Criterion used 
can NOT be 
considered an 
adequate ‘gold 
standard’ 
16 Were there any important flaws in the design or methods of the study? No other important 
methodological 
flaws in the design 
or execution of the 
study 
 
Other minor 
methodological 
flaws in the design 
or execution of the 
study 
Other important 
methodological 
flaws in the 
design or 
execution of the 
study 
Statistical methods     
17 for continuous scores: Were correlations between change scores, or the area under 
the Receiver Operator Curve (ROC) curve calculated? 
Correlations or 
Area under the 
ROC Curve (AUC) 
calculated 
  
Correlations or 
AUC NOT 
calculated 
18 for dichotomous scales: Were sensitivity and specificity (changed versus not 
changed) determined? 
Sensitivity and 
specificity 
calculated 
  
Sensitivity and 
specificity NOT 
calculated 
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Interpretability 
 
We recommend to use the Interpretability box to extract all information on the interpretability issues described in this box of the instruments under study from 
the included articles. 
 
 
Box Interpretability 
Percentage of missing items  
Description of how missing items were handled  
Distribution of the (total) scores  
Percentage of the respondents who had the lowest possible (total) score  
Percentage of the respondents who had the highest possible (total) score  
Scores and change scores (i.e. means and SD) for relevant (sub) groups, e.g. for normative 
groups, subgroups of patients, or the general population 
 
Minimal Important Change (MIC) or Minimal Important Difference (MID)  
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Generalizability 
 
We recommend to use the Generalizability box to extract data on the characteristics of the study populations and sampling procedures of 
the included studies. 
 
Box Generalisability 
Median or mean age (with standard deviation or range)  
Distribution of sex  
Important disease characteristics (e.g. severity, status, duration) and description of treatment  
Setting(s) in which the study was conducted (e.g. general population, primary care or 
hospital/rehabilitation care) 
 
Countries in which the study was conducted  
Language in which the HR-PRO instrument was evaluated  
Method used to select patients (e.g. convenience, consecutive, or random)  
Percentage of missing responses (response rate)  
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Appendix 5:   Guidelines for rating COSMIN 
 
1. If there are only references for the psychometric properties of the comparator 
instruments, we rate them as fair. 
2. If it’s a within-day testing, we rate as excellent the questions of being the patients 
stable & the interval time between testing.  
3. In Box I-12 if the paper talks about global scales, we rate it as n/a.  
4. In Box I-8 if we rate it as poor, then the 9 & 10 are n/a because there is not a 
hypothesis formulated so that there exists a direction or a magnitude.  
5. In Box-B if they describe ICC for continues scores, we rate as n/a the 12-14 
questions.  
6. If hypothesis, magnitudes and directions are formulated in methods section are 
still rated as excellent.  
7. If the instrument is not a questionnaire, then rate as n/a the questions of missing 
items given & how they were handled.  
8. EDSS take it always as a ‘gold standard’ – BUT MENTION IN DISCUSSION 
THAT ITS NOT 
9. EDSS take it as a gold standard only for comparison with walking ability scales 
and rate it as ‘fair’.  
10. In Box – I, every paper that don’t mentions what happened in the interim period 
or mention if the patients changed we rate it as fair.  
11. When we rate the interim period and the OM is a questionnaire, it has to be at 
least 7 days between each measurement, so that the time will be appropriate 
(memory of the previous answers?). 
 
Guidelines between reviewers for rating COSMIN 
When there are only references for the psychometric properties of the comparator instrument, we rate 
them as ‘fair’ 
EDSS we take it always as a ‘gold standard’, but we rate it as ‘fair’  
Box B/C QSN 7 & 8: if it’s a within-day testing, we rate them as ‘excellent’ & if the 
instrument is a questionnaire it has to be at least 7 days to rate them as ‘excellent’ 
Box B/C/F/H/I QSN 1 & 2: if the instrument is not a questionnaire, we rate these questions as ‘n/a’  
Box B QSN 11: if the ICC is calculated for continuous scores, we rate QSN 12-14 as ‘n/a’ 
Box F 
Box I 
QSN 4-6: if they are mentioned in methods, we rate them as ‘excellent’ 
QSN 8-10: if they are mentioned in methods, we rate them as ‘excellent’ 
Box I QSN 6-7: if they don’t mention what happened & if patients were stable, we rate 
them as ‘fair’ 
QSN 8: if this question is ‘poor’, then questions 9-10 are ‘n/a’ because magnitude & 
direction cannot exist if there is no hypothesis 
QSN 12: if the comparator instrument is a global rating scale, we rate it as ‘n/a’ 
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Appendix 6:   Ethical opinion from the National Health Service (NHS) 
Research Ethics Committee (Chapter 4 & 5) 
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Appendix 7:   NHS Lothian Research and Development approval (Chapter 4 & 
5) 
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Appendix 8:   Participant Information Sheet for study in Chapter 4 
& 5 
 
 
 
 
Participant Information Sheet: patients Movement 
fatigue in multiple sclerosis 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve. One of our team will go through the information sheet with you and answer 
any questions you have. This should take about 20 minutes. Ask us if there is 
anything that is not clear. 
This study involves individuals with multiple sclerosis, who exercise regularly 
(at least for 30 minutes twice weekly and can walk/jog for a mile) with no or a 
slight neurological disability. This study does not involve testing drugs. 
 
What is the purpose of the study? 
 
The aim of this pilot study is to measure the symptoms noticed during and 
immediately following physical activity in a laboratory setting at regular 
intervals over a 2 year period, and metabolic changes in the brain using 
scans. 
 
Why have I been invited? 
 
You have been selected because you have MS and exercise regularly. 
During exercise, you may have noticed exercise related symptoms such as leg 
weakness, foot drop and difficulty controlling your leg(s) that are temporary and 
recover with rest. 
 
Do I have to take part? 
 
Taking part in this study is entirely voluntary. If you agree to take part then we will 
ask you to sign a consent form. You can change your mind at any point during the 
study and withdraw without having to give a reason. If you withdraw, the standard 
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of your care will not be affected in any way. 
 
What will happen to me if I take part? 
 
You are invited to visit Anne Rowling Clinic for an interview (approximately 
30 minutes) and consent. You will then be invited to the exercise laboratory at 
Queen Margaret University, for maximum of seven visits, each lasting a 
maximum of 2 hours. 
 
As an optional step before your second visit to Queen Margaret University, you 
may swallow a capsule to record your core body temperature before, during and 
after exercise. The capsule is for single use and it has not been administered 
before. The capsule will be passed in your stools usually within 2--‐3 days. If not 
passed within this time, you may take a laxative to facilitate its passage. You are 
not expected to retrieve the capsule from your stools. 
 
You may be invited to have brain scans on one occasion, lasting no more than 
60 minutes. If you have taken the capsule, we have to perform a plain X--‐ray of 
your abdomen, and if necessary pelvis, before the scan (anticipated to last 5 
minutes) to make sure that the capsule is no longer in your body. We may 
advise you to have a blood test (one teaspoon of blood removed from one arm 
using standard methods) to check your kidney function. 
 
 
Expenses and payments 
 
This study involves traveling to Anne Rowling Clinic (Little France, Edinburgh), 
Queen Margaret University (Musselburgh) and Clinical Research Imaging 
Centre (Little France, Edinburgh). Travel expenses from your home or work place, 
including car--‐parking fees, will be reimbursed upon presentation of the receipts. 
Please note that there are no inducements or additional payments for taking part 
in this study. 
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What will I have to do? 
 
The interview with a neurologist will take place at Anne Rowling Clinic (ARC) and 
he/she will go through this information sheet, answer any questions and provide 
the consent form. You have up to 1 month to return the consent form, if you wish to 
take part. 
 
You will then be sent, by post or email, dates to attend the exercise laboratory 
at Queen Margaret University (QMU) by the researchers and also two 
fatigue questionnaires for you to complete and return by stamped addressed 
envelope to ARC or email. Please bring comfortable clothes and trainers 
(running shoes) to exercise. 
 
Visit 1 to Queen Margaret University. 
 
The first visit to the exercise laboratory is to get accustomed to 
the set up while the researchers develop an individualized 
exercise program based on your usual exercise regime. Small 
balls covered in reflective material will be attached on to your 
pelvis and lower limbs using skin friendly double sided tape. 
You are not expected to exercise outside your comfort zone. 
You are then given a second appointment to attend QMU to 
record your walking/running pattern before, during and after a 
20--‐ minute exercise task and any exercise related symptoms. 
 
Visit 2 to Queen Margaret University. 
 
Before your second visit you may swallow a capsule (optional), containing a 
sensor (optional), to measure your core body temperature before, during and 
after a 20--‐ minute exercise task. It does not contain any medication. The size of 
the capsule is shown relative a 20 pence coin. Further details of 
the capsule can be found on 
manufacturer’s website (www.equivital.co.uk). Researcher will 
provide the capsule. Please swallow it before your appointment 
time and avoid taking any heavy meals with it or after you have 
taken it. 
You can take drinks kept at room temperature. Please avoid hot or cold drinks 
from swallowing the capsule to 3 hours after completing 
exercise. The capsule is usually passed in your stools within 2--‐3 days. We will 
advise you to have a plain X--‐ray (abdominal) 1 week after taking the capsule, to 
ensure that it has passed. 
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The assessment of your walking/running pattern will take place before, during and 
after the exercise task. During this task, you may jog/run at a self--‐ 
selected speed for 20 minutes, with 3 minutes for warm--‐up and 2 
minutes to adjust to your usual speed. You will receive an activity 
monitor (small device) that needs to be attached to your thigh with 
double sided tape for seven days, and which will record the number 
of steps you take. 
 
Visit 3 to Queen Margaret University. 
 
The third visit (within 4 weeks from the second) is to determine whether the 
recordings are reproducible. The exercise tasks and gait assessments will be 
the same as in visit 2, but without having to swallow the capsule. 
 
Visit to Clinical Research Imaging Centre for brain imaging. 
 
You are given the option to have brain scans using magnetic resonance 
imaging. Scanning time will be no more than 60 minute in one visit to the Clinical 
Research Imaging Centre (CRIC), Royal Infirmary of Edinburgh. You must NOT 
enter the MRI scanner until you know that the capsule is no longer in your body. 
This is because it contains metal and can cause internal damage to your body 
when in the scanner. 
The plain X--‐ray(s) will assess safety. 
 
We use foam pads to place your head comfortably in the correct position. During 
the scan you are asked to gently move your foot, hand or mouth at different times 
(for less than 2 minutes) while in the scanner. You may receive a contrast agent, 
called gadolinium, after placing a cannula into a vein on the back of your hand or 
front of the elbow. 
 
Subsequent visits to the exercise laboratory at Queen Margaret University. 
 
Once you have completed the third visit to the exercise laboratory you are 
invited for four more visits, at six monthly intervals. The exercise regime will be 
the same as before. Prior to each visit, the same fatigue questionnaires will be 
sent to you for completion and return by mail or email. If you do not feel up to 
exercising on a given date and would like to rearrange the appointment then 
please get in touch with Dr Don Mahad or Dr Marietta van der Linden (see 
below). 
 
What are the possible risks and disadvantages of taking part? 
 
When exercising in an unfamiliar setting there is a potential risk of injury. We will 
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minimize this by making sure that you are comfortable with the set up at each 
visit. There is a low chance of unexpected complications such as chest pain 
occurring during exercise. If this occurs, we will arrange for a medical 
assessment. The researcher may notice changes in your exercise pattern on the 
recording. If you wish to know of any changes please contact the Chief 
Investigator (Don Mahad). We recommend that you do not exert beyond your 
comfort zone for a couple of days before each visit. 
 
To secure the markers to your pelvis and legs for the assessment of your gait, we 
use double sided ‘toupee’ skin friendly tape, which can cause redness of the skin 
after the tape is removed. If you have an allergy please inform the researchers. 
The capsule to record core body temperature has been shown to be safe in MS 
patients and healthy individuals. The researchers will check that you do not have 
a condition, which will put you at risk from the capsule. MRI of any part of your 
body should not be performed until it is established with certainty that the 
capsule is no longer in your body. 
 
As part of the MRI you may be advised to have a dye or contrast agent 
(gadolinium) injected using a cannula placed in a vein on the back or your 
hand or front of the elbow. If you have kidney disease or take Metformin please 
alert the researchers. This is because of the risk of developing a kidney scaring 
disease. 
 
What are the side effects of any treatment received when taking 
part? 
The study is not a clinical trial and you will not be expected to take a 
drug.  The plain X--‐rays of the abdomen, and if necessary the pelvis, are 
performed approximately 1 week after swallowing the capsule to 
ensure it has passed from the bowel. The amount of radiation exposure 
by these X--‐rays is comparable to 7 months of natural background 
radiation in the UK population. There is a small risk of developing a 
fatal cancer as a result of exposure to this amount of radiation and the 
risk is approximately 1 in 20,000. 
What are the possible benefits of taking part? 
 
The information we will get from this study will help us to develop methods to 
measure MS symptoms during exercise and determine they may changes over 
time. 
 
What happens when the research study stops? 
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We will analyse the data from all subjects within 6 months from completion of 
the study and let you know the outcome, if you wish to be informed. 
 
What if there is a problem? 
 
Any complaint about the way you have been dealt with or any possible harm 
you might suffer will be addressed. The detailed information on this is given 
below. 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and handle information confidentially . 
What if relevant new information becomes available? 
 
Exercise recordings and brain scans may show changes over time. If you wish 
to know, the research doctor will inform you and explain any changes. Any 
change in your recordings is unlikely to influence clinical management, as 
this is an experimental study. 
 
What will happen if I don’t want to carry on with the study? 
 
You are free to withdraw at any point and you do not have to provide a reason. 
We will use your anonymised data collected until the time of your withdrawal. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers or Shuna Colville [shuna.colville@ed.ac.uk], who is the clinic 
manager for the Anne Rowling Regenerative Neurology Clinic. They will try to 
answer your questions [donmahad@nhs.net]. If you remain unhappy and wish 
to complain formally, please contact NHS Lothian: 
NHS Lothian Complaints Team 
2nd Floor 
Waverley Gate 
2--‐4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
Email: craft@nhslothian.scot.nhs.uk 
If there is harm resulting from the study, as a result of any tests or procedures 
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you received, appropriate compensation will be available and details of 
indemnity scheme will be provided to you on request. We would not be bound 
to pay compensation where the injury resulted from a drug or procedure 
outside the trial protocol and when the protocol was not followed. 
 
Will my taking part in the study be kept confidential? 
 
All information, collected about you during the course of the research, will be 
kept strictly confidential. The recordings of your movements during exercise will 
only be stored in the form of a cartoon that joins the detectors placed on your 
body. These cartoons will not contain identifiable images of you. Any 
information about you which leaves the department will have your name and 
address removed so that you cannot be identified. Your data will be collected 
using paper and electronic medical records by researchers and stored under a 
unique number. An electronic file containing your CHI number to match with the 
unique number and identifiable data will be kept in a password protected NHS 
computer held in a secure room at Anne Rowling Clinic until the end of the study. 
The chief investigator (Don Mahad) will have access to this file. In addition, 
regulatory authorities and research and development audit committee may 
access your records, only for monitoring of the quality of the research. This 
anonymised code will be used in all subsequent dealing with data analysis and 
interpretation. The identifiable data will be deleted without any other form of 
data storage once the study is completed (anticipated to be two and a half 
years from the start date of the study). If your data needs to be retained for 
future studies the researcher will request approval from the local ethics 
committee. 
 
Involvement of your family doctor 
 
If you decide to take part in this study, we recommend that a letter is sent to your 
GP to explain the nature of the study and possible implications for your clinical 
care. 
 
What will happen to the results of the study? 
 
Results of this pilot study will be used to design future studies, as this is a 
relatively small study. If you wish to be informed of the results we will do so in 
writing and include your results as well as a summary of the overall findings. 
 
Who is organizing and funding the research? 
 
This research is organized by the University of Edinburgh and funded by Edinburgh 
Bioquarter. 
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Who has reviewed the study? 
 
This study was review by an independent group of people, Research Ethics 
Committee, to protect your interests. The scientific aspects have been reviewed 
by Edinburgh Bioquarter funding committee. 
Further information and contact details 
 
General information about the researcher and their scientific background can 
be accessed online at the following websites: 
Don Mahad: http://www.cnr.ed.ac.uk/Research/mahad.html (email: 
don.mahad@ed.ac.uk) 
Tom Mercer: http://www.qmu.ac.uk/ph/staff_biogs/tom_mercer.htm (email: 
TMercer@qmu.ac.uk 
Marietta van der Linden: 
http://www.qmu.ac.uk/ph/staff_biogs/mariette_van_der_linden.htm (email: 
MVanDerLinden@qmu.ac.uk) 
 
Specific information about the thermistor capsule can be obtained from the 
manufacturer (www.ksi.uconn.edu). For specific information about the study 
and advice as to whether you should participate, please contact Don Mahad. 
 
If you are unhappy and would like to discuss please contact Don Mahad. If you 
wish to submit an official complaint please visit the following website. 
http://www.nhslothian.scot.nhs.uk/YourRights/ComplimentsConcernsComplaints/ 
Pages/MakingAComplaint.aspx 
 
 
 
 
 
 
 
 
 
 
 
 
 332  
days 
Appendix 9: Informed consent form for study in Chapter 4 & 5 
 
 
 
 
 
CONSENT FORM: patients 
 
Title of project: Movement fatigue in multiple sclerosis 
 
Name of Researcher: Dr Don Mahad 
Please initial box 
 
1. I confirm that I have read and understand the information sheet 
dated April 2015 (version 3) for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time 
without giving any reason, without my medical care or legal rights 
being affected. 
 
3. “I understand that relevant sections of [my medical notes and 
data collected during the study may be looked at by individuals 
from the regulator authorities and from the Sponsor(s) (NHS 
Lothian and the University of Edinburgh) or from the/other NHS 
Board(s) where it is relevant to my taking part in this research. I 
give permission for those individuals to have access to my 
records” 
 
4. I agree to take the thermistor capsule, have X-ray(s) and 
understand the issues relating to radiation and MRI 
 
 
5. I agree to wear the activpal device for a minimum of 5 days out 
of 10 following exercise 
 
 
6. I agree to undergo MRI scans 
 
 
7. I agree to my GP being informed of my participation in the study 
 
 
8. I agree to take part in the above study. 
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Name of Patient Date Signature 
 
 
Name of Person taking Date
 Signature consent 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical 
notes. 
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Appendix 10:   Instructions for ActivPal (Chapter 5) 
 
Thank you for wearing the activity monitor. It records how much of the 
day you are sitting, standing or walking. 
We would like you to wear it for at least five days, you can take the 
monitor off your leg during the night, but this means attaching it to your 
thigh in the morning as soon as possible after you get up, and taking 
it off before you go to bed.  
The monitor only records for 10 days starting from the time you were 
given the monitor so please could you wear it next day of receiving it! 
After you have worn the monitor for five days, could you please return 
it in your next visit. We can then download the data from the monitor 
onto a computer and see how much of the day you spent either 
walking, standing or lying/sitting. 
 
Applying the activPAL (activity monitor) 
It is most comfortable to wear the monitor attached to the thigh (see 
picture). It should be positioned on the midline of the thigh, between 
the hip and the knee. However, it will function correctly if placed 
anywhere on the front of the thigh in the orientation indicated by the 
figure on the front panel. (the little man should be standing/UP pointing 
upwards) 
The monitoring device and the tape are not waterproof and they 
should be removed for bathing. The skin should be thoroughly dried 
after bathing to maximise the adherence of the tape/gel. 
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Finally, please return the included form and note which days the 
monitor was attached to your thigh. 
 
 
 
Please contact me on 07873854432 if you have any 
questions regarding the monitor. 
 
Thank you very much for helping with this study, 
 
Georgia Andreopoulou 
PhD student 
Physiotherapy Division 
School of Health Sciences   
Queen Margaret University Drive 
Musselburgh    
EH21 6UU   
Email: GAndreopoulou@qmu.ac.uk 
 
 Days & dates time 
Day 1   
Day 2   
Day 3   
Day 4   
Day 5   
 
 
 
Comments 
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
___________________________________ 
Please fill in the day and the times above  
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Appendix 11: Borg Scale of Perceived Exertion (Borg, 1982) 
 
BORG RATING OF PERCEIVED EXERTION (RPE) SCALE 
 
 
 
Number rating 
 
Verbal rating 
 
6 
 
7 Very, very light 
8  
9 Very light 
10  
11 Fairly light 
12  
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13 Somewhat hard 
14  
15 Hard 
16  
17 Very hard 
18  
19 Very, very hard 
20  
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Appendix 12:   Feeling Scale (Hardy & Rejeski, 1989)  
 
 
  
While participating in exercise, it is common to experience changes in mood. Some 
individuals find exercise pleasurable, whereas others find it to be unpleasant. 
Additionally, feeling may fluctuate across time. That is, one might feel good and bad 
a number of times during exercise. Scientists have developed this scale to measure 
such responses.  
 
 
 
 
+5 Very good  
+4  
+3 Good  
+2  
+1 Fairly good  
0 Neutral  
-1 Fairly bad  
-2  
-3 Bad  
-4  
-5 Very bad 
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Appendix 13:   Fatigue Scale for Motor and Cognitive Functions (Penner et al, 
2009) 
 
 Does not 
apply 
at all 
Does not 
apply 
much 
Slightly 
applies 
Applies 
a lot 
Applies 
comple- 
tely 
1. When I concentrate for a long time, I get ex- 
hausted sooner than other people of my age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. When I am experiencing episodes of exhaustion, 
my movements become noticeably clumsier and 
less coordinated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Because of my episodes of exhaustion, I now 
need more frequent and/or longer rests during 
physical activity than I used to. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. When I am experiencing episodes of exhaustion, 
I am incapable of making decisions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. When faced with stressful situations, I now find 
that I get physically exhausted quicker than I 
used to. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Because of my episodes of exhaustion, I now 
have considerably less social contact than I 
used to. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Because of my episodes of exhaustion, I now 
find it more difficult to learn new things than I 
used to. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. The demands of my work exhaust me 
mentally more quickly than they used to. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. I feel the episodes of exhaustion particularly 
strongly in my muscles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. I no longer have the stamina for long periods 
of physical activity that I used to have. 
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11. My powers of concentration decrease consi- 
derably when I’m under stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12. When I am experiencing episodes of exhaustion, I 
am less motivated than others to start activities that 
involve physical effort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13. My thinking gets increasingly slow when it is hot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14. When I am experiencing an episode of exhaustion, 
my movements become noticeably slower. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15. Because of my episodes of exhaustion, I now 
feel less like doing things which require con- 
centration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16. When an episode of exhaustion comes on, I 
am simply no longer able to react quickly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17. When I am experiencing episodes of exhaustion, 
certain words simply escape me. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18. When I am experiencing episodes of exhaustion, 
I lose concentration considerably quicker than I 
used to. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19. When it is hot, my main feeling is one of extreme 
physical weakness and lack of energy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20. During episodes of exhaustion, I am noticeably 
more forgetful. 
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Appendix 14:   Fatigue Severity Scale (Krupp et al, 1989) 
 
Please circle the number between 1 and 7 which you feel best fits the following 
statements. This refers to your usual way of life within the last week. 1 indicates 
“strongly disagree” and 7 indicates “strongly agree.” 
 
 
Read and circle a number. Strongly Disagree  Strongly 
Agree 
1. My motivation is lower when I am 
fatigued. 
1 2 3 4 5 6 7 
2. Exercise brings on my fatigue. 1 2 3 4 5 6 7 
3. I am easily fatigued. 1 2 3 4 5 6 7 
4. Fatigue interferes with my 
physical functioning. 
1 2 3 4 5 6 7 
5. Fatigue causes frequent 
problems for me. 
1 2 3 4 5 6 7 
6. My fatigue prevents sustained 
physical functioning. 
1 2 3 4 5 6 7 
7. Fatigue interferes with carrying 
out certain duties and 
responsibilities. 
1 2 3 4 5 6 7 
8. Fatigue is among my most disabling 
symptoms. 
1 2 3 4 5 6 7 
9. Fatigue interferes with my work, 
family, 
or social life. 
1 2 3 4 5 6 7 
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Appendix 15:   Ethical opinion from NHS Research Ethics Committee (Chapter 
6) 
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Appendix 16:   NHS Lothian Research and Development approval 
(Chapter 6) 
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Appendix 17:   Participant Information Sheet for study in Chapter 6 
 
 
 
 
 
 
Participant information sheet 
Study title: The effects of FES in a variety of walking conditions 
in people with MS 
 
We would like to invite you to take part in our research study. Before you decide 
we would like you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you like. Ask us if there is anything not clear or you would like 
more information.  
 
What is the purpose of the study?  
The aim of this study is to measure the benefits of functional electrical stimulation 
(FES) to treat foot drop in ‘real life’ conditions, i.e. walking while doing another 
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task that requires your attention and when tired. Previous studies have investigated 
the benefits of FES, but only in people who were just walking up and down a 
laboratory, which may not be an adequate reflection of the benefits people get from 
using FES in daily life. This study therefore will look at the benefits of FES under 
conditions that are closer to those in ‘real life’.  
 
Why have I been invited?  
You have been invited because you have been diagnosed with Multiple Sclerosis, 
you are experiencing foot drop while walking and you are currently using FES.  
 
Do I have to take part?  
No, it is entirely up to you whether or not you take part in this study. Your clinical 
care will not be affected by your decision. You can change your mind and 
withdraw from the study at any point, without giving any reason. If you decide to 
take part in the study, you will be asked to sign an informed consent form. If you 
do withdraw, any data that have been collected will be retained.   
 
What will happen if I take part? 
If you are interested in taking part in this study, you will be invited to Queen 
Margaret University (QMU) for two visits. In the first visit, the nature of the study 
will be explained to you. After clarifying any further questions that you may have, 
Figure 1 Stroop test 
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and you agree to take part in the study, you will be asked to sign an informed 
consent form. This first visit will last approximately one hour and will involve 
measuring your weight, height and leg length.. We will also explain the so-called 
Stroop test which we will ask you to do in the second visit. In this test, the words 
of four colours, but written with  a different colour, will be projected on the wall 
in front of you and you will be asked to identify the 
colour of the text and not the word itself (see fig.1). 
You will be given a few practice trials. 
The second visit will last approximately two and a half hours and you will be asked 
to do eight walks (7 meters each) under the three conditions (24 walks in total). 
Condition A: Normal walking in a straight line with FES on (four walks) and off 
(four walks). Condition B: Walking whilst performing the Stroop test (explained 
above) with FES on (four walks) and off (four walks). Condition C: This walking 
condition is the same as B, but prior to this condition we will ask you to do a 
‘fatiguing task’ i.e. a task that aims to make you feel (physically) tired. For the 
fatiguing task, we will ask you to do an ‘incremental shuttle walk test’ in which 
involves walking between two cones (10m distance) several times. The time you 
have to cover the distance between the two cones (signifies by ‘bleeps’) will 
become increasingly shorter, until you cannot get to the next cone before the next 
‘bleep’. This test will last a maximum of 20 minutes.  
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During the eight walks in each of the three conditions, the 
movement of your legs and pelvis will be recorded using special 
cameras that capture the movement of the markers. Markers are 
small balls covered by a reflective material, which will be placed 
onto your legs and pelvis using skin-friendly tape. The markers and 
their positioning are shown in Figure 2. You can stop at any point 
between the walks described above. In order to make sure you feel safe in the 
laboratory environment a person will walk next to you.  
 
What are the possible disadvantages and risks of taking part? 
We believe that there are no serious risks of taking part. The walking conditions 
are simulating those in daily life, such as walking whilst doing a mental task or 
walking when tired. If you do experience pain or discomfort, you can stop at any 
time. If there is an unexpected complication, the University staff are certified first 
aiders. There is a first aid kit at the laboratory and health and safety assessments 
have been carried out to ensure that the laboratory environment is safe and clear 
of obstacles which can cause trips or falls. We will make sure that it is clear what 
you will be asked to do in each of the conditions.  
 
What are the possible benefits of taking part? 
Figure 2 Marker placement 
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While the benefits of the study are not directly linked with you, the results will 
inform us regarding the benefit of FES while walking and doing a task that requires 
your attention and when physically tired.  
 
Expenses and payments 
The study involves travelling to Queen Margaret University (Musselburgh) twice. 
Upon presentation of receipts, travel expenses up to £20 will be reimbursed. There 
are no payments or inducements for taking part in this study.  
 
Involvement of your family doctor 
If you decide to take part in the study, your GP will be notified by a letter 
explaining the nature of the trial. You could also make other healthcare 
professionals that are involved in your treatment aware of your participation in the 
trial. 
 
What happens when the research study stops?  
The data from all the participants will be analysed upon completion of the study 
and we will let you know about your personal and general outcomes if you wish.  
 
Will my taking part in the study be kept confidential? 
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Yes. All information collected about you during the study will be kept strictly 
confidential. Every participant is given a unique code at the beginning of the study 
and only this code is associated with any recorded data. The data recorded on 
paper, such as questionnaires, will be stored in locked 
cabinets to which only the researcher will have access. 
You will not be identifiable from the electronic data 
that we record with the cameras (fig. 3) and these data 
will be stored on a password-protected network drive 
at Queen Margaret University. Only the researchers 
involved in the study will have access to your data and 
on a few occasions, the research committee 
responsible for monitoring the quality of the research. All data will be stored for 
at least five years. We will make sure that all identifiable information will be 
removed from any presented or published work produced from the data collected.  
 
What will happen to the results of the study? 
The results of this study will be submitted for publications in scientific journals 
and/or conferences. We will make sure that you will not be identifiable in any of 
the manuscripts published. If you wish to be informed of your personal results, we 
will do so by sending you a summary of your findings.  
 
Figure 3 Electronic recording 
from the cameras. 
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What if there is a problem? 
Any complaint about the study, the way you have been dealt with during the study 
or if you believe you have been harmed in any way by taking part will be 
addressed. The university has a liability insurance scheme for compensation in 
case of harm caused by negligence of the researcher, but no compensation for any 
injury resulting from a drug or any procedure outside the abovementioned 
protocol.  
If you have any concerns or complaints throughout the study please contact Kim 
Stuart, Head of Research and Knowledge Exchange Development Unit at Queen 
Margaret University during office hours. 
Kim Stuart 
Head of Research and Knowledge Exchange Development Unit 
Queen Margaret University 
Queen Margaret University Drive 
Musselburgh 
East Lothian 
EH21 6UU 
Tel: 01314740000 (ask for Kim Stuart when prompted) 
E-mail: kstuart@qmu.ac.uk 
 
Who is organizing and funding the study? 
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The study is funded by a PhD bursary awarded by Queen Margaret University. It 
is organized by a university research team that will not receive any additional 
income for being involved in the study. 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion by the Edgbaston-West 
Midlands Research Ethics Committee and the NHS Lothian Research and 
Development (R&D) office. The Queen Margaret University Research Ethics 
Committee also reviewed the study.   
 
Further information and contact details 
Thank you for your valuable time. If you need any further information, please 
contact us. 
Georgia Andreopoulou, MSc   Dr Marietta van der Linden  
PhD candidate     Senior Research Fellow (PhD 
supervisor) 
Queen Margaret University   Queen Margaret University 
Queen Margaret University Drive  Queen Margaret University Drive 
Musselburgh     Musselburgh 
EH21 6UU     EH21 6UU 
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Tel: 07873854432 Tel: 0131 474 0000 (ask for Marietta 
van der Linden when prompted) 
gandreopoulou@qmu.ac.uk    mvanderlinden@qmu.ac.uk  
 
 
 
If you need an independent advice, please contact: 
Gill X. Murray 
Advanced Physiotherapy Practitioner in Neurology 
Physiotherapy Department 
Slateford Medical Centre 
27 Gorgie Park Close 
Edinburgh, EH14 1NQ 
0131 455 9850 mobile 07816 174 293 
(Monday, Wednesday, Thursday, Friday) 
Gill.X.Murray@nhslothian.scot.nhs.uk  
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Appendix 18:   Informed consent form for study in Chapter 6 
 
 
 
CONSENT FORM 
Title of Project: The effects of FES in a variety of walking conditions in 
people with MS 
Name of Researcher: Georgia Andreopoulou 
           
1. I confirm that I have read the information sheet dated....26/3/2018......... 
(version 3) for the 
above study. I have had the opportunity to consider the information, ask 
questions and have  
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time 
without giving any reason, without my medical care or legal rights being 
affected. 
 
3.  I agree to my General Practitioner being informed of my participation in 
the study. 
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4. I understand that during my involvement in this study, the PI will have 
access to my  
 personal information (i.e. home address and email) to arrange my study 
visits to 
the university. 
 
5.   I understand that the Sponsor of the study might review my medical 
records.   
 
6.   I agree to take part in the above study. 
 
          
  
Name of Participant  Date    Signature 
 
          
  
Name of Person  Date    Signature 
taking consent 
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Appendix 19:   Advertisement for healthy volunteers  
 
 
 
Volunteers please! 
 Are you between the ages of 18-80? 
 Are you free of any musculoskeletal injuries or 
neurological disorders?  
 Are you interested in learning more about your 
walking? 
 
If yes, please read on: 
We at Queen Margaret University (Musselburgh) are 
running a study to assess the walking patterns and walking 
speed of people with and without multiple sclerosis.  
Volunteer participants will be asked to attend QMU campus 
for one single visit which would last a maximum of two and 
a half hours. In this visit, we will record your walking 
pattern while you are walking and performing an attention-
demanding task at the same time and repeat this again after a 
physically demanding walking task. Travel costs to and from 
the University up to £20 will be reimbursed. 
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This study has received a favourable opinion from the West 
Midlands NHS Research Ethics Committee and Queen 
Margaret University Research Ethics Committee. 
If you interested in taking part in this study and would like 
more information, please contact Georgia Andreopoulou at 
Queen Margaret University (07873854432 or 
gandreopoulou@qmu.ac.uk) 
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Appendix 20: Multiple Sclerosis Walking Scale  
 
If you cannot walk at all, please tick this box 
In the past two 
weeks, how much 
has your MS . . . 
 
Not at 
all 
 
A little 
 
Moderate
ly 
Qui
te 
a 
lot 
 
Extremel
y 
1. Limited your ability to walk? 1 2 3 4 5 
2. Limited your ability to run? 1 2 3 4 5 
3. Limited your ability to climb up and down 
stairs? 
1 2 3 4 5 
4. Made standing when doing things more 
difficult? 
1 2 3 4 5 
5. Limited your balance when standing or 
walking? 
1 2 3 4 5 
6. Limited how far you are able to walk? 1 2 3 4 5 
7. Increased the effort needed for you to 
walk? 
1 2 3 4 5 
8. Made it necessary for you to use 
support when walking indoors (eg 
holding on to furniture, using a stick, 
etc.)? 
 
1 
 
2 
 
3 
 
4 
 
5 
9. Made it necessary for you to use 
support when walking outdoors (eg using 
a stick, a frame, etc.)? 
 
1 
 
2 
 
3 
 
4 
 
5 
10. Slowed down your walking? 1 2 3 4 5 
11. Affected how smoothly you walk? 1 2 3 4 5 
12. Made you concentrate on your 
walking? 
1 2 3 4 5 
From the numbers you circle against these questions, your healthcare 
professional can calculate your MSWS-12 score. This is done by adding the 
numbers you have circled, giving a total out of 60, and then transforming this to 
a scale with a range from 0 to 100. Higher scores indicate a greater impact on 
walking than lower scores. 
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Appendix 21:   Multiple Sclerosis Neuropsychological Screening 
Questionnaire (Benedict et al, 2003) 
 
 
 
 
 
 
 
 
 
Name:
  
Date:
  
Sex (circle one): Male / Female 
 
INSTRUCTIONS: The following questions ask about problems that you may 
experience. Rate how often these problems occur AND how severe they are. Base 
your ratings on how you have been over the last 3 months. 
Please check the appropriate box.ry often, Quite often, Occasionally, Very rarely,
  Never, very disruptive interferes with seldom a no problem does not 
(4) life (3) problem 
(2) (1) occur (0) 
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1. Are you easily distracted? 
2. Do you lose your 
thoughts while 
listening to 
somebody speak? 
3. Are you slow when trying to 
solve problems? 
4. Do you forget appointments? 
5. Do you forget what you read? 
6. Do you have trouble 
describing shows or 
programs recently watched? 
7. Do you need to have 
instructions repeated? 
8. Do you have to be reminded 
to do tasks? 
9. Do you forget errands that 
were planned? 
10. Do you have difficulty 
answering questions? 
11. Do you have difficulty 
keeping track of two things at 
once? 
12. Do you miss the point of 
what someone is trying to 
say? 
13. Do you have difficulty 
controlling impulses? 
14. Do you laugh or cry with little 
cause? 
15. Do you talk excessively or 
focus too much on your 
own interests? 
   r                r              r              r              
r 
 
   r                r              r              r              
r 
 
   r                r              r              r              
r 
   r                r              r              r              
r 
   r                r              r              r              
r 
 
   r                r              r              r              
r 
 
   r                r              r              r              
r 
   r                r              r              r              
r 
   r                r              r              r              
r 
   r                r              r              r              
r 
 
   r                r              r              r              
r 
 
   r                r              r              r              
r 
 
   r                r              r              r              
r 
   r                r              r              r              
r 
   r                r              r              r              
r
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Appendix 22:   Hospital Anxiety and Depression Scale 
 
Tick the box beside the reply that is closest to how you have been feeling in the past 
week. 
Don’t take too long over you replies: your immediate is best. 
 
 
 
 
D A  D A  
  I feel tense or 'wound up':   I feel as if I am slowed down: 
 3 Most of the time 3  Nearly all the time 
 2 A lot of the time 2  Very often 
 1 From time to time, occasionally 1  Sometimes 
 0 Not at all 0  Not at all 
      
  I still enjoy the things I used to 
enjoy: 
  I get a sort of frightened feeling like 
'butterflies' in the stomach: 
0  Definitely as much  0 Not at all 
1  Not quite so much  1 Occasionally 
2  Only a little  2 Quite Often 
3  Hardly at all  3 Very Often 
      
  I get a sort of frightened feeling as if 
something awful is about to 
happen: 
   
I have lost interest in my appearance: 
 3 Very definitely and quite badly 3  Definitely 
 2 Yes, but not too badly 2  I don't take as much care as I should 
 1 A little, but it doesn't worry me 1  I may not take quite as much care 
 0 Not at all 0  I take just as much care as ever 
      
  I can laugh and see the funny side 
of things: 
  I feel restless as I have to be on the 
move: 
0  As much as I always could  3 Very much indeed 
1  Not quite so much now  2 Quite a lot 
2  Definitely not so much now  1 Not very much 
3  Not at all  0 Not at all 
  Worrying thoughts go through my 
mind: 
  I look forward with enjoyment to 
things: 
 3 A great deal of the time 0  As much as I ever did 
 2 A lot of the time 1  Rather less than I used to 
 1 From time to time, but not too often 2  Definitely less than I used to 
 0 Only occasionally 3  Hardly at all 
      
  I feel cheerful:   I get sudden feelings of panic: 
3  Not at all  3 Very often indeed 
2  Not often  2 Quite often 
1  Sometimes  1 Not very often 
0  Most of the time  0 Not at all 
      
  I can sit at ease and feel relaxed:   I can enjoy a good book or radio or TV 
program: 
 0 Definitely 0  Often 
 1 Usually 1  Sometimes 
 2 Not Often 2  Not often 
 3 Not at all 3  Very seldom 
 
